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Abstract 
 
Background:                                                                                               
Cystic Fibrosis (CF) is one of the United Kingdom’s most common life limiting genetic 
disorders. Improvement in treatment modalities over the last 20 years has resulted in 
this group of patients living longer. The acceptability of accessing early palliative care 
for patients with CF and staff perceptions of a palliative care referral for this group is 
relatively unexplored. Integrated care has been used as a theoretical model to 
underpin this study. 
 
 
Aim:  
To explore the experience and perceptions of patients with CF and staff regarding 
palliative care and the acceptability of this as a service early in the patient’s disease 
trajectory. 
 
Method:  
A Mixed Methods Study informed this research. This three phase study included a 
Focus Group (phase 1) with 8 experts from both CF and palliative care, a national 
survey (phase 2) with 46 experts from CF and palliative care teams, and 17 
interviews (phase 3) with patients with CF and health care professionals who care for 
patients with CF. 
 
Results:  
The term “palliative care” remains a barrier for some professionals in considering a 
referral to palliative care. Patients interviewed did not have such a problem with the 
term. Patients are supportive of palliative care being introduced earlier in the disease 
trajectory. Currently there is evidence to suggest that over 50% of teams do not have 
an integrated service between CF and palliative care. 
 
Discussion:                                                                                                    
This innovative study has identified a lack of clarity relating to when a patient with CF 
should be referred to palliative care services. Uncontrolled symptoms and transplant 
have been highlighted as potential triggers for referral to palliative care services. 
Patients have recognised that transplant may be too late for a referral and would like 
to be made aware of palliative care services earlier in the disease pathway. A model 
of integrated care has been generated from the findings of the study. 
 
Conclusion 
This study has explored early palliative care in adults with CF and considered the 
perceptions and experiences of patients and health care professionals. This three 
phase study has determined the views of patients for the first time regarding early 
palliative care. Together with national data in phase two and in depth interviews in 
phase three, an integrated model between CF and palliative care is proposed that 
illustrates the views of the patients and health care professionals, offering 
considerations for organisations in the development of integrated services.  
 
Key words: Cystic Fibrosis, Palliative Care, Integrated Care, patient and health care 
professional perceptions and experiences. 
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CHAPTER 1: INTRODUCTION TO THE THESIS 
1.1. Introduction 
This study explores the experiences and perceptions of patients with Cystic 
Fibrosis and of health care professionals regarding palliative care and the 
acceptability of this service early in patients’ disease trajectories. The chapters 
of this thesis are structured from 1 to 8. The following presents a guide for the 
reader. Chapter 1 introduces palliative care, non-malignant disease and 
explores the theoretical model of integrated care. Chapter 2 offers a 
background to the study whilst Chapter 3 critiques the existing literature to 
undertake this research. Chapter 4 discusses the methodology used to 
underpin the study and Chapter 5 will discuss the methods applied. Chapter 6 
presents an analysis of the data and findings from the study, following which 
Chapter 7 presents a discussion based on the results. Within this chapter an 
illustration of a proposed model for integrated care will be offered, including 
implications for practice, strengths and weaknesses of the study and 
considerations for further research. Chapter 8 presents an overarching 
conclusion to the study. This thesis culminates with a copy of a clinical 
academic paper based on the results of the study, an overview of the 
integration of knowledge, research and practice as developed in undertaking 
this Doctorate in Clinical Practice and a research log that defines the 
development of this study. 
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The following section offers an introduction to the context of palliative care and 
Cystic Fibrosis which reflects the topic to be examined. The chapter will 
conclude with a summary of this section. 
1.2. Palliative care 
There is evidence that palliative care should be available to all patients and 
their families irrespective of the stage of their disease or diagnosis (Standing 
Medical Advisory Committee 1992; Ahmed et al. 2004; O’Leary & Tiernan 
2008; Weissman & Meier 2011). Palliative care is a sub speciality of medicine 
and refers to  
“an approach that improves the quality of life of patients and their 
families facing the problem associated with life-threatening illness, 
through the prevention and relief of suffering by means of early 
identification and impeccable assessment and treatment of pain and 
other problems, physical, psychosocial and spiritual. It is applicable 
early in the course of an illness, in conjunction with other therapies that 
are intended to prolong life, such as chemotherapy or radiation therapy, 
and includes those investigations needed to better understand and 
manage distressing clinical complications” (WHO 2002 p.2). 
 
It was recognised in 2010 that within the United Kingdom (UK) half a million 
people die each year and within that 36% die from cardiovascular disease, 
27% die from cancer and 14% die from respiratory diseases (Barclay & Maher 
2010). It is estimated that between 70% and 80% of all expected deaths are 
12 
 
likely to need palliative care input which would equate to around 355,000 
people in England requiring palliative care every year (DH 2011). 
1.3 Palliative care and Non-Malignant Disease 
The ethos of palliative care has been embedded in, and grown from, the 
speciality of cancer (Clarke 2007). It was through the emergence of the 
Acquired Immune Deficiency Syndrome (AIDS) in the 1980s that questions 
relating to the provision of palliative care to those with a non- cancer illness 
emerged. Previously it had been recognised that patients dying from diseases 
other than cancer were experiencing symptoms that were not well controlled 
(Hinton 1963). Population based studies using random samples of deaths and 
relating to reports of bereaved carers, indicated that those patients with a non-
cancer disease were likely to have more burdensome symptom problems in 
the last year of life, than those patients with a cancer diagnosis (Weatherall 
2001; Murtagh et al.; 2004; Griffin & Conway 2008). 
 
In 1992, an expert advisory group published recommendations that stated any 
patient with a life limiting illness should have access to palliative care services 
(SMAC 1992). The report suggested that a referral to palliative care should be 
based on the needs of patients rather than the disease type. The report 
referred to patients with no access to palliative care as “the disadvantaged 
dying” (Stewart & McMurray 2002). It was evident that historically palliative 
care had been developed with only those patients with cancer in mind 
(Addington-Hall et al.1998). 
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Resources to offer palliative care to all patients remain an issue for 
commissioners and the preliminary result of the palliative care funding review 
has highlighted a lack of transparency in the current palliative care payment 
system. This has resulted in providers not being incentivised to care for more 
patients due to the current block payment contracts (England PCT 2014). The 
issue of “distributive justice” falls into two categories, that of financial and 
manpower (Wasson &George 2001). Even with additional funding and 
resources that ensued with the End of Life Care Strategy in 2008 (DH 2008), 
there continues to be fundamental differences in offering palliative care 
services to those with cancer and those patients with other life limiting 
illnesses. The most common difference includes the difficulty in recognising 
when patients with non-malignant disease are dying. A lack of understanding 
around the pathophysiology of advanced disease and the availability of active 
treatments up until the end of life for patients dying from non-malignant 
diseases have been identified as contributing to the complexity involved in 
these patients (Dunlop 2001). 
 
There is evidence that palliative care should develop new models of care to 
ensure services are meeting the needs of patients (Bourke.et al. 2009; Quill & 
Abernethy 2013). One way of aiming to achieve this is through an integrated 
model of care. The following section explores this as a model of care. 
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1.4. Integrated Care  
Integrated care relates to principles for delivery of care that aims to improve 
the patient’s experience through improved coordination of care. Integration is 
the bringing together of methods, processes and models that help bring this 
about (Shaw et al. 2011). Planning integrated care involves teams having a 
shared vision and ensuring the patient’s perspectives are kept central 
throughout. 
 
In the current climate of the National Health Service (NHS) quality and 
efficiency are paramount and experience outside of the United Kingdom 
recognises the impact integrated care can make in the delivery of efficient 
care (Shaw et al. 2011). To achieve an integrated service, connecting services 
is pivotal. Services and communication between Cystic Fibrosis and palliative 
care providers appear to be variable and the patient’s perception is relatively 
unknown as the literature review identified a focus towards end of life and 
bereavement studies. This study will add to this unknown area in 
understanding what is needed to develop an integrated approach to care. It is 
suggested that there is no one single model of integrated care that is 
appropriate for all situations and that clinicians should work together to define 
integrated services (Goodwin 2013). The need to see the complete picture 
through different lenses was integral to answering the research questions and 
understanding of what patients and professionals thought about the position of 
palliative care within the Cystic Fibrosis team. 
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The traditional model of palliative care grew from the speciality of cancer 
(Figure 1). The term terminal care was used to describe end of life care. There 
is no defined time on end of life care and this can range from the last twelve 
months of life to last few days or hours (DH 2008). Subsequent changes in 
definitions of palliative care suggest an integrated model of care where 
palliative care can be accessed any time throughout the patient’s disease 
journey. 
 
Figure 1. Models of Palliative care 
 
 
The American Society of Medical Oncology in 2009 released a vision for 
integrating Palliative care services in cancer that they would aspire to have in 
place by 2020 (Ferris et al. 2009). This indicated that as yet the cancer model 
is underdeveloped in its approach to integrated care. 
 
There are five main types of integration considered in the literature namely 
systemic, normative, organisational, administrative and clinical (Kodner 2009; 
Rosen et al. 2011; Shaw et al. 2011). Systemic integration relates to 
coordinating and aligning policies, rules and regulatory frameworks such as 
16 
 
policy levers emphasising better coordinated care outside of hospitals, central 
impetus for diversity of providers, development of national incentive schemes 
(for example the Quality and Outcomes Framework) or financial incentives to 
promote downward substitution (Kodner 2009; Rosen et al. 2011; Shaw et al. 
2011). Normative integration refers to the development of shared values, 
culture and vision across organisations, professional groups and individuals 
for example, developing common integration goals, identifying and addressing 
communication gaps, building clinical relationships and trust through local 
events, or involving service users and the wider community (Kodner 2009; 
Rosen et al. 2011; Shaw et al. 2011). 
 
Organisational integration issues include coordinating structures, governance 
systems and relationships across organisations for example, developing 
formal and informal contractual or cooperative arrangements such as pooled 
budgets or practice-based commissioning; or developing umbrella 
organisational structures such as primary care federations or local clinical 
partnerships (Kodner 2009; Rosen et al. 2011; Shaw et al. 2011). 
Administrative integration issues relate to aligning back-office functions, 
budgets and financial systems across integrating units for example, 
developing shared accountability mechanisms, funding processes or 
information systems (Kodner 2009; Rosen et al. 2011; Shaw et al. 2011). 
Finally, clinical integration alludes to coordinating information and services 
and integrating patient care within a single process such as developing 
extended clinical roles, guidelines and inter-professional education, or 
facilitating the role of patients in shared decision-making (Kodner 2009; Rosen 
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et al. 2011; Shaw et al. 2011). All aspects of integration are significant for this 
study. In particular, the normative and clinical types of integration that aim to 
establish shared values, culture and vision and to be involved in building 
clinical relationships are important aspects to begin with as they set the scene 
for how services can be better coordinated. Other aspects will follow if these 
areas are introduced first. Having a shared vision and building and 
establishing relationships are fundamental to any changes in services. In 
addition to this it is evident that teams should look towards creating shared 
guidelines and education of what each team can provide (Shaw et al. 2011). 
As part of understanding the integration between the two teams it is necessary 
to establish the current relationship, and to determine perceptions of how 
palliative care is perceived by Cystic Fibrosis teams. This is necessary to 
understand what infrastructures would help support integration within these 
specialities.  
 
Providing integrated care is described as being part of national and local 
government policy and that services have a duty to revise how they provide 
services and base them on quality effective care that enhances the needs and 
views of the patients (Shaw et al. 2011). This model of integrated care will be 
considered throughout this study. 
 
1.5. Summary 
The issue of patients with non-malignant disease requiring access to palliative 
care services is not new (Hinton 1963). Development of services and funding 
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of palliative care for all patients is under review within which the needs of the 
patient are seen as a priority to drive payment (England PCT 2014). 
 
Integrated care should be considered as a way of developing new models of 
care. The following chapter will offer background information relating to the 
development of palliative care services and its position within non-malignant 
disease as well as exploring Cystic Fibrosis and justifying the rationale for the 
focus of this study 
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CHAPTER 2: BACKGROUND TO THE RESEARCH 
Following an opportunity for service development, the hospital Trust where the 
researcher worked was invited to provide the palliative care service to a 
neighbouring Trust where the specialty was heart and lung disease. At that 
time, the researcher had over twenty-five years’ experience in cancer and 
palliative care and was working in a large comprehensive cancer centre. The 
researcher had an interest in palliative care being offered to patients early in 
their disease trajectory for symptom control. As a result of this service 
development, the researcher, as the Nurse Consultant for palliative care, had 
a responsibility to scope the need for palliative care within the new service. On 
assessing the current provision of palliative care to patients with Cystic 
Fibrosis, and through talking to staff it became evident that access to palliative 
care services was limited and often only accessed for end of life care, if at all. 
The researcher became intrigued by this as observations on clinical visits 
demonstrated that patients with Cystic Fibrosis appeared to be in hospital for 
long periods of time throughout which they were burdened with symptoms 
including pain, cough, breathlessness, nausea and vomiting. This led to 
further discussions with experts in both Cystic Fibrosis and palliative care and 
thus the development of this study. 
 
Cystic Fibrosis is one of the United Kingdom’s most common genetic life 
limiting illnesses and can result in death at an early age (Sawicki et al. 2008; 
Barr et al. 2011, Braithwaite 2011). It is an autosomal recessive disease 
caused by mutations in the cystic fibrosis membrane conductance regulator 
(CFTR) gene that results in abnormal transportation of sodium and chloride in 
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and out of cells leading to the production of thick sticky mucus in organs 
(Davies et al. 2007; Conway et al. 2008). Cystic Fibrosis usually presents in 
infancy with respiratory or nutritional symptoms (Mitchell 2000). The main 
systems affected are the respiratory and gastro intestinal tract and over time, 
chronic pulmonary infection and progressive pulmonary impairment become 
prominent features (Mitchell 2000). As the disease progresses other 
complications such as diabetes, liver disease, osteoporosis, arthritis and 
sinusitis may develop.  
 
The management of Cystic Fibrosis requires daily and life-long treatments. 
These include physiotherapy to clear the lungs of sticky mucus, pancreatic 
enzymes to digest food, regular antibiotics, a high calorie diet and exercise 
(Edwards et al. 2013). Patients with Cystic Fibrosis face a number of 
symptoms including chest pain, cough, abdominal pain, breathlessness, 
haemoptysis, anorexia, depression, anxiety and the potential of requiring a 
lung transplant (Robinson 2011). With this burden of symptoms and 
uncertainty of the patient’s prognosis, the support that palliative care could 
offer early in the patient’s disease trajectory is relatively unknown and requires 
further exploration. 
 
Lung transplantation is viewed as an end stage option for respiratory failure in 
patients with Cystic Fibrosis. Transplantation can offer hope to some patients 
for an improvement in symptom control, however for others the hope of a 
transplant can result in a lack of attention surrounding the progression of the 
disease (Robinson 2011).  
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The European Cystic Fibrosis standards in 2014 give reference to palliative 
care services and recognise the importance of raising end of life care issues, 
however this is only referred to when considering lung transplantation (ECFS 
2014). This does, however, demonstrate a move towards Cystic Fibrosis 
services becoming more integrated with palliative care, as previous European 
standards in 2005 (Kerme 2005) did not recognise palliative care services 
being involved with this group of patients. 
 
There are twenty three adult Cystic Fibrosis specialist centres within the 
United Kingdom providing specialist treatment to patients with Cystic Fibrosis. 
Historically few patients lived beyond early childhood but with the 
improvement in treatment modalities, quality of life and the life expectancy of 
the person with Cystic Fibrosis have improved. Over the last twenty years 
these improvements have resulted in patients living longer with Cystic Fibrosis 
with an identified need for Palliative care for symptomatic management 
(Sawicki et al. 2008; Stenekes et al. 2009; Wiehe & Amdt 2010; Braithwaite et 
al. 2011). The most recent available data in the United Kingdom confirmed 
that over 9,000 patients were registered as having a diagnosis of Cystic 
Fibrosis. Table 1 illustrates the number of patients with Cystic Fibrosis as 
reported by country. 
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Table 1. Numbers of patients with Cystic Fibrosis reported by each country in 
2010 
Country                                          2010                     Estimated Coverage                                   
Austria 511   57% 
Belgium* 1138 >90% 
Czech Republic* 523 100% 
Denmark* 450 100% 
France* 5759   90% 
Germany* 5003   95% 
Greece 96   20% 
Hungary* 557   90% 
Israel* 429   72% 
Italy* 4119   70% 
Latvia 30 >90% 
Rep of Moldova* 42 100% 
The Netherlands * 1306   97% 
Portugal 138 48% 
Russian Federation 359 15-20% 
Serbia 121 >90% 
Slovak Republic* 333 >90% 
Slovenia 80 75% 
Spain 918 30% 
Sweden* 509 80-85% 
Switzerland 443 55% 
United Kingdom* 9385 100% 
Total 32248  
*Represents countries who have a national registry  
(European Cystic Fibrosis Society 2010) 
 
The column labelled estimated coverage shows the estimated percentage of 
patients with Cystic Fibrosis living in those countries that are included in the 
national registries/national data collections.  
 
A summary of patients registered with Cystic Fibrosis (CF) from the United 
Kingdom (UK) registry between 2009 -2014 is displayed in Table 2 showing 
an increase since 2009. 
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Table 2. Summary of Cystic Fibrosis United Kingdom Registry 2013 
Summary of the United Kingdom Cystic Fibrosis Registry  
 2009 2010 2011 2012 2013 
CF patients registered excluding 
diagnoses that year 
9029 9385 9749 10078 10338 
CF patients with complete data 7377 7937 8679 8794 9052 
Age at diagnosis in months; 
Median 
3 3 3 3 3 
Median predicted Survival in 
years (95% CI) 
34.4 41.4 41.5 43.5 36.6 
Total Deaths reported 141 103 118 196 146 
Age at death in years; (95% CI)5 27 29 26 28 29 
 
CF/UK Trust (2013) 
 
Transplant can be considered for some patients and Table 3 below illustrates 
the number of patients referred for transplant and also represents the number 
of patients who have received a transplant. 
 
Table 3. Transplant Activity in United Kingdom 
Transplant Activity 
 2009 2010 2011 2012 2013 
Number of patients with annual 
review data evaluated for 
transplants 
143 169 204 225 220 
Numbers accepted on the 
transplant  list 
79 82 121 120 136 
Numbers receiving transplants 
(> 16) 
Bilateral Lung 
Heart and Lung 
Liver 
22* 
16 
0 
5 
2 
26 
24 
1 
0 
1 
48 
40 
4 
2 
3 
52** 
43 
1 
6 
4 
54* 
48 
0 
3 
4 
*One patient received 2 transplants 
**Two patients had 2 transplants 
CF/UK Trust (2013)  
 
Although the age at death has increased, patients continue to have a reduced 
life expectancy with a median age of death of 29 years. In terms of patients 
with Cystic Fibrosis receiving transplants it is evident that the number of 
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bilateral lung transplants has increased from 16 in 2009, to 48 in 2013 (CF/UK 
Trust 2013). However, not all patients who are identified as needing 
transplants will be accepted onto the transplant list as illustrated in Table 3. 
Regardless of whether a patient with Cystic Fibrosis is accepted onto the 
transplant list or not, the involvement of palliative care service providers is 
unclear. 
 
The need to acknowledge the potential unmet need of patients dying from life 
limiting illnesses other than cancer has been well documented (Hinton 1963; 
Addington-Hall 1998; Murray et al. 2002; Braithwaite et al. 2011).  Various 
National Service Frameworks (NSF) refer to patients from groups other than 
cancer requiring access to palliative care services. These groups included 
Chronic Obstructive Pulmonary Disease, Heart Failure, Renal Disease and 
those with Neurological diseases (DH, 2000; DH 2004; DH 2005; DH 2008). 
Cystic Fibrosis has transitioned into a chronic illness and supporting patients 
living with symptoms caused by the disease could be offered by palliative care 
services. The acceptability of how this would be for patients with Cystic 
Fibrosis and staff in palliative care delivering the service is relatively 
unexplored.  
 
2.1. Trajectory of Palliative Care 
The historical perspective of the integration of cancer and palliative care 
relates to the implementation of palliative care in the last few days or weeks of 
a patient’s life and was often referred to as terminal care (Clark 2007). This 
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supported the WHO definition in 1990 when palliative care was viewed as a 
service for patients at the end of life. With the updated definition in 2002 
current palliative care aims to offer services based on needs of patients rather 
than the stage of disease and has extended to both cancer and non-cancer 
patients. The introduction of guidance in 2004 from the National Institute for 
Heath and Care Excellence (NICE 2004), recommended that patients should 
be able to access palliative care support whilst having investigations prior to a 
confirmed diagnosis and that this should be referred to as supportive care. 
Patients would therefore, at earlier stages of their illness, have access to 
supportive care. 
 
It has been acknowledged that there is overlap between supportive and 
palliative care services and this has, for some professionals, resulted in 
confusion (NICE 2004; National Council for Palliative Care (NCPC) 2006). The 
more integrated trajectory suggests that palliative care should be involved at 
the earlier stages of the patient’s illness (Pitcher & Davis 2001). Evidence 
suggests that in some circumstances diseases such as HIV or Cystic Fibrosis 
will require highly technical interventions that are appropriate to run alongside 
palliative treatment with each becoming dominant at different stages of the 
disease process (Goldman & Schuller 2001). 
 
Currently palliative care offers a comprehensive service for people with 
cancer. For those with a non- malignant disease palliative care services are 
continuing to develop (Andrews & Seymour 2011). It has been identified that 
there are large numbers of patients with a non-malignant disease who have 
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problems that are as equally distressing as those experienced by cancer 
patients and who would benefit from palliative care support (Addington-Hall et 
al. 1998). The service model for patients with non-malignant disease is not as 
well developed as in the case of patients with cancer. 
 
The purpose of this research is to explore how patients with Cystic Fibrosis 
and professionals from both Cystic Fibrosis and palliative care perceive early 
palliative care and the perceptions and understanding what a referral to a 
palliative care service means for them. Understanding what professionals and 
patients think about a palliative care service will help the development of 
models of care in the future between Cystic Fibrosis and palliative care. In 
order to differentiate between palliative and supportive care the following 
section will offer definitions in addition to the background relating to policy 
affecting palliative care in the Cystic Fibrosis population. 
 
2.2. Definition of Palliative care 
The first definition of palliative care, which has subsequently undergone 
several iterations, was in 1990. The definition stated “palliative care is the 
active total care of patients whose disease is not responsive to curative 
treatment. Control of pain, of other symptoms, and of psychological, social 
and spiritual problems is paramount. The goal of palliative care is 
achievement of the “best possible quality of life for patients and their families” 
(WHO 1990 pp.94). In 2002, the definition had a further iteration as described 
previously in Section 1.2. This current definition also includes patients 
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undergoing additional investigations to allow a better understanding of the 
stage and complexities of the disease process. 
 
The difference between the two definitions relates to palliative care being 
involved with patients who may not die, and being involved with therapies to 
prolong life. There remains no definition of when “early” palliative care should 
start but the perception and interpretation by professionals in the field of 
cancer, was that palliative care should be offered in parallel with anti-cancer 
therapies. 
 
2.3. Definition of Supportive Care 
The term supportive care was first alluded to in 1994 and was used to 
describe a comprehensive programme to meet patients need from an holistic 
point of view and was available to patients, pre diagnosis, at diagnosis, during 
treatment and through the follow up phase (Fitch 1994). Supportive care 
included patients with cancer who required symptom control and also others 
with life limiting illnesses (Fitch 1994; NCPC 2006). A systematic review 
recognised that best supportive care is considered by professionals to be the 
same as palliative care (Hui et al. 2013) and for patients in a randomised 
controlled trial they found it easier to describe supportive care in their own 
words as opposed to palliative care (Maciasz 2013). A further study 
established that the term palliative care has become more commonly used 
and has increased in use over time, whereas the frequency of use of the term 
supportive care has remained the same (Hui et al. 2013). This may signify 
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professionals recognising the need to be consistent in the terminology applied. 
It is clear from the definitions available that there is a lack of consensus 
regarding what palliative care actually is. This has resulted in the timing of 
referral to palliative care becoming increasingly complex especially for the 
professionals caring for the patients with Cystic Fibrosis. 
Supportive care is provided to people with cancer and their carers throughout 
the patient pathway from pre-diagnosis onwards (NICE 2004). The term 
supportive care was used in relation to adults with cancer; however with slight 
modification in the terminology it is applicable to anyone with a life limiting 
illness (NCPC 2006). By definition, this would be applicable to those patients 
with Cystic Fibrosis. Supportive care is an over-arching term for all palliative 
care services, both generalist and specialist, that may be required to support 
people with cancer and non- malignant conditions and their carers. It is not a 
response to a particular stage of disease, but is based on an assumption that 
people have a need for supportive care from the time that a possibility of 
cancer or other life limiting illness is first raised. It was recognised that 
palliative care should become a gradually increasing part of care from 
diagnosis to death, rather than being concerned only with the terminal phase 
(Higginson 1993). 
Having a number of different definitions of both supportive care and palliative 
care has resulted in a considerable degree of confusion, not only for health 
professionals but also for patients. Not only are many people unsure about 
what palliative care is, and when it should be provided, but also confusingly 
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that palliative care is, in some circumstances, part of supportive care and vice-
versa (NICE 2004; NCPC 2006). 
Many people have only heard about palliative care as something that is 
provided in hospices for people who are dying (Addington-Hall & Higginson 
2001; Ahmed et al. 2004; NICE 2004; Walsh et al. 2008). Offering palliative 
care early in the course of a disease is not without difficulty. Some people 
refuse the offer of palliative care believing that to accept it will mean that they 
are going to die (Ward et al. 2009). They may also believe that they will no 
longer be offered any disease modifying or curative treatment. Whether the 
terminology refers to supportive or palliative care the experience of someone 
faced with a life limiting illness is different for each person with each having a 
unique need for information, support and care. 
The introduction of supportive care as well as palliative care has often led to 
confusion regarding the timeliness of referrals to palliative care. For 
professionals there remains at times a direct association between referral to 
palliative care and an association with death (Ahmed et al. 2004). There 
remains concern from professionals that referral to palliative care will result in 
patients giving up hope and that the focus of palliative care will be around 
death (Johnson et al. 2008). 
For this study palliative care is defined as a service that can become involved 
with patients at any stage of their illness and is based on need rather than 
diagnosis or stage of disease as previously defined by WHO (2002). 
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2.4. The Confusion of Language to Describe Palliative care 
Palliative care appears to be struggling with its identity and patients and health 
care professionals either have no knowledge about palliative care or believe it 
is synonymous with end-of-life care (Parikh et al. 2013). Palliative care is 
appropriate at any stage of a serious illness, and can be provided together 
with curative treatment. Several clinical trials have shown benefits of early 
palliative care in patients with advanced cancer (Temel et al. 2010; Greer et 
al. 2013).  The effect of early palliative care on other non- malignant patient 
populations is less well researched. 
There is to date, a myriad of terms used to describe palliative care. In 2013 
Hui et al. identified twenty four different definitions of palliative care. Some of 
these terms include care of the dying, terminal care, supportive care, hospice 
care, comfort care and actively dying. The term palliative care was derived in 
1973 from Balfour Mount who was looking for a name to call a terminal care 
ward. As the phrase terminal care was already in existence he used the term 
palliative care to replace terminal care. Criticism for this ensued with 
challenges being made to the creation of a euphemism for terminal care 
(Doyle 1993; Billings 1998). 
2.5. Policy Development 
In the United Kingdom a report entitled “The Principles and Provision of 
Palliative” care identified by the Standard Medical Advisory Committee in 1992 
acknowledged “the disadvantaged dying”, and referred to those dying from 
diseases other than cancer. The document highlighted that patients with life 
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limiting illnesses other than cancer should be able to access palliative care 
services (SMAC report 1992). The Calman-Hine Report (DH 1995) although 
focused on a policy framework for commissioning cancer services 
subsequently led to a review of palliative care services.  The historical 
development of palliative care is illustrated in Table 4 below as discussed 
within the palliative care literature. 
 
Table 4.Timeline of Palliative care Development  
 
 
(Adapted from Clark 2000) 
 
The development of both the guidance on supportive and palliative care for 
Adults with Cancer (NICE 2004) and the National End of Life Care Strategy 
(EoLC), (DH 2008) were significant in the management of patient care and 
service development. The supportive and palliative care guidance 
acknowledged involving palliative care services earlier in the patient’s cancer 
illness referring to this as supportive care, whilst also recognising the need to 
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support 
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support patients at the end of life (NICE 2004). Although written for cancer 
patients, it was recognised that with a slight change to the definition of 
supportive care all patients should have access to palliative care at any stage 
of their illness (NCPC 2006). The EoLC strategy was produced with a plan to 
be implemented by the National Health Service (NHS) working in collaboration 
with local authorities and with support from the Department of Health (DH 
2008). It was referred to as being the first comprehensive framework which 
was aimed at promoting high quality care for all adult patients approaching the 
end of their lives including cancer and other life limiting illnesses (DH 2008). 
The EoLC strategy was supported financially by the then Labour Government. 
A potential unintended effect of the EoLC strategy is in the association of 
palliative care with death and increased public awareness of this association. 
The focus relates, primarily, to the end stages of a patient’s life. The strategy 
encourages patients to choose to die where they wish, which in the majority of 
cases is home (NCPC 2011). Whilst this is supported by clinicians there was 
limited funding to support this to happen, therefore palliative care services 
have had to increase provision to allow patients to die at home. With limited 
resources this could inhibit the availability of palliative care services to support 
patients earlier in their disease trajectory as the focus was to support patients 
who were dying. 
 
2.6. Cystic Fibrosis and Palliative care 
There has been limited exploration in the UK on the involvement of palliative 
care early in patients with Cystic Fibrosis’ disease trajectory to support 
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symptom management. Rather, studies looking at end of life care and 
advance care planning for adults with Cystic Fibrosis have been conducted 
(Mitchell et al. 2000; Chapman et al. 2005; Iles & Lowton 2008; Sawicki et al. 
2008). It is known that potentially this is a group of patients who may benefit 
symptomatically from either direct support from a palliative care team or 
indirect through support and advice to Cystic Fibrosis professionals (Bourke et 
al 2009; Braithwaite et al. 2011). Pain, breathlessness and cough have been 
recognised as being significant problems for patients with Cystic Fibrosis 
(Stenekes et al. 2009). 
 
The contribution that palliative care services can make towards the control of 
patients symptoms has been recognised within the literature (Edmonds et 
al.1998; Klepstad et al. 2005; Stevens et al. 2005; APM 2012). In a 
retrospective review looking at predictors of access to a palliative care service 
it was identified that 499 out of 1453 (34%) patients had access to palliative 
care services. It was indicated that palliative care services can help in 
supporting those patients who have physical and psychological distress but 
that referral patterns should be more clearly defined (Fadul et al. 2007). 
 
There are several possible reasons for variability in the pattern of referral to 
palliative care. These reasons include different patient needs, variability in the 
referrer and possible perceptions of patients towards the palliative care 
referral and ongoing care (Catt et al. 2005; Burt & Raine 2006; Ewing 2009). 
From a professional viewpoint lack of knowledge or skill may trigger a referral 
or alternatively may prevent a referral from occurring (Bestall et al. 2002; 
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Bradley et al. 2002; Aitken 2006). In earlier studies education and training for 
professionals were observed as facilitating referrals to palliative care services 
(Schim et al. 2000; Friedman et al. 2002). Therefore understanding what 
patients with Cystic Fibrosis think about palliative care and those caring for 
them will be instrumental in developing new models of care. 
2.7. Summary 
Cystic Fibrosis is a chronic life limiting illness that is rising in the United 
Kingdom. The average age at death remains at 29 years. Policy development 
since 1992 has mentioned patients with diseases other than cancer and their 
unmet needs. There is some existing confusion around the definition of 
supportive and palliative care that can result in uncertainty as to when it is 
appropriate to refer patients to a palliative care service. The definition of 
palliative care from the World Health Organisation, (WHO 2002) has been 
selected to underpin this research as it encompasses the ethos of access to 
palliative care at different times in the patient’s journey and supports patients 
having ongoing active treatment. Research is needed to explore the 
experiences and perceptions of patients with Cystic Fibrosis and of health 
care professionals regarding palliative care. The acceptability of palliative care 
as a service early in the Cystic Fibrosis patient’s disease trajectory needs to 
be explored. 
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CHAPTER 3: LITERATURE REVIEW 
 
3.1. Introduction 
 
The following chapter will explore and critically appraise existing evidence that 
has been used to support the development of the research questions. Whilst 
the researcher recognised that she had expert knowledge in palliative care 
she had limited knowledge of Cystic Fibrosis and therefore had limited pre 
conceived ideas regarding available literature. However it is recognised that 
most researchers will have some pre conceived ideas about the topic to 
studied (Bryant & Charmaz 2007). It was necessary to review the literature 
from both the patient and professional perspectives to see if any other study 
had researched views of palliative care from patients and health care 
professionals. Exploring the literature to identify if patients and health care 
professionals had previously been asked regarding timing of referral to 
palliative care was essential. 
 
The interest in this topic had arisen from clinical exposure to patients with 
Cystic Fibrosis. Reviewing the literature relating to symptom control issues for 
patients with Cystic Fibrosis was necessary to ensure the researcher’s 
observations were not circumstantial. In the clinical setting it had been 
observed that patients with Cystic Fibrosis were symptomatic from their 
disease and admitted to hospital for long periods of time but it was evident 
that palliative care was not always involved. In considering the way to 
approach the literature review it was necessary to consider the position of 
non- malignant diseases within palliative care and to consider barriers and 
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access to this group towards palliative care services. Literature relating to 
palliative care and Cystic Fibrosis was also reviewed. This chapter will discuss 
the literature found and will offer an overview of search strategies used and 
the tools used to guide analysis of the research literature. The chapter will end 
with a summary of the gaps in the literature and a rationale for research 
questions developed the methodology and the selected research design. 
 
3.2. Search Strategies 
Figure 2 illustrates the search strategy applied for this literature review. Key 
phrases and MeSH terms were applied to the searches. 
 
Figure 2. Searched Databases 
 
The search included accessing the databases listed in Figure 1. The 
databases were accessed from 1980-2014. The rationale for this was that 
palliative medicine did not become a sub speciality of medicine until 1986. 
Hand searched 
Palliative 
Medicine and 
Journal  of 
Cystic Fibrosis 
MEDLINE 
CINAHL 
BNI 
PROQUEST 
PSYCHOINFO 
COCHRANE 
DATABASE 
NATIONAL 
STRATEGIES  
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Search terms included: 
Cystic Fibrosis and Palliative Care 
Perceptions of Palliative care in Patients with Cystic Fibrosis 
Perceptions of Palliative care/Professionals Views 
Timing of referral to Palliative Care in Cystic Fibrosis/Non-Malignant Disease 
Non-Malignant disease and Palliative Care 
Barriers of referral to Palliative Care 
Integrated Care in Cystic Fibrosis and Palliative Care 
Models of care in Palliative Care and Cystic Fibrosis 
 
English language studies were included and review articles were included if 
Cystic Fibrosis was mentioned or had relevance to chronic chest conditions 
and involvement of palliative care. Searches were limited to adult references 
only and children and adolescent literature were excluded. Where there was 
no evidence available between Cystic Fibrosis and palliative care the 
researcher looked to other non-malignant conditions where patients with 
Cystic Fibrosis might have been included. Critical appraisal skills programme 
(CASP) questions were used to support appraisal of both the qualitative and 
quantitative research articles (CASP 2006). These tools were used as they 
support the appraisal of both qualitative and quantitative research studies.  
Figure 3 below illustrates the articles reviewed. 
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Figure 3. PRISMA Diagram of Articles Searched and Reviewed 
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3.3. Cystic Fibrosis and Palliative care 
The search between Cystic Fibrosis and palliative care was interesting as the 
majority of the articles sourced related to Cystic Fibrosis and end of life care. 
Although palliative care was inputted to the search engines in many instances 
end of life care was mentioned in the title and within the abstract. These 
articles have been included due to the understanding of palliative care and its 
definition as equating to death and dying. 
 
3.3.1. Timely introduction of Palliative care Services 
Within Cystic Fibrosis there has been limited exploration on the involvement of 
palliative care early in the patients’ disease. Studies looking at end of life care 
and advance care planning for adults with Cystic Fibrosis have been 
conducted (Mitchell et al. 2000; Chapman et al. 2005; Iles & Lowton 2008; 
Sawicki et al. 2008).  The study by Chapman et al. in 2005 focused on end of 
life care in adult patients with Cystic Fibrosis. Interviews were conducted with 
patients, staff and relatives. The results of this study indicated that the staff felt 
they had open communication about end of life care and with psychological 
input staff felt supported. The concern of patients being actively managed and 
receiving palliative care at the same time was raised by staff as an issue. The 
patient’s annual review was raised by professionals as being a place to 
discuss end of life care. The authors of this study conclude that providing 
active and palliative care at the same time can occur up to the time of the 
patient’s death. They suggest that this results in there being less need to bring 
in other sub specialities for end of life care although they did acknowledge that 
the palliative care team was available for advice on symptom control. The 
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article does not discuss how the palliative care team would become involved, 
whether it would be advisory to the Cystic Fibrosis team only, or if they would 
in fact review the patient. It is unclear if patients’ having a relationship with the 
palliative care team is of any significance. This study used interviews to collect 
data which is an acceptable way to explore sensitive areas such as end of life 
care which can cause unanticipated distress to participants. 
 
The study by Iles and Lowton in 2008 interviewed young people to try and 
establish when and who should address the concerns of people with Cystic 
Fibrosis. Patients internalising concerns about the future were identified as 
well as staff concerns regarding discussing the future with the patients. At no 
time was palliative care mentioned as a potential resource to help with 
patients or to support staff. This study highlights the limited input from 
palliative care services. 
 
A study by Lowton (2009) explored meanings of place of death for adults with 
Cystic Fibrosis. This research involved in depth interviews and analysis of 
letters received from parents of twenty seven adults who had died from Cystic 
Fibrosis during a four year period. Letters were forwarded by the Cystic 
Fibrosis Trust to 275 families; however the authors recognised that many 
families break all links with the Trust once someone has died which may have 
inhibited participation. Whilst the focus of this study related to end of life care 
interesting information is made available to the way in which palliative care 
was introduced to some families. In one instance a mother recounts how two 
hours before the death of her daughter she was asked to meet the palliative 
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care nurse for the first time. In this extract the opportunity to be reviewed by 
palliative care was declined by the participant as she chose not to meet a 
stranger at that time. This illustrates that introducing palliative care at this 
stage may be too late for families and may be the same for patients. There are 
no research studies available to clarify what patients perceive as a good time 
to be introduced to palliative care teams which signifies a gap in the literature 
in this area and supports further exploration of this topic. 
 
In 2000 Mitchell et al. research surveyed Cystic Fibrosis physicians to ask 
them about circumstances in which patients died the role of different 
caregivers and the extent to which palliative care was involved. Forty five 
completed questionnaires were returned, based on the numbers of deaths in 
the time period. The results from this study highlighted that in 25% of cases 
palliative care had never been discussed and in 40% of cases palliative care 
was not discussed until four weeks before the patient’s death. The research 
states that palliative care/comfort measures were applied in 76.3% but does 
not discuss if these measures were used as a result of integrated working or if 
this was initiated by the Cystic Fibrosis team. This study acknowledged the 
perception of palliative care being to stop unpleasant treatments in diseases 
such as AIDS or cancer and how patients with Cystic Fibrosis require active 
treatments up until the end of life. They also state that this can make it difficult 
for clinicians to identify the right time to transition from active to palliative 
treatment. This final statement does not recognise the option of Cystic 
Fibrosis and palliative care working together in an integrated model of care. It 
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is viewed as either one or the other and leaves the reader open to considering 
that palliative care would not concur with active treatments. 
 
The challenge of active and palliative care working together is discussed by 
Clisby et al. (2013). A qualitative explorative design was used and ten 
interviews with staff working in Cystic Fibrosis were undertaken to research 
the psychological impact of working with patients with Cystic Fibrosis at the 
end of life before transplant. One of two themes that emerged from the data 
analysis was the difficulty for staff in juggling both the acute and palliative side 
of care for patients. It was indicated that the relationship between the patient 
and the professional is deepened through this time especially when staff are 
working closely with the patients and that this may also be related to their 
similar ages. This article recognised the importance of relationships between 
those delivering and receiving care but was limited in terms of directing health 
care professionals regarding how best to overcome the issue of Cystic 
Fibrosis and palliative care working concurrently. 
 
3.3.2. Cystic Fibrosis and Symptom Control  
The literature review highlighted that patients with Cystic Fibrosis may benefit 
symptomatically from either direct support from a palliative care team or 
indirect through support and advice to Cystic Fibrosis professionals and that 
palliative care in Cystic Fibrosis is poorly understood (Bourke et al. 2009; 
Braithwaite et al. 2011). The study undertaken by Braithwaite involved 
interviewing staff, patients and families with the focus being on determining 
unmet needs in end of life care. Although within this study it was recognised 
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that patients lacked knowledge about palliative care services, there was no 
discussion about what type of service the patients would like. The questions to 
inform the interviews were focused towards end of life and did not include 
asking the patients about when would be a good time to consider being 
introduced to the palliative care team. Staff acknowledged that they felt a 
more integrated care system would be better for them and the patients but 
recognised that they felt there was an unwritten rule that they were expected 
to cope with patients’ needs without additional support. This study was limited 
by the lack of patient views on when would be best to meet the palliative care 
team. 
 
Pain, breathlessness and cough have been recognised as being significant 
symptom problems for patients with Cystic Fibrosis (Stenekes et al. 2009). In 
this study 123 participants completed a survey which produced a response 
rate of 64%. Of the participants who did respond 84% had pain, 64% reported 
breathlessness and 83% reported experiencing a cough. The survey 
questions did not include the stage of the patient’s illness but irrespective of 
this the level of symptom burden would suggest a review by a palliative care 
specialist for assessment of symptoms to be appropriate. This research 
contributes to the understanding of symptoms experienced by patients with 
Cystic Fibrosis but does not offer any suggestions in how to manage them. 
 
A further study by Kelemen et al. (2011) recognised that patients with Cystic 
Fibrosis have pain that can limit the ability to undergo important physiotherapy 
sessions. In this observational study of 73 patients the authors demonstrated 
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that mild pain was reported in 89% of patients with stable disease and 79% of 
patients who were having an exacerbation of their disease. There was no 
reference to how the pain would be managed other than a suggestion that 
clinicians may need to be forward thinking in initiating pain treatments to 
support the patients. There was no mention of working alongside other 
services such as pain or palliative care services. The literature also identified 
that due to the high prevalence of low bone mineral density in patients with 
Patients with Cystic Fibrosis were at an increased risk of bone fractures. Rib 
fractures have been recognised as occurring after coughing and can be 
difficult to gain symptom relief (Haworth et al. 1999; Conway et al. 2000; 
Jones et al. 2001; Dean et al. 2014). 
 
A literature review by Havermans et al. (2013) explored thirteen studies that 
commented on pain in Cystic Fibrosis. Abdominal and chest pains were stated 
as being the most frequently reported sites of pain. This review acknowledged 
that pain control for patients with Cystic Fibrosis has no guidelines and 
assessment tools are lacking to support treatment plans. The authors also 
recognised how inadequate pain control can limit active treatment for patients 
such as physiotherapy. There was no discussion relating to who outside of the 
Cystic Fibrosis team could perhaps help support both patients and staff with 
the development of guidelines and assessment tools. 
 
 In 2004, Festini et al. recognised following a survey of 239 adults with Cystic 
Fibrosis that there was a high prevalence of painful episodes with almost a 
third of patients having over ten episodes of pain. The most commonly 
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referred to pain was headache, gastro intestinal pain and backache. In this 
study just over 40% of patients asked for help from the Cystic Fibrosis 
specialists and 3.5% asked for help from their General Practitioner. In this 
paper there was no discussion of other services that could help with pain 
control. 
 
Self -reported physical and psychological symptom burden of adults with 
Cystic Fibrosis were studied by Sawicki et al. (2008). In this research patients 
were invited to complete a validated symptom burden tool to assess their 
symptoms. There were 303 respondents which offered an excellent 91% 
response rate. Within this study it was recognised that the most common 
symptoms were cough (94%), breathlessness (77%) and lack of energy 
(77%). In addition to this over half of the patients reported psychological 
issues such as worrying, feeling irritable and feeling sad. The introduction of a 
thorough symptom assessment is concluded in this paper however there was 
no plan as to how to integrate with other services. It was clear from this study 
that patients with Cystic Fibrosis do have symptom control needs that could 
be further optimised through support from palliative care. 
 
A study in Australia explored unmet need in patients with Cystic Fibrosis, their 
families and carers. In total there were forty two participants involved in 
interviews and focus groups. Following thematic analysis this study identified 
6 themes. It was recognised that maintaining hope and planning for death was 
a particular challenge for patients, families and staff (Braithwaite et al. 2011). 
The research did not consider if palliative care inhibited maintaining hope and 
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concluded that access to palliative care should increase but did not suggest 
how that should evolve. 
 
These findings are further supported by the responses of 27 bereaved care 
givers who were interviewed regarding symptoms and treatments. The 
interviews took place with the carers of family members who had died in the 
last 4 years. The actual time between death of the family member with Cystic 
Fibrosis and the interview is not discussed within the paper. This does bring 
into question the accuracy of recall in carers who may have experienced a 
death 4 years previously. Caregivers identified that breathlessness (100%), 
fatigue (96%), anorexia (85%), anxiety (74%); pain (67%) and cough (56%) 
were the most common symptoms experienced. They also expressed a belief 
that symptoms could not be controlled and were concerned about the role of 
opioids such as morphine and their potential for hastening death (Dellon et al. 
2010). 
 
3.4. Palliative care and Non-Malignant disease 
The literature relating to palliative care and non-malignant disease was 
reviewed to determine if Cystic Fibrosis was acknowledged within the 
literature and to ascertain how palliative care relates to other diseases other 
than cancer.  
 
A study by Murtagh et al. (2014) looked at how many people needed palliative 
care. The study design was founded on refinement of existing population 
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based methods based on the views of an expert panel and application and 
comparison of existing and refined approaches in an example dataset. This 
study looked at all deaths in England between the years 2006-2008. The 
results of this study demonstrated that an expert panel suggested changing 
practice and extending palliative care to include more non-malignant 
conditions and to also change working patterns in the hospital and home care. 
This study highlighted the need for palliative care to further develop services 
for patients with non-malignant disease but how to enable this was unclear. 
 
In determining how palliative care has evolved, a concept analysis 
demonstrated that there was progress towards embracing a definition of 
palliative care that involved being accessible at any stage of a patient’s illness 
(Meghani 2004). However it was also recognised that health care 
professionals continued to use the term palliative care interchangeably with 
end of life care. This research acknowledged that palliative care has evolved 
to include a wide range of different patient groups who that not are dying but 
that may require access to palliative care services to improve quality of life. 
The author discusses the importance of new models of care to meet the 
demands of patients and success would depend on integrating the changing 
face of Palliative care into daily practice. This research is significant in 
considering, for the researcher, what current models of care exist between 
Cystic Fibrosis and palliative care. 
 
Identifying the needs of patients with non-malignant disease was recognised 
in 1998 by Addington-Hall et al. In this study a secondary analysis of data 
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from a retrospective national population based interview survey was 
presented. A total of 3,696 patients were randomly chosen from death 
registration, this occurred late in 1990. The results of this study showed that 
for the patients who had died with a non-malignant disease 16.8% had 
reported symptoms similar to patients with cancer in the last year of life. It was 
estimated that caring for the projected numbers of patients with non-malignant 
disease who would need access to specialist palliative care would require an 
increased caseload of at least 79%. At this time it was recommended that 
clinicians working with patients with non-malignant disease should work 
closely with palliative care services, commissioners, including commissioners 
to develop services which meet the needs of patients for symptom control and 
psychosocial support. 
 
The unmet need of patients with non-malignant disease was described in a 
study by Currow et al. (2008). This was part of a wider randomised face to 
face population health survey over six years. Questions were asked of people 
bereaved in the previous five years when someone close to them had an 
expected death. These results illustrated that uptake of palliative care services 
was significantly lower in people with a non-malignant disease. This study also 
stated that carer responses had suggested that for other groups of patients 
poor uptake of palliative care services did not always equate with an unmet 
need in patients; however the same pattern did not follow in patients with non-
malignant disease. 
 
49 
 
Palliative care services for those with chronic lung disease were studied by 
Fitzsimons et al. (2007). In this study the aim was to explore palliative care 
needs of non-cancer patients from the patient’s perspective using a mixed 
methodology. Eighteen patients were interviewed, six of whom had a 
respiratory condition. The actual diagnosis was not stated for the participants 
and therefore the researcher is unable to determine if patients with Cystic 
Fibrosis were included. The results from this study confirmed that patients 
dying from chronic illnesses had many concerns and unmet clinical needs. 
The authors confirmed the need for an earlier implementation of palliative care 
for patients but did not highlight how to implement this. 
 
A further study examined the experience of patients with non-malignant 
disease (Mckechnie et al. 2010). This group of participants included patients 
with diseases representing respiratory, renal, cardiac, cancer and neurological 
disease. Thirteen patients were interviewed in this study with eight carers and 
five professionals. A limitation of this study is that of the patients only three 
had respiratory disease and did not state what disease type the patients had 
therefore the researcher is unable to say if Cystic Fibrosis was represented in 
this group. The results of this study demonstrated that patients with non-
malignant conditions make similar demands on professionals and their 
families/carers as those with a diagnosis of cancer. This study also focused on 
end of life care and did not discuss palliative care being accessed earlier for 
patients or integration with other services. 
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In identifying the need of patients with a non-malignant disease a literature 
review of 14 studies undertaken by Luddington et al. (2001) reported that 
patients had similar physical and psychosocial needs compared to patients 
with cancer. The focus of this review was on patients dying from non-
malignant diseases but acknowledged that achieving equity for this group of 
patients may be difficult to achieve as palliative care services may become 
overwhelmed by numbers of referrals. This review discussed a model of 
developing shared care between the primary and palliative care teams but no 
guidance as to how this should be offered. 
 
In the same year (2001) Edmonds et al. published a study comparing the 
palliative care needs of patients dying from chronic respiratory diseases and 
lung cancer. This study involved post bereavement structured interviews with 
informal carers of 449 lung cancer patients and 87 chronic lung disease 
patients. It is clear that the diagnosis of patients who had died did not include 
anyone with Cystic Fibrosis. However in the results of this study it was 
acknowledged that patients with chronic lung disease appeared to have 
experienced symptoms for a longer time period in comparison with the lung 
cancer group. It is interesting that Cystic Fibrosis as a group were not 
represented in this study perhaps indicating that the level of need had not yet 
been realised. 
 
A study by Pinnock et al. (2011) researched the views of patients living and 
dying with chronic obstructive airways disease. The study involved serial 
qualitative interviews with patients, carers and professionals. The results 
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highlighted that symptom burden was accepted as part of living with a lifelong 
condition. As in other studies this research equated to studying end of life care 
in this group of patients. In the conclusion the authors recognised that trying to 
find the correct time-point to introduce palliative care to these patients could 
be counter-productive as it may inhibit patients being able to access 
supportive and palliative care earlier in their disease trajectory. The authors 
suggest that patients should be assessed at key disease milestones such as 
after hospital admissions or after an exacerbation of their disease. This would 
then facilitate supportive and palliative care becoming more integrated with 
these patients. There was no discussion regarding patients with Cystic 
Fibrosis in this research, however some of the milestones are similar in terms 
of hospital admissions and episodes of exacerbation. 
 
Dharmasena & Forbes (2001) questioned if physicians would refer patients 
with non-malignant disease to specialist palliative care services. The design of 
this study was a quantitative methodology and involved a postal questionnaire 
being forwarded to one hundred physicians working in hospitals in Wales. The 
physicians were working as general physicians and represented areas in 
geriatrics, rheumatology, neurology and other sub specialities of medicine. 
The response rate was 78%. Of those, 94% stated that they would consider 
referring patients with non-malignant disease to palliative care services. Whilst 
patients with chest disease are mentioned, the researcher was unable to 
identify if patients with Cystic Fibrosis were part of this. The sample of chest 
physicians surveyed was one of the smallest in the group of clinicians 
questioned (n=6). The results of this study demonstrate that there was a 
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positive feeling towards palliative care being available to patients and 
demonstrated support for a shared care approach. This was viewed as being 
a way of addressing the concerns of general physicians regarding the lack of 
disease specific knowledge within palliative care teams and would lead to a 
more integrated approach to care. 
 
Interestingly in the same study physicians working with both stroke and 
dementia were less likely to refer to palliative care. The rationale for this 
related to either the long prognosis of these patients or that these conditions 
are without symptoms, despite previous evidence that has suggested this 
(Addington-Hall et al.1998). A further interesting point is that this research 
explored what the actual concerns of physicians would be in referring to 
palliative care services. The most reported concern related to what patients 
would think about being referred to palliative care. Further concerns included 
a difficulty defining when end of life care begins, that doctors would become 
de skilled in delivering palliative care, and a concern that patients would feel 
abandoned by the primary treating team. Patients’ perceptions were not 
included in this study. Although this study did not mention Cystic Fibrosis it is 
helpful in identifying what clinicians feel about palliative care being involved in 
patient’s care. Shared care was highlighted as being the way forward for 
patients with non-malignant diseases but there was no guidance on how this 
could be achieved. The respondents described the difficulty in identifying end 
of life care in their groups of patients which may reflect clinicians’ perceptions 
of palliative care as an end of life care service. 
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Within the literature relating to non-malignant disease and palliative care 
Cystic Fibrosis is rarely mentioned. In 2001 a specific book relating to 
palliative care and non-cancer patients was published. Within this book Cystic 
Fibrosis was discussed over just two sentences (Addington-Hall & Higginson 
2001). This may indicate the original lack of identified need in this speciality or 
perhaps may signify the complexities surrounding Cystic Fibrosis, because of 
the need for acute and palliative treatments running concurrently. 
 
A study in 2009 offered questionnaires to 210 respiratory physicians exploring 
access to palliative care services for those patients with life limiting lung 
disease other than cancer. Patients with Chronic Obstructive Pulmonary 
Disease, Cystic Fibrosis, Asbestos disease and Diffuse Parenchymal Disease 
did not have equitable access to palliative care services compared to those 
with a lung cancer diagnosis, thus demonstrating the inequality of access to 
palliative care services (Partridge et al. 2009). Patients with Cystic Fibrosis 
accounted for approximately one third of the patient group. It was also 
acknowledged that in the majority of respondents (87.9%) there was no formal 
process in the hospitals for identifying patients at end of life. In only 20% of 
responses was there recognition that practice would extend to those patients 
with non-cancer related lung issues. In terms of access to hospice and day 
care facilities only 23% reported easy access to these services.  Of the 210 
questionnaires distributed a 51% response rate was achieved (n=107) 
(Partridge et al. 2009). This article again suggested that limited access at the 
end of life for patients with Cystic Fibrosis is likely to indicate limited access to 
palliative care early in the patient’s disease. 
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The contribution that palliative care services can make towards the control of 
patient symptoms has been recognised within the literature (Edmonds et 
al.1998; Klepstad et al. 2005; Doyle et al. 2011). A study by Potter et al. 
(2003) identified, through a retrospective case note review, symptoms 
experienced by 400 patients over three clinical sites. In this study it was 
acknowledged that 95% of referrals were patients with a cancer diagnosis with 
symptoms of pain, anorexia, constipation, weakness and breathlessness. The 
remaining 5% with a non-malignant diagnosis were not discussed in this 
paper. It is unclear why these patients were not included in the findings. 
 
It was important to identify from the literature how non-malignant diseases and 
access to palliative care services are perceived. This was helpful in 
considering the development of the research questions. A qualitative study in 
2004 by Bestall et al. interviewed patients and professionals. This study 
focused on patients in the community and reported five key themes. These 
included reasons why patients are referred to palliative care, reasons why 
patients are not referred to palliative care, timeliness of referrals, and 
continuity of care and the use of referral criteria. This research highlighted that 
a lack of standardised triggers for referral to specialist palliative care was a 
limiting factor in the referral process. In this study the disease of the patient 
was not disclosed therefore the researcher was unable to determine if patients 
with cancer or non-malignant disease were interviewed. 
 
From a hospital perspective a study was conducted using methods of focus 
groups and interviews with doctors and nurses (Ewing et al. 2009). The aim 
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was to describe user and provider perspectives on delivering a specialist 
service in the hospital. This research identified that there was agreement 
between users and providers of the service that hospital palliative care teams 
should be providing expertise in managing difficult symptoms and complex 
psycho-social issues. There was, however, disagreement with respect to what 
ward staff may be able to offer and when specialist palliative care should 
become involved. Specialist palliative care teams were concerned that they 
would be asked to provide generalist palliative care in areas of care neglected 
by ward staff such as ‘basic psychological care’. The authors did not disclose 
if ward staff were competent and educated in the provision of palliative care. 
 
The views of patients were identified by MclIfatrick (2006). Patients were 
recruited from the general practitioner with diseases of the circulatory, 
respiratory or nervous systems. This study involved a mixed methods 
approach that incorporated semi structured interviews with patients and lay 
carers receiving palliative care services. Focus Groups were also conducted 
with health care professionals. The results of this study demonstrated that all 
participants recognised that there was inequity between palliative care service 
provision for patients with cancer and those with non-malignant disease. The 
patients that were selected for this study were from a range of different non-
malignant diseases but only one had respiratory issues related to pulmonary 
fibrosis. No patients with Cystic Fibrosis were included in this study. 
 
56 
 
3.5. Barriers of Referral to Palliative care in Non-Malignant Disease 
There are several possible reasons for variability in the pattern of referral to 
palliative care. These reasons include different patient needs, variability in the 
referrer and possible perceptions of patients towards a palliative care referral 
and ongoing care (O’Leary 2008; Broom et al. 2013). 
 
In a quantitative study, a survey forwarded to palliative care managers 
demonstrated that specialist palliative care services were limited for patients 
with non-malignant disease in some way (O’Leary 2008). The number of 
patients seen with a non-malignant disease at that time accounted for only 
7.2% of all referrals. In this study the top three barriers to referral of patients 
with a non-malignant disease included the unclear disease trajectory of other 
diseases, the difficulty in determining referral criteria and the lack of non-
malignant expertise of specialist palliative care. This study had a 100% 
response rate to the questionnaire but was conducted in Ireland only. 
 
In a similar way education and knowledge were also raised in heart disease 
where it was identified that barriers of referral to palliative care services 
included a limited knowledge of the heart failure specialists about palliative 
care and misperceptions (Kavalieratos et al. 2014). Difficulties in a lack of 
referral guidelines between heart failure and specialist palliative care were 
also identified. In this study the authors interviewed eighteen professionals to 
ascertain their perceived needs of patients with heart failure. Knowledge, 
attitudes and experiences of palliative care including timing of referral and 
what, perceived barriers were to referral to palliative care were generated as 
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concerns. However this study is limited because it focused on the 
perspectives of professionals only and did not ask patients what they would 
want from a specialist palliative care service. It was also limited in being 
representative of one area of the country only. 
 
Broom (2013) interviewed twenty medical professionals from general medicine 
and surgery. When asked about how they introduce palliative care the authors 
concluded that professional responses were mediated by the specialists' 
individual desires, subjective experiences and emotional characteristics. Each 
one had individual reasons regarding when and how they introduced palliative 
care. 
 
A further study interviewed community professionals to explore influencing 
factors of referring patients with non-malignant disease to specialist palliative 
care (Andrews & Seymour 2011). The results from nine interviews indicated 
that perception of palliative care involved an association with services for 
dying patients. Although this study occurred in the community it is important to 
consider this as patients with Cystic Fibrosis are often not referred to 
community palliative care services, therefore being aware of the views of the 
community teams are important in considering how services can be integrated 
in future developments. 
 
In 2014, Beernaert et al. conducted a qualitative study looking at identification 
of palliative care needs and potential barriers and facilitators of referrals to 
specialist palliative care. Focus groups were held with General Practitioners 
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(GPs) and community nurses. Eighteen interviews were conducted with 
patients. These patients were diagnosed with cancer, chronic obstructive 
airways disease, heart disease or dementia; no patients with Cystic Fibrosis 
were included. The perceived barrier in this study was patients’ perceptions of 
what to discuss with the family practitioner as they did not see them for 
anything other than acute care. The opportunity to build relationships with 
professionals was highlighted by the patients as being important. 
 
A systematic review demonstrated concerns in accessing specialist palliative 
care services (Ahmed et al. 2004). Out of 9921 articles identified, 40 met the 
inclusion criteria. From this it was established that several barriers resulted in 
problems in accessing palliative care. These included lack of knowledge about 
specialist palliative care and that standardised referral criteria needed to be 
developed. It was also recognised within this review that some patient groups 
did not receive a timey referral to palliative care; this was inclusive of patients 
with non-malignant disease. 
 
From a professional perspective a lack of knowledge or skill may trigger a 
referral or alternatively may prevent a referral from occurring to palliative care 
(Bestall et al. 2002; Bradley et al. 2002; Aitken 2006). In earlier studies 
education and training were observed as facilitating referrals to palliative care 
services (Friedman et al. 2002; Schim et al. 2000). Therefore understanding 
what patients with Cystic Fibrosis think about palliative care and those caring 
for them will be instrumental in developing new models of care. 
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In a retrospective review looking at predictors of access to a palliative care 
service it was identified that 499 out of 1453 (34%) patients had access to 
palliative care services. It was recognised that palliative care services can 
help in supporting those patients who have physical and psychological 
distress but as with other research it was highlighted that referral patterns 
should be more clearly defined.  This review did not suggest what these 
should be (Fadul et al. 2007). 
 
Other areas of non-malignant disease have acknowledged perceived barriers 
in referring to palliative care and have tried to identify ways of overcoming 
these (Gelfman et al. 2014). Whilst this article refers to heart failure some of 
the issues raised could be considered in the Cystic Fibrosis population. The 
authors identified that the lack of integrated care may be related to several 
factors. These factors include symptom control measures that involve active 
management such as intravenous antibiotics and it is stated that palliative 
care clinicians may not fully appreciate the benefits of such treatments. The 
authors also recognise the need for early palliative care to be considered but 
actually when this should happen is unclear. The timing of referral to palliative 
care and perceptions of clinicians both using and providing the service needs 
to be further explored. 
 
Hayle et al. in 2003 investigated the experiences of 8 patients receiving 
specialist palliative care. Patients were recruited from chronic obstructive 
airways disease and had to have been known to a palliative care service for at 
least one month if the patient was an out- patient, or one week if the patient 
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was an in- patient. The results demonstrated that patients felt the benefits of 
access to this service including reduced frequency of hospital admissions with 
improved physical and psychological symptoms. Patients acknowledged how 
discussions about palliative care caused distress which related to the 
historical perspective of palliative care and the association with death and 
dying. Interestingly over time patients views of palliative care changed and the 
patients associated palliative care with social inclusion. In searching the 
literature there was no such study for patients with Cystic Fibrosis.  
 
It is recognised that perceptions about palliative care can cause confusion and 
lead to misperceptions about the service. A study in 2010 by Melvin explored 
misperceptions of palliative care and interviewed patients and families. In this 
study thirteen patients were interviewed (one withdrew) and six family 
members. It is not clear from this research what the patients’ diagnoses were 
therefore the researcher was unable to determine if the patients had cancer or 
a non-malignant disease. The results of this study illustrated that patients had 
either no knowledge of palliative care or perceived that palliative care was a 
service that you had access to in the last 48-72 hours of life. The perception of 
palliative care being linked to end of life is not new and has been discussed in 
several other studies (Mitchell et al. 2000; Lowton 2009). 
3.6. Patient and Professional perceptions of Palliative care in Cystic 
Fibrosis. 
 
One article was identified relating to end of life care and this was reviewed in 
an attempt to try and determine views of the patients with Cystic Fibrosis 
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relating to any perception of palliative care (Braithwaite et al. 2011). In this 
qualitative study a combination of focus groups and interviews was used to 
explore experiences of patients, families and staff on end of life care. The 
results highlighted areas regarding lack of knowledge for the patients relating 
to palliative care. Actual perceptions of palliative care were not addressed in 
this article from a patient perspective. Although this article related to end of life 
care it did identify that knowledge of palliative care for patients’ required 
further exploration. 
 
Interestingly a qualitative study researched public awareness of perceptions of 
palliative care (MclIfatrick et al. 2014). This study was on the basis of an 
understanding that the public were confused regarding the meaning of 
palliative care. This study involved telephone interviews with 50 members of 
the public. The results from this study illustrated that the public’s knowledge of 
palliative care is determined by their own personal experiences. They 
indicated that palliative care related to care of people who were dying and 
maintaining comfort. There was no mention of access to palliative care earlier 
in the patient’s disease trajectory. 
 
There were no articles retrieved that had researched professionals working in 
Cystic Fibrosis and their perception of palliative care. The researcher did 
however look at a sample of articles to assess other professional perceptions 
of palliative care. In 2007 Pavlish & Ceronsky invited oncology nurses to be 
part of Focus Groups to explore their perceptions of palliative care. In total 33 
nurses participated in the study. The study concluded that the oncology nurse 
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understood the goals of palliative care however they recognised that the 
nurses considered palliative care being synonymous with end of life care.  
 
A further qualitative study (Davidson et al. 2003) explored perceptions of 
palliative care with cardio-respiratory nurses. This study involved 35 nurses 
and six focus groups participating in Focus Groups the results from which 
determined that some of the nurses felt that palliative care was only for cancer 
and dying patients. They also referred to the challenge of acute and palliative 
care being offered simultaneously. 
 
3.7. Integrated Care between Palliative Care and Cystic Fibrosis 
The literature referred to the fact that people who live with complex care 
needs receive health and social care services from multiple providers. This 
occurs across different care settings and suggests that with a more 
coordinated care system better planning of more cost-effective services will 
ensue to facilitate a more individualised service for the user with timely access 
to appropriate information (Shaw et al. 2011). In enabling integrated care it is 
hoped that barriers to services can be identified and where possible, solutions 
developed that currently prevent integrated working. 
It has been indicated that palliative care requires a different model of care due 
to an increasing demand for the service and concern over the number of 
current providers (Quill & Abernethy 2013). This article recognised that whilst 
patients should be assessed by a palliative care specialist the patient’s care 
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should be returned to the primary clinician when indicated by the clinicians 
involved. In this way there would be an increased availability of palliative care 
services to a wider population. 
Only one article retrieved addressed an integrated model of care between 
Cystic Fibrosis and palliative care (Bourke et al. 2009). This article’s title refers 
to an integrated model of palliative care to patients with Cystic Fibrosis. The 
retrospective review reported on 40 patients with Cystic Fibrosis who were 
referred to as terminal patients. Whilst the introduction to the article is 
suggestive of an integrated model in palliative care on further reading it clearly 
relates to end of life care. The article suggested a way of palliative care 
supporting the Cystic Fibrosis team to deliver palliative care which actually 
referred to end of life care. This study did not discuss the relationships of 
palliative care with patients or if any of the patients had been reviewed by 
palliative care earlier in the patient’s disease trajectory. The study indicated 
palliative care being involved when needed but as acknowledged in a previous 
study (Lowton 2009), families do not want palliative care being introduced 
towards the end of the patient’s life. The significance of this being that 
involving palliative care earlier in Cystic Fibrosis has not been researched. 
3.8. Summary 
In concluding this chapter the researcher has identified that there is a gap in 
the literature relating to palliative care and Cystic Fibrosis. Studies reviewed 
focused predominantly on end of life care. In undertaking the literature review, 
when the term palliative care was entered into the search engines, the articles 
generated identified end of life care literature suggesting the association of 
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palliative care with death and dying. There were no studies identified that 
offered perceptions of patients with Cystic Fibrosis towards palliative care. 
The literature has highlighted that patients with non-malignant disease have 
similar symptom control needs to those with cancer and that there is an 
apparent inequity of access to palliative care for patients with Cystic Fibrosis. 
 
Interestingly when palliative care was alluded to in the literature there was no 
discussion of how or when that actual referral would take place. This was 
highlighted in one of the qualitative articles when a mother commented on a 
palliative care nurse coming two hours before the death of her adult child 
(Lowton 2009). Clinicians recognised their hesitancy in referring to palliative 
care in case of causing upset to patients, however in patients with Cystic 
Fibrosis their views have not yet been explored. Access to palliative care 
services was not discussed in any of the articles relating to symptom control in 
patients with Cystic Fibrosis. 
 
In both qualitative and quantitative studies relating to non-malignant disease 
and palliative care, patients with Cystic Fibrosis were invariably not included 
within the sample of participants; however not all studies declared the 
diagnosis of the patients. Within the literature the focus of palliative care in 
Cystic Fibrosis equates with end of life care and there were no studies looking 
at early palliative care for patients with Cystic Fibrosis. It is also indicated that 
health care professionals equate palliative care with death and dying. Whilst 
integrated working is alluded to in a limited number of articles there are no 
recommendations as to how this could evolve earlier in the patient’s disease 
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trajectory. The literature critiqued involved both qualitative and quantitative 
studies, there were limited numbers of mixed methods studies and none 
looking at early palliative care in patients with Cystic Fibrosis. The majority of 
methods used involved focus groups and interviews. The literature relates to 
sensitive topics of palliative care, end of life care and bereavement therefore 
the use of interviews and focus groups are appropriate. The focus of the 
studies relate to end of life care and whilst issues such as symptom control 
and inequity of services are indicated there are limited solutions offered to 
support the development of future services. 
 
The literature review highlighted gaps in the following areas: 
1. Although study titles included palliative care, the studies actually 
related to end of life care 
2. There were no studies identified where early palliative care had been 
explored in patients with Cystic Fibrosis or health care professionals 
caring for patients with Cystic Fibrosis. 
3. There was a limited number of research articles offering an integrated 
model of care between Cystic Fibrosis and palliative care.  
4. There was a limited number of mixed methods studies used and none 
exploring early palliative care in patients with Cystic Fibrosis. 
Palliative care as a service is one which should be available to patients at all 
stages of their disease trajectory (WHO 2002). The literature review has 
highlighted barriers to such referrals in specialities of cancer and other non- 
malignant conditions. It is evident that patients with Cystic Fibrosis are living 
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longer but this is with a significant symptom burden for which there is some 
perception was that these symptoms could not be controlled (Stenekes et al. 
2009; Keleman et al. 2011; Havermans et al. 2013). The role of palliative care 
reviewing this group of patients early in their disease trajectory for symptom 
control has not been explored. Exploring what both patients with Cystic 
Fibrosis and health care professionals caring for them understand about 
palliative care will help in determining when it would be a good time to 
introduce palliative care services, resulting in the potential to develop new 
models of integrated working between the two specialities. As a result of the 
literature review, research questions have been developed with an overall aim 
and are illustrated in Table 5. 
Table 5. Research Aim and Questions 
Research Aim 
1. To explore the experiences and perceptions of patients with Cystic 
Fibrosis and staff regarding palliative care and the acceptability of this 
as a service early in the patient’s disease trajectory.  
Research Questions 
1. What are patients with Cystic Fibrosis and health care professionals’ 
experiences and perceptions of palliative care? 
2. What are the barriers and facilitators of a palliative care referral in 
Cystic Fibrosis? 
3. Are the services for the provision of palliative care within Cystic 
Fibrosis integrated as part of a multi-disciplinary team? 
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CHAPTER 4: RESEARCH METHODOLOGY  
4.1. Introduction 
This chapter will begin by considering the purpose of this study and will 
discuss the research design used. In undertaking a literature review the need 
for this study was defined and in order to answer the research questions a 
mixed methods study has been adopted. The following chapter will address 
the understanding of qualitative and quantitative research, and will reflect on 
the researcher’s epistemological standing. Within this section, a rationale will 
be given behind the choice of a mixed methods study and clarify the type of 
mixed methods study used. The following chapter will also explore the 
concept of integrated care, the underpinning theoretical framework for the 
current study. The chapter will close with a summary of the preceding 
discussion. 
 
4.2. The Epistemological Position of the Researcher. 
It is suggested that before any research can take place the researcher should 
consider their own philosophical beliefs about how they see the world 
(Packford & Polifroni 1992). In previous accounts Parahoo (1997) recognised 
that nurses have beliefs and values that are consistent with a qualitative 
paradigm and that this is the chosen method of many nursing studies. In 
taking this further Paley (2001) proposed two reasons for this, either nurses 
have acquired the assumptions associated with the qualitative paradigm 
through professional socialisation or, he believes,  they have a temperament 
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that attracted them into a profession where caring is paramount and suggests 
that this sits easier with a qualitative paradigm. 
 
The researcher reflected on her own philosophical and ontological 
perspectives and it became clear that she sits within the constructivism 
paradigm as she believes that human beings construct their social reality 
where participants and researchers will construct meaning together (Holloway 
& Wheeler 2010). It is clear from reflections that the paradigm of 
constructivism, whereby individuals construct their own reality resulting in their 
being multiple interpretations, sits comfortably with the researcher (Glaser 
2002). In considering the development of the research questions it was 
necessary to address the most appropriate way to answer them. Following 
discussions and further research into other methodologies the researcher 
decided the use of mixed methods was the only way to address the research 
questions completely. This would entail considering both qualitative and 
quantitative paradigms. Figure 4 below illustrates a diagrammatic 
representation of the process in developing the eventual research 
methodology. The actual process included consideration of the researcher’s 
clinical experience on the topic to be researched as well as the lack of 
evidence available in the literature proving that there was a gap in this area of 
research. Being aware of the researchers own beliefs, and values as well as 
discussion with research supervisors, was important in establishing the final 
methodology. Whilst the researcher does sit within a qualitative research 
paradigm it was clear that in order to answer the research questions, mixed 
methods would be the most appropriate methodology to use. 
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Figure 4. The Development Cycle of the Research Methodology 
 
 
 
4.3. Position of the Researcher within the Study 
The literature reminds us that researchers choose an area to research usually 
out of interest in the topic (Holloway & Wheeler 2010). In this study the 
researcher became interested in the integration between palliative care and 
patients with Cystic Fibrosis as a result of being clinically exposed to this area. 
It is important at the beginning of the research to be transparent about pre-
existing assumptions regarding the topic to be studied. The researcher 
recognised that her experience spanned more than twenty-five years in 
palliative care and with that came views on palliative care both personal and 
professional. The researcher has a passion for palliative care but also 
acknowledged that she had limited knowledge of palliative care and Cystic 
Fibrosis. Clinical experience of the researcher helped her identify that the 
Clinical Experience 
Development of Research 
Questions 
Literature Review 
Consideration of personal 
philosophical perspective 
Discussion wih supervisors 
Mixed Methods 
Methodology 
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referral process was not always predictable and thus, she considered this 
warranted further investigation. The researcher was known to one of the 
research sites but was not delivering the clinical services or directly managing 
any members of staff. Existing assumptions were acknowledged through 
reflecting on the literature and after each part of the data collection. A copy of 
part of the reflection can be found in Appendix 1. 
 
4.4. The Purpose of the Research 
As a result of reconfiguration of specialist palliative care services in a tertiary 
referral cancer centre, the researcher was asked to be involved in the 
development of services at a local tertiary heart and lung hospital. In 
undertaking a clinical review of this group of patients as requested by the 
Cystic Fibrosis team it became apparent that patients with Cystic Fibrosis had 
palliative care needs but that the palliative care service was called in only at 
the end of the patient’s life, if at all. Based on this clinical experience the 
researcher became intrigued with what appeared to be a palliative care 
service that delivered end of life care on an as required basis only. As 
discussed in Chapter 3 a critique of the existing literature highlighted areas for 
further research in palliative care and Cystic Fibrosis. 
 
4.5. An Overview of Quantitative and Qualitative Paradigms and the 
Position of Mixed Methods Research 
 
Research methodology defines the way in which a research project is to be 
undertaken. It also establishes the methods to be used within such 
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methodology (Neuman 2009).  In developing the methodology it was important 
for the researcher to consider the research questions and the advantages and 
disadvantages of both qualitative and quantitative research. A useful table of 
advantages and limitations of qualitative and quantitative research can be 
viewed in Table 6 below. 
 
Table 6. Advantages and Limitations of Qualitative and Quantitative Research 
(Creswell 2014 pp.5). 
Qualitative research 
Advantages Disadvantages 
Provides detailed perspectives of a 
few people 
 
Captures the voice of participants 
 
Allows participants’ experiences to be 
understood in context 
 
Is based on the views of the 
participants not of the researcher 
 
Appeals to people’s enjoyment of 
stories 
Has limited generalisability 
 
Provides only soft data (not hard data 
such as numbers) 
 
Studies few people 
 
Is highly subjective 
 
Minimise use of researcher’s 
expertise due to reliance on 
participants 
 
Quantitative Research 
Advantages Disadvantages 
Draws conclusions from large 
numbers of people 
 
Analyse data efficiently 
 
Investigates relationships within data 
 
Examines probable causes and 
effects 
 
Controls bias 
 
Appeals to people’s preference for 
numbers 
It is impersonal, dry 
 
Does not record the words of 
participants 
 
Provides limited understanding of the 
context of the participants 
 
Is largely researcher driven 
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Starting from the 19th century the traditional approach to social and 
behavioural research was quantitative which had its routes in the positivist and 
early natural science model (Holloway & Wheeler 2010). Positivism was 
described as “an” approach to science based on a belief that attempts to 
present an objective picture of the world” (Paley 2001). It is also considered 
that this research has a quest for objectivity and suggests that distance 
between the researcher and those being studied can be avoided. In contrast 
qualitative research is described as a form of social inquiry that focuses on the 
ways in which people make sense of their experiences and the world in which 
they live (Neuman 2009).  
 
Researchers use this methodology to explore behaviour and feelings and 
experiences of people. It is suggested that the basis of this approach sits in 
the interpretive approach to social reality and in the lived experiences of 
human beings (Holloway & Wheeler 2010). Mixed methods research has been 
referred to as the third methodological movement following first quantitative 
research and then qualitative research (Creswell & Plano Clark 2011). Health 
care managers are placing greater emphasis on clinicians being able to prove 
their impact on the delivery of the care they provide (Gaziano et al. 2007). 
Mixed methods research has been recognised as being able to meet the 
needs of health care professionals in undertaking this complex research 
(Andrew & Halcomb 2009).  
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4.6. Mixed Methods Research 
A mixed methods study was selected to investigate early palliative care in the 
adult Cystic Fibrosis population. Mixed methods studies have been defined 
as: combining qualitative and quantitative approaches into the research 
methodology of a single study or multi-phased study, and integrates or 
connects data at some point of the research process (Andrew & Halcomb 
2009; Tashakkori & Teddlie 2010). The use of both qualitative and quantitative 
design can be useful to both answering the research question and  minimising 
research bias as well as enhancing the validity of the results by testing the 
consistency of findings obtained by different methods (Bowling 2009). It has 
also been advocated that the nature of investigating complex health care 
issues can benefit from a more flexible mixed methods approach (O’Cathain 
et al. 2007; Bowling 2009; Holloway & Wheeler 2010). Mixed methods are 
defined as an approach in which the researcher collects, analyses, and 
integrates both quantitative and qualitative data in a single study or in multiple 
studies in a sustained programme of inquiry. Thus mixed methodology sits 
well within the multi-phase model of complex intervention development and 
evaluation. This is particularly important for the researcher in considering the 
sensitivity of the subject to be researched and the issue of Patients with Cystic 
Fibrosis being a relatively small group living with a chronic complex life limiting 
illness diagnosed primarily from birth. 
The idea of mixing qualitative and quantitative methods has stimulated much 
interest and debate. The concept of mixing data has been used for 
approximately forty years (Andrew & Halcomb 2009). Researchers 
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increasingly have used mixed methods to expand the scope of, and deepen 
their understanding of particular topics. It is suggested that the complexity of 
human phenomena mandates more complex research designs to capture 
them and it is argued that a mixed methods methodology can address this 
issue (Swanson, 1992; Sandelowski, 1995; Greene & Caracelli, 1997; 
Creswell 2003; Fleming 2007; Tashakkori & Teddlie, 2010). 
Mixed methods are particularly valuable in palliative care research, where the 
majority of interventions are complex, and the process of evaluation and 
identification of suitable outcomes is particularly challenging (Patterson et al. 
2009; Cawley et al. 2011). Qualitative data will yield information about 
subjective experiences, understandings, effects and impacts, and can 
therefore augment quantitative data in hypothesis generation, defining 
interventions, questionnaire or instrument design (Farquar et al. 2011). 
It is suggested that it is important to be clear about why a mixed method 
design is being used (Creswell & Plano Clark 2011). There are at least sixteen 
reasons why a researcher may consider applying a mixed method design and 
the literature acknowledges that often researchers are alluding a myriad of 
reasons as to why mixed methods are being used Bryman (2008). There are 
several reasons why on this occasion a mixed methods design is being used. 
The reasons can be viewed in Table 7. 
The research questions in this study will be best answered using a mixed 
methods methodology. This will allow the researcher to not only understand 
the perceptions of patients and professionals about palliative care but will also 
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allow the researcher to better understand how care is currently delivered 
between palliative care and Cystic Fibrosis services nationally. 
Table 7. Reasons for selecting Mixed Methods (Bryman 2008) 
              Reason                                                     Rationale 
Completeness The researcher can bring together a more 
comprehensive account of the area of inquiry 
Instrument 
development 
Refers to the context in which qualitative  research 
is employed to develop questionnaires 
Credibility Employing both approaches enhances the 
integrity of the findings 
 
4.7. The Research Design 
Researchers are advised that there are several key questions that must be 
considered before deciding on a mixed methods study (Creswell 2003). They 
include in what sequence will the qualitative and quantitative data collection 
be implemented, secondly what relative priority will be given to the data 
collection and analysis, at what stage of the research will the data be 
integrated. Each of these questions will now be considered to demonstrate 
transparency to the choice of the research method. 
 
The evidence regarding mixed methods suggests that both qualitative and 
quantitative data can be collected either sequentially or simultaneously 
(Andrew & Halcomb 2009; Creswell & Plano Clark 2011). The sequence 
should be informed by the research questions to be answered. The researcher 
identified that the data in this study would be collected sequentially in order to 
answer the research questions. 
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The literature suggests determining the priority of the quantitative and 
qualitative strands of the research (Creswell & Plano Clark 2011). There are 
three possible options for a mixed methods study. The options are either to 
treat the different strands equally or for the study to use a quantitative priority 
or a qualitative priority. For the purposes of this research each strand has 
equal priority as all strands contribute to answering the research questions. 
 
Integration of the data can occur at various stages of the research process, 
either during data collection, data analysis and/or interpretation of the data 
(Andrew & Halcomb 2009). There are several points when mixing of the 
different strands can occur. In this research project the mixing of the methods 
occurred through the data collection period. This is referred to as using a 
strategy of connecting where the results of one strand of the research builds 
to the collection of the next form of data (Cresswell & Clark 2011). The so 
called connection occurs by using the results from the first strand to form the 
collection data in the second strand and subsequently for the third strand 
(Cresswell & Clark). This is done to specify research questions, select 
participants or to develop data collection tools (Creswell & Plano Clark 2011). 
The type of design used in the study is described as an exploratory sequential 
design. 
 
4.7.1. Introduction to the Qualitative and Quantitative Methods 
The qualitative arm of the study was guided by the principles of Grounded 
Theory analysis using one Focus Group in Phase 1 and semi structured one 
to one interviews in phase 3. The quantitative data were collected following a 
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short survey of twenty one questions in Phase 2. The following table adapted 
from Crotty (1998) demonstrates the research methods for each phase. These 
will be discussed further in the methods section. 
 
Table 8. Research Methods (Adapted from Crotty 1998) 
 Methodology Methods Analysis 
Qualitative Principles of 
Grounded Theory 
Phase 1 Focus 
Group 
Phase 3 One to 
one semi 
structured 
interviews 
Constant 
comparison and 
thematic analysis 
Quantitative Survey Research Phase 2 
Questionnaires  
emailed directly to 
leads for palliative 
care and Cystic 
Fibrosis   (n=46) 
Descriptive 
analysis using 
SPSS version 21 
 
4.7.2. Grounded Theory Approach 
The principles of a constructivist Grounded Theory approach have been 
applied to analyse the qualitative data generated from this study. First 
developed by Glaser & Strauss in 1967, this theoretical approach was situated 
towards an objective perspective that is affiliated more towards positivist 
traditions. Over the years the methodology has been developed and 
constructivist Grounded Theory espoused by Charmaz (2014), more recently 
underpins the epistemological paradigm of Phase 1 and 3 of this study. 
Grounded Theory has been recognised as focusing on the development of 
theory from the ground up as well as identifying that Grounded Theory 
methods are of particular significance within a mixed method research design 
(Birks & Mills 2011). The place of Grounded Theory is recognised within 
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mixed methods research as an approach to ensure rigorous management of 
qualitative elements of the research (Cagle & Wells 2008; Birks & Mills 2011). 
 
Grounded Theory is referred to in the literature in the late 1960’s following the 
publication of research relating to death and dying by Glaser & Strauss 
(1967). Glaser was recognised as having a strong quantitative background as 
opposed to the qualitative background of Strauss. Following this research they 
proceeded to equip researchers with methodological strategies that could be 
adapted to further research in other areas as well as proposing that 
systematic qualitative analysis had its own reasoning and could create theory 
(Charmaz 2014). The literature also recognised that theorists of Grounded 
Theory who come from a different view point all begin with inductive logic and 
subject the data to rigorous comparative analysis and to develop theoretical 
analysis that will inform future practice (Charmaz 2014). 
 
The Grounded Theory method seeks through focus groups and interviews to 
discover concepts and to construct theories originating from the data. Authors 
have suggested that generating a theory about a topic is effective when there 
is little known about a subject (Crotty 1998; Denzin & Lincoln 2000). Whilst 
there is much known about the construct of palliative care there is little known 
about Cystic Fibrosis and palliative care regarding the views and perceptions 
of patients and staff earlier in the patient’s disease trajectory. 
 
Constructivist is the term used to acknowledge the subjectivity and the 
researcher’s involvement in the construction and interpretation of data 
79 
 
gathered (Charmaz 2014). If researchers believe that social reality is 
constructed then the researcher’s position perspectives and interactions 
should be taken in to account (Charmaz 2014). It is also suggested that this 
approach does not aim to recognise truth but does identify the true reality or 
views of the participants’ experience (Charmaz 2014). This perspective of 
Charmaz (2014) recognises that the main issue is in the identification and 
analysis of data through the relationship with the participants and through the 
shared experience. The researcher recognised existing paradigms related to 
Grounded Theory (Glaser & Strauss 1967; Strauss & Corbin 1990 & Charmaz 
2000) but identified that the constructivist approach was the one best suited to 
the research and the epistemological stance of the researcher. 
 
In Grounded Theory the data collection and analysis occurs simultaneously; a 
process that the researcher adhered to in this study. Initially the sampling was 
taken from a purposive sample and subsequently transitioned to theoretical 
sampling based on the clues the researcher gained from the data being 
generated (Birks & Mills 2011). 
 
4.7.3. Criteria for Rigour in the Qualitative Phase 
In qualitative research the term trustworthiness is more often referred to than 
validity and reliability (Holloway & Wheeler 2010). Researchers make 
judgements of trustworthiness possible through developing dependability, 
credibility, transferability and confirmability. It is proposed that of these, 
credibility is the most important (Guba & Lincoln 1985). In this study rigour 
was achieved through the following: 
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Dependability: findings from the study should be consistent and accurate and 
readers should be able evaluate the analysis through following the decision 
making process of the researcher as well as having a clear audit trail 
demonstrating how conclusions were reached. Each phase of this study was 
described in detail and the development of categories were discussed with 
peers and supervisors. A clear plan of the study is available in Figure 5, 
Chapter 4. 
 
Credibility: relates to the findings being compatible with the perceptions of 
the people being studied. The experience of the researcher within the field, 
peer examination and reflexivity are all considered within credibility. 
The researcher had over twenty-five years experience in the field of palliative 
care and throughout the study used a reflective journal. The interviews and 
the focus group findings were discussed at length with supervisors and results 
from the data were discussed at research meetings with peers and at regular 
meetings with supervisors. 
 
Transferability: relates to the findings in one context being transferred to 
similar situations or participants. The ability to transfer concepts from this 
study could be helpful in applying to other patients with non-malignant 
conditions where the evidence for early palliative care is under researched. 
 
Confirmability: the researcher is judged by the way in which the findings and 
conclusions achieve their aim and are not the result of the researcher’s prior 
assumptions. This was achieved through a clear decision trail relating to the 
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development of themes and categories previously discussed with peers and 
supervisors. Extracts from the researcher’s reflective journal were discussed 
at monthly supervision sessions and an extract is available in Appendix 1. 
 
4.7.4. The Quantitative Method 
The following definition, taken from Aliaga & Gunderson (2002), describes 
quantitative research methods as explaining occurrences by collecting 
numerical data that are analysed using mathematically based methods. In 
order to answer the research questions it was important to try and establish 
what the national picture was for completeness of the study in terms of referral 
processes between the two services and perceptions of such referrals. 
Surveys are used to measure certain topics and to look at the behaviour and 
attitudes of the population of interest (Bowling 2009). This type of survey is 
referred to as a descriptive survey and descriptive measures will be calculated 
(Bowling 2009). This type of survey is also referred to as a cross sectional 
survey because the data are collected from the population at one point in time. 
The need to ensure that the questions for the survey were not based on 
assumptions of the researcher is an important factor in the construction of the 
questionnaire (De Vaus 2002). The questions for the survey were based on 
findings raised by experts in both Cystic Fibrosis and palliative care from the 
focus group in Phase 1. The development of the questionnaire and the 
conduct of using the survey are described in the methods section. 
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4.7.5. Decisions for Analysing and Interpreting Data in Mixed Methods 
Research 
 
In the exploratory sequential design the data analysis is clearer as the 
qualitative and quantitative elements are analysed in different phases and are 
not merged (Creswell & Plano Clark 2011). The use of a data analysis 
procedure can help in the process of ensuring rigorous data analysis 
procedures for both quantitative and qualitative analysis. Table 9 illustrates 
the mixed methods data analysis applied and the areas in bold illustrate the 
process taken within this study. 
 
Interpreting connected results can also be referred to as drawing conclusions 
or drawing inferences (Creswell & Plano Clark 2011). Although inferences can 
be described after each phase of the research the meta-inferences should be 
concluded later in the study. For the researcher in considering the exploratory 
sequential design the meta- inferences relate to whether the additional strands 
of the study provide a more generalized understanding of the problem rather 
than using a single data set alone (Creswell & Plano Clark 2009). This will be 
further discussed in Chapter 6 in the data analysis. 
 
 
 
 
 
 
83 
 
Table 9. Mixed Method Data Analysis (Adapted from Creswell & Plano Clark 
2011). 
Type of design  Type of data analysis                          Data analysis steps taken in Study                         
Decision 
Exploratory 
 
 
 
Connected 
data:  each 
phase 
informed the 
next phase 
1.Collect the qualitative data 
 
2.Analyse the data using the 
most appropriate method 
Based on the principles of 
Grounded Theory 
 
3 Design the quantitative phase 
based on results 
Questionnaire tool developed 
 
4 Collect the quantitative data 
Questionnaire approved by 
ethics and forwarded to 
specialist teams in research 
centres 
 
5 Analyse the quantitative data 
based on the most appropriate 
approach 
SPSS Version 21 used 
descriptive statistics 
generated 
 
6. Develop the interview topic 
guide 
Interview topic guide 
developed 
 
7. Conduct the interviews 
17 interviews conducted 
 
8. Analyse the interviews 
Interviews analysed using the 
principles of Grounded 
Theory 
 
9. Interpret how the connected 
results answer the research 
questions 
 
Interpretation of results 
 
 
Decide what data can 
inform the quantitative 
phase 
 
 
 
 
 
 
 
 
 
 
Decide how the 
qualitative and 
quantitative results 
build or expand on the 
findings 
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4.7.6. Validity in Mixed Methods Research 
The term validity in mixed methods research is viewed as one of the most 
important issues in the research project (Creswell & Plano Clark 2011). 
Validity is frequently related to the design and the interpretation stage of the 
design. Onwuegbuzie & Johnson (2006) discuss issues of validity preferring to 
label it legitimisation when they refer to the design, the data analysis and 
interpretation of the study.  It is suggested that validity relates to employing 
strategies that address potential issues in data collection, analysis and 
interpretation that might compromise the connecting of the data and the 
conclusions drawn from this (Creswell & Plano Clark 2011). The researcher 
considered the issues they attribute to potential issues of connecting data. 
The following table describes the issues of validity as suggested by Creswell 
& Plano Clark (2011). The table below (Table 10) includes the way in which 
threats to validity were minimised in this study based on these principles. The 
column on the right hand side of this table has text written in bold to 
demonstrate ways in which the threat to validity was minimised. 
 
Figure 5 illustrates the actual final research design of the study and how each 
phase and method applied would answer the research questions 
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Table 10. Strategies for minimising threat to Validity (Creswell & Plano Clark 2011) 
Potential Validity Threats Using Mixed Methods Strategies for Minimising Threat 
      Data Collection Issues 
Selecting inappropriate individuals for both qualitative and 
quantitative design 
Select same individuals to follow up the findings. Use different individuals when 
building new components 
Research: different appropriate individuals selected in each phase  
Using inappropriate sample sizes Larger size for the quantitative arm 
Research: Sample size larger in the quantitative arm 
Not designing an instrument with sound psychometric properties Using appropriate procedures for validating the instrument 
Research: Survey tool piloted by experts in developmental phase; approved by 
ethics 
Data Analysis Issues 
Choosing weak quantitative results to follow up with qualitative Choose the issues that need further follow up 
Research: each phase informed next i.e. Results from questionnaire informed 
semi structured interviews 
Choosing weak qualitative findings to follow up on quantitatively Use major themes for the qualitative follow up 
Research: Main theme from focus group informed some of the questions of the 
survey 
Including qualitative data in an intervention trial without a clear 
intent of its purpose 
Specify how each form of the qualitative data be used in the study 
Research: each phase of the data was placed to answer the research questions 
Interpretation Issues 
Comparing the 2 data sets when they are meant to build rather 
than merge 
Interpret the data to answer the research questions 
Research: each dataset interpreted separately 
Interpreting the databases in reverse order Order the interpretation to fit the design 
Research: data interpreted as the research design stated 
Not taking full advantage of the potential of before or after 
qualitative findings for an interventional trial 
Consider the reasons for using qualitative data in an interventional trial 
Research: Not Applicable 
Not relating the stages or projects in a multiphase study to each 
other 
Consider how a problem, a theory or a lens might be an overarching way to connect 
the stages or projects 
Research: All stages built upon next phase of the study 
Irreconcilable differences among different researchers on a team Researchers on a team need to agree to the overall project objectives and to negotiate 
methodological differences 
Research: Researcher and supervisors in agreement with study design 
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Figure 5. Diagrammatic representation of research 
Phase 1 (Developmental: Qualitative) 
 
 
Phase 2 (Quantitative) 
  
1. Will help answer research questions 
2 .What are the barriers and facilitators to staff making a referral to Palliative care 
3 How are services integrated between CF and PC? 
Phase 3 (Qualitative) 
 
 
 
 
 
 
 
 
Will answer second part of question 1 regarding patient perception and experiences of palliative care 
Will also add in depth knowledge to question 2 regarding barriers and facilitators and  
question 3 in determining further how services are integrated between CF and PC,  
following which interpretation of the data will take place 
 
 
Ethics  
approval 
Focus group to identify 
domains and questions 
for survey questionnaire 
and will offer insight and 
answer part of research 
question 1 
Participants recruited from 
the 2 research sites 
participating in the study 
Development of 
questionnaire and 
Pilot study of 
questionnaire  
 
 
23 UK Cystic Fibrosis 
centres contacted and 
respective Palliative care 
providers identified 
Survey forwarded to Cystic Fibrosis team and palliative 
care teams 
Interviews in specialist Cystic Fibrosis centre local, 
nurses, physiotherapists, doctors from both 
specialities (up to 8)  
 
Interviews in specialist Cystic Fibrosis centre outside 
London, nurses, physiotherapists, doctors from both 
specialities (up to 8) 
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4.8. Summary 
This chapter has stated the epistemological position of the researcher and 
explored the choice of a mixed methods study. The design of the study has 
been described and detailed information regarding validity and data analysis 
has been presented. The following section will address the methods used to 
collect the data in the three phases of the study. 
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CHAPTER 5: RESEARCH METHODS 
 
5.1 Introduction 
The methods to be discussed will include the focus group that was used to 
gather data in Phase 1, a survey in Phase 2 and semi structured interviews 
that were used in phase 3. The rationale for the choice of methods was based 
on the methodology chosen and research questions.  The aims of the study 
and research questions are illustrated in Table 11 below.  
 
Table 11.  Research Aim and Questions 
Research Aim 
1. To explore the experiences and perceptions of patients with Cystic 
Fibrosis and staff regarding palliative care and the acceptability of this 
as a service early in the patient’s disease trajectory  
Research Questions 
1. What are patients with Cystic Fibrosis and health care professionals’ 
experiences and perceptions of palliative care? 
2. What are the barriers and facilitators of a palliative care referral in 
Cystic Fibrosis? 
3. Are the services for the provision of palliative care within Cystic 
Fibrosis integrated as part of an multi-disciplinary team 
 
The three phases of the study will be discussed separately to fully understand 
necessary considerations in each of the different areas. The chapter will 
conclude with an overview of ethical considerations throughout the study and 
a risk assessment. The chapter commences with illustrating the inclusion and 
exclusion criteria of the participants for the focus group, the survey and the 
interviews in Table 12 below. 
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Table 12. Inclusion/Exclusion Criteria 
Phase 1 Focus Group 
Inclusion Exclusion 
Experts in both Cystic Fibrosis   and 
Palliative care. (working in senior 
positions within speciality and working 
in specialist centres, more than 12 
months  
Professionals not working in senior 
positions within speciality 
 
Professionals not working in specialist 
centres 
Phase 2 Survey 
All adult specialist Cystic Fibrosis   
teams listed on the Cystic Fibrosis   
website 2012 (Lead clinician 
identified) 
 
All hospital palliative care teams 
associated with Cystic Fibrosis   
teams identified on the Cystic Fibrosis   
website (Lead clinician identified) 
Teams not listed on the Cystic 
Fibrosis   website 
Phase 3 Interviews  
 Adult patients with a confirmed 
diagnosis of Cystic Fibrosis   at any 
stage of illness (aged 18 or over) 
 
 Patients who understand English 
 
 Patient has mental capacity to 
participate (assessed by the Cystic 
Fibrosis team) 
 
 Any trained clinical member of staff 
involved in the care of a patient with 
Cystic Fibrosis  /Palliative care 
working at the specialist centre who 
has: 
 
 worked with Cystic Fibrosis/Palliative 
care patients for more than 12 
months 
 
 who spend more than 20% of their 
working day caring for patients with 
Cystic Fibrosis   
 Patients who are deemed clinically 
too unwell to participate in an 
interview. 
 
 Any patient who lives more than 2 
hours away from the research site 
 
 
 Patient who does not understand 
English (no funding for interpreting 
service) 
 
 
 Staff who have less than 12 months 
experience in the speciality 
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5.2. The Selection of Research Sites 
Following a re-configuration between two specialist hospital Trusts an 
opportunity had arisen for the palliative care team to work closer with the 
Cystic Fibrosis team. The lead clinician of the Trust for Cystic Fibrosis was 
approached and agreed to that site being involved in the study. From clinical 
experience, and the literature, it appeared that current integration of services 
was not understood between Cystic Fibrosis and palliative care teams. 
Therefore it seemed appropriate to answer the research questions it would be 
necessary to secure a second site outside London to explore another service. 
From the list of specialist adult sites on the Cystic Fibrosis Trust website a 
second Trust was identified. The lead clinician was approached by the 
researcher. The suggested research project was presented at both sites and 
both agreed to be part of the study. Teams based in Scotland were excluded 
as the healthcare system is different and configuration and funding of services 
are not designed in the same way as in the English health care system. 
 
5.3. The Rationale of a Focus Group as a Method of Data Collection 
It is recognised that focus groups are group discussions that are conducted to 
review a particular subject and that they are useful in examining what people 
think, their views and beliefs about a particular topic (Kitzinger 2005). The 
focus group is also an effective way of determining why different groups think 
of things in a different way. As the two groups of Cystic Fibrosis and palliative 
care were coming together to discuss a sensitive topic, a focus group seemed 
the most appropriate method to gain understanding into this subject area. 
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There was no validated questionnaire to use for the survey in phase 2 
therefore the use of focus group with experts from both Cystic Fibrosis and 
palliative care was the best way to understand perceptions and thoughts 
regarding palliative care. The results from this would inform the questions to 
be asked in phase 2. Previous research has recognised the use of focus 
groups as being particularly effective in survey item development (Nasser-
McMillan & Borders 2002). Although the research aim of this study was not to 
address death and dying, the nature of the life limiting aspects of Cystic 
Fibrosis and the known links from the literature between palliative care and an 
association with death and dying meant that consideration of potential upset of 
the professionals was important to be aware of. The researcher ensured 
additional support from the staff support department was made available to 
participants if needed. 
 
5.4. Phase 1: The Focus Group 
The study was approved by the local research committees of both research 
sites with ethical approval from South East Surrey Coast and the University of 
Surrey Ethics Committees (Appendices 2 and 3). Following this approval, the 
focus group was planned. Due to financial and time constraints a decision was 
made to invite experts from both Trusts involved in the study to take part in the 
focus group.  Prior to starting any of the data collection the researcher met 
with both respective teams to inform them that the data collection phase was 
due to start. 
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As addressed in the literature in planning the focus group consideration was 
given to recruitment and gaining access to potential research participants, 
funding issues with respect to travelling expenses, the location and venue, the 
use of a field note taker and practicalities such as the securing of tape 
recording equipment (Liamputtong 2011). The purpose of the focus group was 
to establish professional perceptions of palliative care and inform part of the 
question development for the survey that would take place in Phase 2. It was 
therefore identified that a purposeful sample of experts in Cystic Fibrosis and 
palliative care would be approached to take part in the focus group. 
 
5.4.1. The Venue 
In preparation for the focus group it was important to establish a suitable 
venue for the meeting to be held. Within one of the research sites there is an 
established research department that allows researchers to have private 
rooms free of charge. As there was no additional funding for this research it 
was felt this would be an appropriate venue to hold the focus group. 
 
A room was selected that had an oblong table. This would ensure that all the 
participants would be able to see each other with ease and there was a 
suitable position identified for the field note taker that would allow them to be 
able to see all the participants to assess non-verbal communication. The 
digital recorder to record the focus group had two microphones one of which 
would be placed at each end of the table. It was established that the room 
would accommodate 10-12 people. 
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5.4.2. The Participants 
There were a few important issues to consider in whom to involve in the focus 
group. It has been suggested that participants in focus groups are often 
selected as a homogenous group because they have something in common 
which is of interest to the researcher. Taking into consideration the 
participants’ social and cultural backgrounds may also help them to talk more 
freely about the topic although this does not include the participants’ views or 
attitudes regarding a situation (Ivanoff & Hultberg 2006, Peek & Fothergill 
2009).  Several disciplines are involved in the care of patients with Cystic 
Fibrosis and it was important to ensure those doctors, nurses, clinical nurse 
specialists and allied health care professionals were invited to participate as 
these are the 4 main groups who deliver care to patients with Cystic Fibrosis 
on a daily basis. 
 
Consideration was given to the number of focus groups needed in order to 
achieve the intended aim of the study as well as the actual numbers of 
participants needed for the focus group. On average the recommended 
number of participants should be somewhere between 4 and 12 (Kitzinger 
2005; Peek & Fothergill 2009; Liamputtong 2011). Numbers of participants are 
based on ensuring there are enough participants to have a discussion but not 
too many that people may feel intimidated if talking in a large group (Smithson 
2008). The rationale for  undertaking one focus group related to the expertise 
and diversity of the expert participants and for pragmatic reasons related to 
cost and time constraints. The focus group was not segmented by age, class 
or sex which can indicate the need for more than one focus group 
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(Liamputtong 2011). An important issue for the focus group is ensuring that 
the population of Cystic Fibrosis and palliative care are reflected within the 
participants. It also became clear that representation within the group was 
from a centre where Cystic Fibrosis and Palliative care teams were aiming to 
deliver a more integrated service and another centre where there was limited 
integration. This resulted in the opportunity to understand perceptions and 
experiences from different view- points. 
 
Both teams were approached and those who met the inclusion criteria were 
made aware of the focus group at the multidisciplinary meetings. The names 
of appropriate team members were confirmed by telephone and email 
addresses were confirmed. A letter of invitation and a study information leaflet 
was forwarded to potential participants asking them if they would be interested 
in taking part in this focus group.  A copy of the invitation letter and study 
information leaflet can be viewed in Appendices 5 and 6. Those approached 
were informed that this would take place on site at Trust A. They were given a 
deadline of response time of three weeks and a reminder was sent out at the 
end of the second week. There were eleven invitation letters forwarded and 
eleven responses received all who agreed to take part in the focus group. As 
there was no additional funding for the team from Trust B to come to Trust A, 
the researcher managed to secure funding from a research budget within her 
current place of work. This secured funding for all travel expenses. It was felt 
face to face would be better as opposed to using other means such as video 
linking/Skype due to the sensitive nature of the topic. Following the 
participants’ agreement to be part of the focus group a list of potential dates 
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and times were forwarded to them. It was possible to achieve agreement on 
dates and times of eight out of the eleven participants. They were reminded 
about the focus group start time and venue the day before. 
 
5.4.3. Timing of the Focus Group 
The focus groups should last between 1 to 2 hours. This ensures the 
participants do not find the discussion tiring, they may run out of issues to 
discuss or they may need to leave due to personal reasons (Liamputtong 
2011). The researcher was also aware that there would need to be sufficient 
time to allow the group to warm up before discussion occurred (Conradson 
2005). In view of these issues the focus group timing was for an hour and a 
half and was towards the end of the day to ensure staff would then be able to 
leave for home in time if needed. 
 
5.4.4. The Moderator 
It is recognised that in market research focus groups often have people 
specifically employed to facilitate/moderate the focus group, however with 
health and social sciences it is identified that it is often the researcher 
themselves who will moderate the focus group and an independent note taker 
is encouraged (Smithson 2008; Holloway & Wheeler 2010). The researcher 
considered the skills needed prior to undertaking the facilitation of the focus 
group and made sure she was informed on the specific skills required. The 
literature suggests a number of characteristics that inform a good moderator.  
These are listed in Table 13 below 
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Table 13. Characteristics of a good moderator of Focus Groups 
Sensitive to the needs of the participants 
Non-judgemental about the responses from the participants 
Respect of the participants 
Open-minded 
Have adequate knowledge about the project 
Good listening skills 
Good leadership skills 
Good observation skills 
Patience and flexibility 
Be able to withhold own opinions or assumptions 
(Liamputtong 2011) 
 
The researcher had many of the suggested characteristics and had also 
previously moderated a focus group. Whilst there is some suggestion that a 
moderator should be neutral to the research project (Smithson 2008) in 
contrast, it is also alluded to that an awareness of the moderator’s social 
position and awareness of how their behaviour can impact on the interaction 
of the group is as important as well as their own experience encouraging 
discussions (Wilkinson & Kitzinger 1996; Stokoe & Smithson 2002). In 
addition to this the researcher needed to consider the position of the 
moderator in maintaining control of the group. The aim as the moderator was 
to ensure that all participants were given the opportunity to speak and that the 
topic guide which was created from a review of the literature was used as a 
mechanism to guide the questions to the experts in the focus group (Munday 
2006; Bryman 2008). The researcher did have experience as a leader in 
facilitating groups and supporting groups of people when discussing difficult 
issues. 
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Within the focus group the moderator ensured the experts were introduced to 
each other and that the scene in terms of introduction to the topic was set. All 
the participants had received an information leaflet prior to the focus group 
and were given the opportunity to ask questions again when consent was 
taken prior to the beginning the focus group. The focus group participants 
controlled the running of the group themselves to some extent. Following the 
introduction to the topic and the opening issue for discussion the experts 
naturally generated discussion themselves covering most of the topic guide. 
When there was a natural pause within the group the moderator clarified what 
had been said. If it was clear that there was no more to add to that particular 
issue then the moderator took this as an opportunity to move the conversation 
forward by introducing the next area of discussion from the topic guide. 
 
5.4.5. Note taker 
A note taker is essential in focus group interviews as the moderator is unable 
to coordinate the focus group and take notes at the same time. The note taker 
was selected to support the moderator to check to see if any issues have 
been overlooked. The note taker was introduced at the beginning of the focus 
group and her role was explained. She sat outside of the focus group so she 
was not in any of the participant’s eye view so as to distract any of the 
participants (Hennink 2007). 
 
The note taker had responsibility for the starting and stopping of the digital 
recorder equipment throughout the interview as well as being responsible for 
any support participants required throughout the meeting. It was established 
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that no fire alarm tests were anticipated throughout the focus group. The note 
taker selected was a clinician who would be familiar with some of the 
language and conversations that may be used within the group in the hope 
that additional information could be captured. The note taker was also known 
to have clear easy to read hand writing. The moderator and the note taker met 
on two occasions prior to the focus group. On the first occasion the note taker 
was made familiar with the venue for the meeting and the equipment that was 
to be used. The topic guide was shared with the note taker and the note taker 
was advised on the type of information that would be helpful to capture.  This 
included observing interactions between the group members, activity within 
the group and facial expressions that would be written as field notes and 
memos (Willis et al. 2009). The moderator checked with the note taker at the 
end of the focus group, to confirm that all areas of the topic guide had been 
discussed. 
 
5.4.6. Consent 
The participants were informed in the participant information sheet that written 
consent would be obtained prior to starting the focus group. All participants 
were offered a consent form and all agreed to sign; a quiet area in the room 
was secured for this to allow discussion and confirmation of understanding of 
the focus group process to take place. The participants were given a copy of 
their signed consent form and the original was placed in the researcher’s site 
file. Consent was obtained in line with the research site stipulations of the 
Committee for Clinical Research and South East Surrey Coast ethical 
recommendations. A copy of the consent form can be viewed in Appendix 6. 
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5.4.7. Equipment 
A digital recorder was used for the focus group. Additional batteries were 
taken to ensure taping was continuous. The note taker checked the equipment 
at the beginning and throughout the focus group to ensure recording was 
taking place. This equipment allowed for the information to be immediately 
downloaded onto a secure password protected computer for analysis. 
 
5.4.8. Topic Guide 
A topic guide for the focus group was designed based on information from the 
literature review. In order to answer the research questions and to identify 
questions to be asked in the questionnaire that would inform the survey in 
phase 2 of the study areas of current service provision between Cystic 
Fibrosis and palliative care would be established as well as reasons for 
referral, barriers to referral and how appropriate seeing patients earlier in their 
disease trajectory might be (See Appendix 7). 
 
5.4.9. Analysis of the Focus Group 
The data from the focus group was downloaded onto a password protected 
lap top. The information was transcribed verbatim by the researcher and 
organisation and analysis of the data was aided by NVivo 10.  When using 
focus groups the general principles of conducting interviews apply (Birks & 
Mills 2011). A wide margin on the right was left so that the researcher could 
add comments whilst reading the focus group. The focus group was read 
several times and constant comparative analysis was applied. From this 
nodes were created and from this one theme was generated with categories 
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and sub categories and analysed applying the principles of a constructivist 
Grounded Theory approach. Further data analysis is illustrated in Chapter 6. A 
copy of the interactions of the participants within the focus group can be 
viewed in Appendix 8. 
 
The focus group was undertaken in a safe environment with an experienced 
moderator. A topic guide was used to inform the discussions within the focus 
group. It was clarified at the end of the focus group that all areas of the topic 
guide had been explored. The findings from the focus group can be viewed in 
Chapter 6. This chapter will now discuss the survey applied in phase 2 of the 
research. 
5.5. Phase 2: Survey 
 
5.5.1. Development of the Questionnaire 
There was no current tool available to apply to this survey therefore it was 
necessary to develop a questionnaire to ensure the data collection answered 
the research question.  It was clear from the information gathered from the 
focus group that one of the areas to explore within the survey would be 
referral patterns between Cystic Fibrosis and palliative care. As the literature 
had highlighted a limited number of articles relating to how Cystic Fibrosis and 
palliative care teams currently work together, exploring existing models of 
service delivery would be important questions to include within the national 
survey to establish current practice. It was also important to be able to 
recognise the demographics of the services. Therefore the questionnaire was 
structured into three domains namely, referral patterns, models of care and 
demographics. In designing the questionnaire it was important to consider the 
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five distinct types of question that refer to behaviour, beliefs, knowledge, 
attitudes and attributes (Schonlau et al. 2002; Dillman et al. 2009). The design 
of the questionnaire and the wording of the questions were based on the 
recommendations by De Vaus (2002) and can be viewed in Appendices 9 and 
10. The validity of the questionnaire was also considered. Validity determines 
what survey questions to use, and ensure researchers are using questions 
that measure the problems that matter.  A survey is considered to have 
validity if it measures what it plans to measure (De Vaus 2002). Content 
validity was achieved through ensuring the concepts to be examined were 
defined from within the literature and construct validity was achieved through 
the expertise of the participants from the Focus Group informing the 
questionnaire development.  
 
Survey Monkey a leading provider of web-based surveys was approached to 
help with the development and processing of the survey. A combination of 
open and closed question formats were used.  A structured questionnaire was 
developed within some of the questions a free text area was available if 
respondents had anything extra they wanted to add in to the answer. 
Numerical rating scales were used for some of the questions. The questions 
were set up to ask non-threatening , simple questions first, to engage the 
participant , no personal details were asked at the beginning of the 
questionnaire as this has been determined as a precursor to the respondent 
losing interest (Bowling 2009). The questionnaire had twenty one questions to 
be answered.  Questions 1-13 related to referral patterns between the Cystic 
Fibrosis and Palliative care teams. Questions 14-18 related to models of care 
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and ways of working. Questions 19-21 related to demographics around length 
of time in the speciality and multi- disciplinary representatives within the team.  
 
The web- based provider helped in making the questionnaire look as clear as 
possible by using colour and layout which would hopefully encourage 
respondents to complete the questionnaire. A copy of the final questionnaire 
can be viewed in Appendix 11. 
 
5.5.2. Length of the Questionnaire 
Within the literature it is suggested that the length of the questionnaire is not 
too long as this can increase reluctance on the part of respondents to 
complete it. A questionnaire that is too short can also bring in to question the 
value of completing it (De Vaus 2002; Bowling 2009). Twenty one questions 
were built into the questionnaire split into three sections.  
 
5.5.3. Pilot of Questionnaire 
The questionnaire was piloted by two independent clinical teams who were 
similar in speciality to the teams that the survey was aimed at which is 
recommended in the pilot phase (De Vaus 2002). The researcher met with 
both teams to gather feedback and discuss the questionnaire. Following the 
pilot three changes were identified which related to the wording of the 
questions. The questions were answered in the same way which indicated the 
tool being reliable and unambiguous. The changes were made to the 
questionnaire which was subsequently forwarded to South East Coast Surrey 
 103 
 
ethics committee for approval. Following approval of the questionnaire the 
survey was forwarded to the identified population. 
 
5.5.4. Sample 
The sample population for the survey was purposive. The rationale for this 
relates to aiming to identify specific answers to questions between Cystic 
Fibrosis and Palliative care teams. This type of sampling is recognised as 
being useful when this method is being used (De Vaus 2002). The Cystic 
Fibrosis Trust holds a list of all the adult specialist Cystic Fibrosis centres 
within the United Kingdom. These centres were selected as the sample with 
their respective Palliative care services. There were twenty-three adult Cystic 
Fibrosis centres on the website in 2012 (Cystic Fibrosis Trust 2012). The 
Palliative care teams were identified and in total forty-six questionnaires were 
forwarded. 
 
5.5.5. Set up of the Survey 
Both Cystic Fibrosis and Palliative care teams were contacted initially by 
telephone to establish who the clinical leads were for both teams. This helped 
in establishing if Cystic Fibrosis teams had access to Palliative care teams in 
the hospital, ensured that the email address for the clinical lead was correct 
and informed the teams that a questionnaire would be forwarded to them in 
the coming weeks. It was identified that all the Cystic Fibrosis teams had 
access to Palliative care. 
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5.5.6. Methods Employed to Increase the Response Rate 
Two weeks in advance of the survey, a letter was forwarded to inform 
potential participants of the survey and that the survey would be forwarded to 
them. A covering letter was forwarded to the study population with an 
information leaflet explaining the rationale of the study and the survey and can 
be viewed in Appendices 12 and 13. A reminder was noted in the letter 
regarding the pre email telephone call that had occurred in the hope this 
would help them remember that the survey was going to take place. Within the 
email an URL link was embedded that would take the participant directly to the 
questionnaire. Email reminders were forwarded to participants at two time 
points, the first at three weeks and the second at six weeks. 
 
5.5.7. Data Analysis 
Data from the survey was inputted into a Statistical Package for Social 
Sciences (SPSS). Descriptive statistics were collated and can be viewed in 
Chapter 6. There was a complication identified within question nineteen of the 
study that related to the numbers of professionals within each team and whole 
time equivalents (WTE). It became apparent that this question would only 
accept whole numbers. This particular issue was not highlighted in the pilot 
phase of the survey. The following section will describe the conduct of the 
interviews that informed phase 3 of the study. 
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5.6. Phase 3: Patient and Professional Interviews 
In order to understand the perceptions of patients and professionals about a 
referral to Palliative care in patients with Cystic Fibrosis semi structured 
interviews were undertaken. The view of employing semi structured interviews 
when using a Grounded Theory approach is discussed within the literature 
(Bryant & Charmaz 2010; Birks & Mills 2011). It is recommended that having a 
too structured interview can inhibit flexibility to respond to the participant and 
in allowing the conversation to flow (Birks & Mills 2011). It is however alluded 
to in Grounded Theory that an interview guide can be helpful in aiding the 
conversation, but that researchers must expect it to alter as data gathering 
continues (Bahora et al. 2009; Bryant & Charmaz 2010; Birks & Mills 2011). 
An interview guide was developed for both patients and professionals to 
ensure that similar kinds of information were discussed with all the 
participants. The information in the interview guide was based on information 
documented in the literature review identifying that there was a need to 
undertake this research and data gathered in Phases 1 and 2 of the study that 
required a more in depth understanding. A copy of the interview guides can be 
viewed in Appendices 14 and 15.  
 
5.6.1. Recruitment of Patients  
Following discussion at both Trusts key clinical members of staff were 
identified who would help to identify patients to participate in the study based 
on the inclusion criteria. Both sites had information regarding the study and 
were equipped with patient information leaflets. Since Trust B was located 
several hundred miles away from the researcher’s base it was decided 
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following discussion with the clinical team that the researcher would identify a 
period of time where she would reside locally to recruit both patients and staff 
to the study. Due to location, it was easier for the researcher to be more 
spontaneous in terms of recruitment and subsequent interviewing of both 
patients and staff at Trust A. Participants who were identified by the clinical 
teams were recruited into the study by the researcher. Initial conversations 
took place either by email, telephone or face to face contact. Following 
confirmation of interest in the study by the patients a suitable time and place 
was secured for the interview to take place. It was identified that data 
saturation would occur when the researcher recognised that the categories 
that had been developed were robust as no new properties were established 
(Charmaz 2014). Memos were used to support this development. 
 
5.6.2. Recruitment of Professionals 
Both Cystic Fibrosis and Palliative care teams were made aware of the study 
and discussed at the multi-disciplinary team meeting. Both multidisciplinary 
team meetings are attended by all members of their team.  Therefore 
dieticians, physiotherapists, occupational therapists, doctors and nurses were 
made aware through this meeting on both sites. Ward staff were made aware 
through meeting with the ward teams and information leaflets for professionals 
were offered for further information. In using the principles of a Grounded 
Theory approach it was important to make all staff and patients who met the 
inclusion criteria to be aware of the study. This is important since as the data 
emerge there is a possibility that different issues may be raised that may 
warrant interviewing different types of patients and /or professionals. As an 
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example it became clear that talking to patients who had already met a 
Palliative care team would be helpful after analysing one of the transcripts. 
The sampling was purposive to begin with and became theoretical as data 
emerged. This is supported in the literature (Sbaraini et al. 2011). As the 
researcher was not at the research sites daily, two clinicians were identified, 
one on each site, to help with the recruitment process. Names were forwarded 
to the researcher of interested professionals and they were subsequently 
followed up by email or telephone. Following this if they continued to be 
interested in the study a suitable date, time and venue was secured and 
communicated to the professional by email. Trust B interviews were all 
planned over a two week period. Trust A interviews occurred over a period of 
six weeks. 
 
5.6.3. Place of the interview 
In Trust A it was possible to secure a room for patients who were attending as 
out patients. Patients with Cystic Fibrosis who are  in hospital all require single 
rooms due to the risk of cross infection from other patients, therefore privacy 
was secured for all patients. 
 
Patients were given the opportunity to be interviewed either at the respective 
hospitals or at home. Of the eight patients interviewed six patients were in 
hospital which took place at a convenient time for the patient. The remaining 
two patients were well and out of hospital and decided to come to the 
respective hospital to be interviewed. The interviews with professionals were 
secured at a convenient time for them. 
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All interviews except one were face to face and in the hospital. One 
professional from Trust B had to cancel the interview due to personal 
circumstances. She was keen to be interviewed and therefore the interview 
was conducted on the telephone. The consent form for this professional was 
emailed, signed and returned by email.  
 
5.6.4. Conduct of the Interviews 
The day before the interviews all participants were contacted to ensure they 
were still able to participate. Prior to the interview starting the researcher 
ensured that the information leaflet had been read and understood and any 
outstanding questions were answered, illustrated in Appendices 16 and 17.  A 
consent form was signed prior to the interview. A copy was given to all the 
participants and a copy placed in the research file at each site.  These are 
illustrated in Appendices 18 and 19. Following the interview consent was 
obtained again to ensure the participants were happy with everything they had 
said and for extracts to be used to confirm the development of themes. The 
interviews were taped using a digital recorder that had been used in the focus 
group so the researcher was familiar with the equipment. Although within the 
literature it is identified that tape recording when using a Grounded Theory 
approach is not always recommended (Glaser 1998), it is supported when the 
researcher is a novice and whilst the researcher has undertaken other forms 
of research, experience remains limited therefore it was appropriate to digitally 
record the interviews (Birks & Mills 2011). The recordings were downloaded 
onto a password protected computer. Field notes were documented 
immediately after the interview to capture observations made of non -verbal 
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communication used by the participants. A copy of one of the field notes 
maintained can be viewed in Appendix 20. 
 
Participants were made aware that they could stop the interview at any time.  
Water and tissues were made readily available for the participants. 
Throughout the patient interviews the researcher checked regularly to ensure 
the patients did not feel too breathless to continue as breathlessness can be 
problematic for patients with Cystic Fibrosis. On both research sites staff 
support had agreed to support either patients or staff if anyone became 
distressed following the interviews. 
 
The interviews were transcribed verbatim and organised using NVivo 10 
stored on a password protected secure laptop. NVivo is a qualitative data 
analysis computer software package recommended for use in storing and 
analysing qualitative data (Holloway & Wheeler 2010). This software was used 
as an additional tool to support data analysis as opposed to actually analysing 
the data itself. The researcher transcribed four of the interviews, two patients 
and two professionals. A recommended external transcribing service was 
recommended and approached to transcribe the remaining thirteen interviews; 
this was mainly to help with time constraints. Each interview was listened to at 
least twice before any analysis commenced. A dropbox system was used to 
transfer the interviews between the researcher and the transcriber. The 
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external transcriber deleted the transcripts immediately following the transfer 
of the completed transcription.  
 
5.6.5. Analysis of the interviews 
The information from the initial data gathering were coded before further 
information was collected as supported in the literature (Birks & Mills 2011; 
Charmaz 2014). The data were coded using constant comparative analysis. In 
constant comparative analysis data is compared with data to ascertain 
similarities and differences, interview statements and incidents are compared 
within the same interviews and then with other interviews. In the researcher’s 
study data were coded initially line by line, this is followed by intermediate 
coding and finally advanced coding and theoretical integration which are seen 
as reconnecting the data (Birks & Mills 2011). Undertaking constant 
comparative analysis occurred concurrently with the data collection. 
 
5.6.6. Constant Comparative Analysis 
The process of constant comparative analysis aids the development of the 
emergent theory (Holton 2007). The rationale for applying constant 
comparative analysis is to observe if the data supports the development of the 
emerging categories (Bryant & Charmaz 2007). 
 
In this study open coding was established with line by line coding of the data. 
This helps in keeping the researcher close to the data (Charmaz 2014).  An 
extract of this can be viewed in Appendix 21. The initial coding phase helped 
the researcher identify further areas for data collection that were lacking. For 
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example it became clear that being able to interview patients who had both 
been referred to Palliative care and those who had not been referred was 
important in identifying perceptions of Palliative care. Line by line coding with 
gerunds is recognised as a heuristic way of bringing the researcher into the 
data (Charmaz 2014). This helped in recognising meaning and helped direct 
the researcher in areas for further exploration. The constant comparative 
method is recognised as consisting of three distinct phases. The process 
involved firstly comparing incidents with incidents that lead to the development 
of codes. Further incidents were subsequently compared with existing codes. 
Codes were compared with codes from which groups of codes were collapsed 
into categories. Ongoing developments of codes were compared with 
categories and categories were compared with developing categories. It was 
recognised that this process of constantly comparing results in generating 
data that results in abstract categories rich with meaning (Bryant & Charmaz 
2007). 
 
Following the development of open coding the researcher engaged in focused 
coding which in recognised as the second phase in Grounded Theory 
(Charmaz 2014). The development of the focused coding was a result of 
identifying codes that appeared on a more frequently occurring basis in the 
initial coding phase. In defining focused codes Charmaz (2014) suggested a 
list to incorporate into the development of these. Table 14 illustrates this list. 
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Table 14. Guide for Developing Focused Codes 
 Guide for developing Focused Codes  (Charmaz 2014) 
1 What do you find when you compare your initial codes with the data? 
2 In which ways might your initial codes reveal patterns? 
3 Which of these codes best account for the data? 
4 Have you raised these codes to focused codes? 
5 What do your comparisons between codes indicate? 
6 Do your focused codes reveal gaps in the data? 
 
The development of focused codes was not a linear process. The 
development of the focused codes resulted in the researcher going back to 
the initial data to re explore findings. The analysis process is discussed further 
in Chapter 6. 
 
5.6.7. Anonymity and Confidentiality 
Participants involved in the interviews were coded, and names and details of 
hospital trusts were removed. Only the researcher was able to link the identity 
of the participant with the tape and transcript. All information was stored on a 
password protected computer. Research files were stored in a locked fire 
proof cupboard on all sites. Consent was requested again after the interview 
to ensure that participants were in agreement with anything that had been said 
being used to inform the research findings and that quotes from interviews 
would be used to support findings. Participants were aware that research 
supervisors would have access to the transcripts but that names would be 
removed. It was important to ensure that the two sites were not identifiable 
throughout the study. Professions were removed to reduce the risk of 
participants being identified. 
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5.6.8. Ethical Considerations 
 
All research needs sensitivity, caution and respect for the physical and 
emotional well-being of participants (Kendall et al. 2007).  In general, 
interviews with patients who may be near the end of life and their carers need 
not cause significant distress and are often valued by participants (Casarett et 
al. 2003). No reason exists as to why the management of patients who may 
die should be excluded from the scientific scrutiny necessary to improve care 
for patients/carers with non- terminal conditions. However it is recognised that 
gate keeping can be seen as the hesitance of well- meaning health care 
professionals in suggesting patients/carers for research studies (Kendall et al. 
2007; Rees & Hardy 2003; White et al. 2008). Patients were made aware that 
they could stop or withdraw from the study at any point without prejudicing 
care. Ethical considerations for this study are listed in Table 15 below. In 
addition to this a risk assessment of this study was undertaken and can be 
reviewed in Appendix 22.  
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Table 15. Ethical Considerations for all 3 Phases of the Study 
Voluntary Participation of Research Participants 
Patients and professionals would be invited to take part in the study. Attention 
was given to informed consent, ensuring no harm came to the patient or 
professional and confidentiality, anonymity and privacy were maintained 
 
Managing distress of patients  
Additional support was arranged through the hospital Palliative care team, 
Cystic Fibrosis teams or GPs 
 
’To manage any distress of staff 
Additional support from staff support teams would be made available or the 
psychological support team 
 
To manage any complaint/concern discussed with the team 
The patient was advised to discuss issues with either a member of the team 
or the appropriate patient advice and liaison service 
 
Managing distress of the researcher undertaking the interviews 
Additional support from colleagues and supervisors 
 
To ensure safety of the researcher 
The researcher worked within the guidance of the lone worker policy 
 
To maximise patient autonomy and anonymity 
Use of encrypted data  
 
To maintain privacy and dignity throughout the interviews 
The study achieved ethical approval and the survey was taken back to ethics 
following the pilot phase 
 
To ensure the researcher has undertaken Good Clinical Practice 
Training 
 
Attended before and updated during the study 
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5.6.9. Reflexivity 
It is recognised in the literature the importance of the researcher taking a 
reflexive approach towards their study (Andrew & Halcomb 2009; Holloway & 
Wheeler 2010). The researcher had previously recognised that she had over 
twenty five years’ experience in palliative care and therefore, with that, came 
pre-existing ideas about palliative care as a speciality and how patients should 
have access to it. The use of memos and a reflective diary aided the 
researcher in identifying actions and feelings. This did not occur at a single 
time-point. The memos were revisited to support learning from previous 
interactions. Field notes were made following interactions with participants 
where the researcher documented about emotions or thoughts that occurred 
following each data collection. Discussion with the researcher’s supervisors 
also facilitated personal reflections of pre-existing thoughts and assumptions 
regarding Cystic Fibrosis and palliative care. Although the researcher was in a 
position with overall responsibility for a palliative care service she recognised 
that she had no direct managerial responsibility for any of the staff members 
who might be interested in taking part in the study. Being in clinical practice 
resulted in the researcher re-visiting the data on more occasions than 
necessary and keeping memos and a diary to ensure misinterpretation of the 
data did not occur. 
 
5.6.10. Theoretical Sensitivity 
It is suggested that theoretical sensitivity can be a concept that is difficult to 
fully understand (Birks & Mills 2011). As a researcher it was important to 
analyse what the researcher knew about the topic in advance of the research. 
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As alluded to in Chapter 3 the researcher had expert knowledge in palliative 
care but much less so regarding Cystic Fibrosis. The key issue for the 
researcher was not to apply theoretical schemes to the research data based 
on previous experience of palliative care. The researcher used her previous 
experiences as a conceptual comparison with the data and used previous 
experiences to stimulate thinking using a reflective diary to capture these 
thoughts. 
 
5.7. Summary 
This chapter has provided detailed information relating to the methods applied 
in this study. It is clear that a mixed methods approach was the most 
appropriate to ensure the research questions were answered. Quantitative 
and qualitative research alone would be insufficient to understand the 
research topic due to the complexities of the research questions to be 
answered. Information has connected the rationale between the selections of 
the research design, the research methods used and illustrated issues for 
analysing the data and discussed validity of the study. 
 
 
 
 
 
 
 
 
 
 117 
 
CHAPTER 6: FINDINGS OF STUDY 
6.1. Introduction 
Mixed methods underpin this research and three methods of data collection 
were used to ensure the research questions were answered and the aim of 
the study achieved. In Phase 1of the study a Focus Group was conducted to 
understand professional perceptions of palliative care and to inform the 
development and content of the Phase 2 survey.  Phase 2 data were gathered 
through a survey whereby a questionnaire was forwarded to recognised adult 
Cystic Fibrosis specialist centres within the United Kingdom and their 
respective palliative care Teams. Phase 3 data were gathered through semi 
structured interviews with both patients diagnosed with Cystic Fibrosis and 
professionals caring for patients with this illness. The patients and 
professionals involved in the study were recruited from both Cystic Fibrosis 
and palliative care specialties within the two research sites. The data 
generated were analysed in the context of a mixed methods methodology. 
The principles of a constructivist Grounded Theory approach were used to 
explore the qualitative data. Constant comparative analysis was used to 
analyse the qualitative data. Themes, categories and sub categories are 
presented within this chapter. Data from the survey was analysed and 
presented through descriptive statistics and interpretation of all three phases 
is discussed. 
 
Initially the theme identified in the Focus Group will be explored. Extracts from 
the participants in the Focus Group are presented throughout this section to 
support the development of the theme. The extracts are illustrated in italics 
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and supported by the name “FG” and CF (Cystic Fibrosis) or (Palliative care) 
PC to denote the speciality the extract is from. This is followed by a number 
which allowed the researcher to maintain anonymity of the participants. The 
findings of the Focus Group clearly demonstrated how part of research 
questions one and two were met and generated areas for particular questions 
to be poised to inform the development of the questionnaire in Phase 2. This 
section will now present the findings from the Focus Group in Phase 1 and will 
conclude with a summary of this phase. The research aim and questions are 
illustrated below as a reminder to the reader. 
 
Research Aim 
1. To explore the experiences and perceptions of patients with Cystic 
Fibrosis and health care professionals regarding palliative care and the 
acceptability of this as a service early in the patient’s disease 
trajectory.  
Research Questions 
1. What are patients with Cystic Fibrosis and health care professionals’ 
experiences and perceptions of palliative care? 
2. What are the barriers and facilitators of a palliative care referral in 
Cystic Fibrosis? 
3. Are the services for the provision of palliative care within Cystic 
Fibrosis integrated as part of an multi-disciplinary team 
 
6.2. Phase 1. Findings from the Focus Group 
The data gathered from the Focus Group answered part of research questions 
one and two which explored professional perceptions and experiences of 
Palliative care and informed the questions to be asked nationally to  
Cystic Fibrosis and Palliative care Teams in Phase 2 of the study. Whilst 
undertaking a focus group with patients was not possible due to issues 
regarding cross infection other methods could have been initiated such as 
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interviews. The rationale for not selecting to interview patients at this stage 
related to the literature review in Chapter 3 which recognised perceived 
barriers from professionals in referring patients to palliative care some of 
which were related to how professionals felt patients perceived a referral to 
palliative care. The researcher wanted to first establish the perceptions of 
professionals and to explore the reasons why they may not perceive palliative 
care as acceptable, the information from which would be used to inform the 
interviews with patients. The data from the Focus Group were organised using 
NVivo 10 that was downloaded onto a password protected lap top. One over-
arching theme was generated from the Focus Group using constant 
comparative analysis, named ‘Digging a Hole’. This theme was 
conceptualised through comparing interview statements from participants 
within the Focus Group. The participants used this term to explain the concern 
they had in discussing palliative care. The participants also illustrated the 
concept of ‘Digging a Hole’ when they discussed how concerned they were 
about starting conversations about palliative care that resulted in discussions 
about death and dying. Recording what was observed throughout the Focus 
Group was important in capturing non-verbal communication which 
substantiated the verbal information gathered. 
 
The following data are presented with coded extracts from the focus group 
interview to support the generated themes. Table 16 below offers descriptive 
details of the participants that took part in the focus group. The participants 
included nurses, doctors and allied health care professionals. 
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Table 16. Description of the Focus Group participants 
Speciality  Experience in speciality 
Cystic Fibrosis 5 years 
Palliative care Over 10 years 
Palliative care Over 10 years 
Cystic Fibrosis 0ver 10 years 
Cystic Fibrosis 5 years 
Cystic Fibrosis Over 10 years 
Cystic Fibrosis Over 10 years 
Cystic Fibrosis Over 10 years 
 
The participants were a purposive sample of eight multidisciplinary 
professional experts working in either Cystic Fibrosis or palliative care. All the 
participants were female. As the research topic related to exploring early 
Palliative care in patients with Cystic Fibrosis, purposeful sampling was used 
as the researcher required information on Cystic Fibrosis and palliative care 
from specialists who had relevant experience working with this group of 
patients (Holloway & Wheeler 2010). The participants within the focus group 
were expert representatives from the two research sites. Table 17 illustrates 
the theme that has been generated from the Focus Group. The following 
section will discuss the theme, ‘Digging a Hole’ which related to talking about 
palliative care. The meaning of palliative care was generated as a category 
with the term palliative care and barriers and facilitators as sub categories. 
These data were instrumental in answering part of research questions one, 
and two and in developing questions for the survey in Phase 2. 
 
6.3. Theme 1: Digging a Hole 
The theme generated through constant comparative analysis related to the 
professionals’ description of digging a hole. The meaning of palliative care and 
 121 
 
what this inferred to professionals and the connotation of the term Palliative 
care were created as a category and sub category. Facilitators and barriers 
towards palliative care were recognised as a sub category within this theme. 
 
Table 17. Theme generated from Focus Group 
Theme 1 Category Sub-Category 
“Digging a Hole”; talking 
about palliative care. 
  
Meaning of palliative 
care from the 
professionals viewpoint 
 
 
 
The term palliative care 
 
Barriers and facilitators 
of referral to palliative 
care  
 
 
What the referral to palliative care purposed and when the referral to palliative 
care should occur was discussed repeatedly throughout the Focus Group. The 
majority of the group were in agreement that referral to palliative care should 
occur at any time depending on the needs of the patient. The experts 
repetitively alluded to the barriers and facilitators perceived regarding referral 
to palliative care 
 
6.3.1. Meaning of Palliative Care to Professionals  
The participants were cognisant that there was an association with death 
when palliative care was mentioned. They referred intermittently throughout 
the Focus Group about the term Palliative care and acknowledged that they 
denote palliative care as the symptom control team. Seven of the participants 
discussed that they perceived palliative inferred more than dying and tried to 
inform other professionals about what Palliative care services could offer to 
patients. 
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6.3.1.1. The Term Palliative care 
The professionals acknowledged how they rarely talked about Palliative care 
and used different language to describe the Palliative care team to patients 
and other members of the multi -disciplinary team. The term symptom control 
was used interchangeably with palliative care to describe the service. Three of 
the professionals captured this in their extracts below. From the first extract 
there was laughter within the group with reference to rarely talking about 
palliative care. The extract was from one of the Cystic Fibrosis professionals 
who seemed embarrassed by what she had said but looked relieved when she 
saw others in the group agreed with her. It was interesting as although she 
said she did not have a problem with the name, what was said and the tone of 
her voice almost said the opposite inferring a problem with the term palliative 
care. This detail of tone of voice and body language were acknowledged 
through the field notes that were kept throughout the Focus Group. 
 
We rarely talk about palliative care (laughter), when you’re first introduced to it 
or if we talk to some of our doctors about how helpful they can be. I always 
say to help with your symptoms if I see them in clinic…it’s about sometimes 
misconceptions the dying thing. So we re- name you basically. I don’t have a 
problem with the name but others do (FG/CF Professional 8).  
 
 
But it does… we do introduce ourselves as the palliative care team so even if 
you’ve introduced us as the symptom control team (laughter from the group) 
and I will often couch that as both with the symptom control and Palliative care 
team and we do a whole range of things so that’s usually my starting point 
because then if I’m actually then there to talk about symptoms they actually 
know that they can talk about advance care planning if they want to…Because 
the reality is they probably are going to die so you know you find yourself 
going Palliative care are going to see you but you’re not going to die emmm 
yet you start like and your just digging yourself this massive hole (pretends to 
dig a hole) (FG/PC Professional 2). 
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We don’t access Palliative care and I’m guessing that’s because we associate 
it with death and almost don’t want to refer, maybe we should (FG/CF 
Professional 1). 
 
 
As new understandings of the needs of people at the end of life emerge, 
communication needs to be unambiguous with groups of people with different 
perspectives and needs (Palliative care Australia 2008). The language that 
professionals use and the meanings that are attached to specific terms 
become increasingly problematic. The lack of consistency in the use of 
terminology has created confusion as professionals try to communicate and 
understand the needs of different cohorts of people facing the challenges of 
providing palliative care. From the Focus Group both Cystic Fibrosis and 
palliative care professionals referring to the term symptom control was a way 
of easing the introduction of palliative care but also felt it helped describe what 
the palliative care team did. One of the professionals in Cystic Fibrosis 
summed this up in the extract below. 
 
I think it’s a lot easier on the ward (to use the term symptom control) and it’s a 
lot easier to talk about especially with the patient and the family it’s not 
palliative care, we’ve got 1 week 2 weeks left it. It’s more welcoming it’s like 
the cancer word of old the ‘C’ (cancer) the dreaded word. And at the MDT 
when palliative care is mentioned you know the patient might still have years 
to live. Patients need the help and symptom control helps them understand 
what palliative care does (FG/CF Professional 5). 
 
 
From the literature it is clear that there has been a rapid growth of palliative 
care services. This has raised several problems in the way that services are 
perceived by both the public and professionals and therefore accessed 
(Ahmed et al. 2004). Specific problems have resulted in a reluctance to refer 
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to palliative care because of misunderstandings of what it offers, or fear of its 
association with imminent dying (Ahmed et al. 2004). One of the Palliative 
care professionals below described how she constantly feels like she has to 
sell the palliative care service. It was also interesting interpreting the response 
of laughter when the palliative care professional stated that “I can do 
optimism” There was a sense of togetherness within the group recognising 
that whilst palliative care is associated with death and dying, not all palliative 
care specialists think that way. The sense of togetherness was illustrated 
through non- verbal communication and a physical movement of the group 
members towards the table they were sitting around signifying that there were 
shared concerns about the introduction of palliative care. 
 
I can do optimism … (huge amount of laughter within the group) but you know 
I think the team the palliative care team has a responsibility to work with the 
other teams and to negotiate there’s a lot of negotiation and selling yourself, 
selling palliative care to the other teams so that it seems helpful to patients 
and the families (FG/PC Professional 5). 
 
The participants recognised that not everyone understands the term palliative 
care and discussed how when introducing palliative care they always need to 
explain what it is actually about. They discussed their perception of how 
patients respond when Palliative care is mentioned. 
Well exactly and I was going to say that at the start like what does palliative 
mean and could you just get rid of it, people haven’t a clue I would never for 
the first time explaining somebody that somebody from the palliative care was 
going to see them without feeling like I had to explain what that was so you 
can’t ever I don’t think I could ever cos they just say palliative care are coming 
to see you without carrying on and explain because you know straight away 
the look you’re going to get that knowing look of. Oh God she’s telling me I’m 
dying (FG/CF Professional 6). 
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The last extract discussed changing the name of palliative care to something 
more easily understood. In studies relating to perceptions of Palliative care in 
non-malignant disease this association of the term palliative care with death 
and dying has also been identified (Dharmasena & Forbes 2001; Waterhouse 
2013). There is over a decade between these two studies and yet from the 
current research, palliative care continues to be perceived as an end of life 
care service. 
 
6.3.1.2. Barriers and Facilitators to a Palliative care Referral  
A discussion evolved regarding access to palliative care services for symptom 
control earlier in the patient’s disease trajectory and not just focusing on end 
of life care. The issue of palliative care being used in a wider context was 
considered in one of the areas where a more integrated approach between 
the Cystic Fibrosis and palliative care teams was developing. The concept of 
the reason for referral to palliative care was important for some of the team to 
discuss and to confirm the rationale behind making a referral to palliative care. 
For some it was clear that a referral to palliative care would only be initiated 
when the Cystic Fibrosis team perceived they were struggling to control 
patients’ symptoms and consideration of referring to the palliative care team 
would normally only occur leading up to the patient’s death, if at all. The 
participants acknowledged that selected barriers to palliative care were 
professionally led rather than related to patient perceptions. These related to 
previous experience and misconceptions about when to refer to palliative 
care. 
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The extracts below recognised the difficulty in palliative care involvement at 
the end of life, and also recognised how the professionals themselves may act 
as a barrier. They considered the difference in the mind-set between Cystic 
Fibrosis and palliative care indicating that Cystic Fibrosis focused on curative 
care and Palliative care on death and dying. This is reflected by professionals 
from both specialities in the extracts below and was reiterated by three others. 
 
I guess one of the barriers to palliative care not being involved is if you only 
involve them at end of life…. cos you don’t know when end of life is so actually 
more often than not you’re going to miss it or you will be involved too late to 
get to know anyone. I think we hesitate cos we don’t know when to refer and 
we are all about making the patient better whereas…maybe pall care might 
want to stop some treatment (FG/CF Professional 3).  
 
And I think that mirrors other areas where at times sometimes we have the 
impression that actually the barrier is the professionals being able to 
acknowledge where things are at rather than the patients and families 
sometimes there is a sense of relief for patients and families when you realise 
that’s to be talked about (palliative care) um but that’s I accept very hard when 
in a professional role you are in a curative mode we’re in a slightly different 
position in terms of how we work so that’s easier, although palliative care 
doesn’t mean no to active treatment (FG/PC Professional 2). 
 
 
Professionals’ lack of clinical experience was regarded as a barrier with an 
inability to see changes in patients' status that indicated a serious decline in 
health. Having triggers to support clinicians was discussed as a way to 
overcome this barrier and become facilitative to referrals. Furthermore 
traditional training has focussed primarily on curative measures, health 
professionals were considered to find the complex transition from curative to 
palliative treatment difficult to acknowledge (Gardiner et al.2011). This was 
described by one of the professionals in Cystic Fibrosis below. 
 
But perhaps if you were a CF team that didn’t access palliative care triggers  
would be useful in terms of educating the team and cos it’s really the only way 
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that relationship is formed is through positive experiences and steps and when 
the CF team feel the benefit of having that relationship that’s how the 
relationship evolves further so it you have to start somewhere so I suppose if 
you are a team where you are having to access a palliative care team that’s 
not necessarily integrated then having those triggers, like a trigger at 
transplant  to start that relationship off are probably really helpful to give ideas 
of when you can introduce it (FG/CF Professional 8). 
 
 
The perception of palliative care not having the resources to support patients 
with Cystic Fibrosis was highlighted as a potential barrier by one of the 
professionals working within Cystic Fibrosis and reflected on experience within 
Europe. 
 
I think it’s changing  cos I have this discussion frequently in different European 
meetings and I think actually CF teams are wanting it more and more and are 
looking around  to see where they can find pall care teams to work with them 
so as said earlier resources probably is a really key thing cos for many 
palliative care teams really haven’t got any resources to add CF to their emm 
working lives and the time it takes the learning takes but there’s a big rounds 
well now of CF teams trying to look not just here but everywhere, but 
resources must be a huge barrier (FG/CF Professional 5). 
 
 
The participants who were developing services between Cystic Fibrosis and 
Palliative care recognised how the palliative care team being visible and 
approachable on the in-patient unit really helped in facilitating referrals. This is 
captured in the extract below. 
 
Having palliative care on the ward round and coming to the MDT has really 
helped in terms of us making other referrals, when we see the team we think 
oh I must just refer xxx (FG/CF Professional 5). 
 
The participants also discussed how patients can act as facilitators and 
communicate through social media about seeing the palliative care team 
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Equally that can work in that it’s helped them and they some of them do then 
say something positive about it cos they’re always on face book or texting 
each other they know about each other’s treatments faster than we do 
sometimes (FG/CF Professional 7). 
 
The extracts from the focus group reflected what others in the literature have 
alluded to. Several papers concluded barriers towards referring patients to 
Palliative care are that many physicians had significant gaps in their 
knowledge about hospice referral policies and practices and that knowing 
when to refer to palliative care is complex (Bradley et al. 2002, Ahmed et al. 
2004). 
6.4. Summary  
The Focus Group has offered significant insight into the perceptions and 
experience of professionals regarding palliative care. Based on the findings 
from the Focus Group, areas for further questioning in the survey include the 
meaning and understanding of palliative care, referral patterns to palliative 
care, time points for referral between Cystic Fibrosis and palliative care that 
will further question barriers and facilitators of referrals to palliative care 
(Appendix 11, Questions 2-13). The literature review highlighted gaps in 
determining  current models of service provision between Cystic Fibrosis and 
palliative care teams which would be important to explore further within the 
questionnaire (Appendix 11, Questions 14-19). These three areas informed 
the domains for the questions to be asked in the national survey. 
6.5. Phase 2. Findings from the Survey 
The following section will present the findings from the survey that informed 
phase 3 of the study. The survey was conducted to examine in more detail the 
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issues that had been raised by the Focus Group in Phase 1. The participants 
of the Focus Group were approached as they were considered to be experts 
either in Cystic Fibrosis or specialist palliative care. Given that these 
participants were drawn from 2 sites, they were not therefore representative of 
the national picture.  
 
It is clear from the Focus Group data that issues raised related to the 
perceptions and meaning of palliative care and when to refer to palliative care 
services, as well as acknowledging the different ways that teams work. The 
questionnaire was therefore categorised into three domains. Section 1 related 
to referral patterns, section 2 models of care and section 3 demographics of 
respondents. The findings from the survey will be presented under these three 
domains using categorical data and descriptive findings. 
 
It was important to be mindful that in questioning professionals about 
perceptions of palliative care and how services are offered, is often dependent 
on the organisation, its ethos and the way in which it values and integrates 
with palliative care. Organisational culture and service provision are influenced 
by many factors within the current health service. Organisations, on this 
occasion hospitals, are thought of as systems ordered to gain certain goals 
and outcomes. Whilst these organisations can be seen as iterative processes 
of communication and interactions, they are prone to become systems of habit 
however they are not without the potential for transformation (Fonseca 2002). 
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Thus individuals may respond according to their own personal views or simply 
as a product of their organisational culture. This is important in considering the 
analysis of the survey and its wider applicability. 
 
The questionnaire was forwarded to all adult specialist Cystic Fibrosis hospital 
based centres that were registered at the Cystic Fibrosis Trust in 2012 (23 
registered centres). Their potential respective palliative care teams were 
identified based on location. This second professional group were also 
approached to ascertain their view on current service provision for patients 
with Cystic Fibrosis, irrespective of whether or not the Cystic Fibrosis and 
palliative care teams currently had a working relationship. It was clarified, by 
telephone, that all Cystic Fibrosis teams had access to a hospital palliative 
care service. The lead team member for the respective team was identified by 
telephone and the questionnaire was forwarded to them via email. The 
following section will demonstrate the response to questions. 
6.5.1. Responses to Answered Questions 
The overall response rate to the survey was 61% (28/46). Of the respondents, 
the palliative care team return was higher than the Cystic Fibrosis team, 57% 
(n=16/23) were specialists in palliative care versus 41% (n= 11/23) were 
specialists in Cystic Fibrosis. Of the 28 respondents who did return the 
questionnaires, eighteen questionnaires were completed fully. Of the ten 
remaining partially answered questionnaires, 8 respondents completed 
questions 1-13 regarding referral patterns but did not complete the 
subsequent questions on models of care, perhaps reflecting their clinical 
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experience thus far. Of the 10 respondents who did not complete all the 
questions 7 were from palliative care, 2 were specialists in Cystic Fibrosis and 
one was unknown as only the first question was completed. Additional 
comments were documented in thirteen of the questions with the most 
documented in questions 2, 18 and 21. These questions related to why 
specialists felt patients with Cystic Fibrosis may not be routinely referred for 
palliative care, any changes that they would make to the existing service and 
a general comments box for additional information.  
 
One respondent completed only questions 1-4. This was a specialist unit 
working in palliative care and stated that Cystic Fibrosis teams did not refer to 
palliative care therefore they were unable to complete any of the ongoing 
questions. One respondent completed the first question only, stating that 
Patients with Cystic Fibrosis were not referred to palliative care and hence did 
not complete any of the remaining questions. Below Table 18 illustrates the 
response to the questionnaire. 
The following section will describe the data from the first domain of the 
questionnaire which relates to referral patterns between Cystic Fibrosis and 
palliative care teams 
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Table 18. Number of Respondents to Survey Questions 
Total numbers of Questionnaires forwarded 46 
Total Number of Questionnaires returned     28  
Questions answered Numbers of Respondents Response by Speciality 
Cystic Fibrosis (CF) 
Palliative care (PC) 
Unknown (UK) 
All questions 18/28 CF (9) 
PC (9) 
Questions 1-13 8/28 CF(1) 
PC(6) 
UK(1) 
Questions 1-4 1/28 PC 
Question 1 1/28 CF 
 
6.5.2 Referral Patterns 
When professionals were asked if patients with Cystic Fibrosis were routinely 
referred to the palliative care team, 100% (n=28) of respondents replied with 
less than 50% of the teams indicating they routinely refer patients between 
Cystic Fibrosis and palliative care. In aiming to understand why patients with 
Cystic Fibrosis may not be referred and to further understand the perception 
of a referral to palliative care the participants were asked why they thought 
such referrals may not occur. Fourteen of the fifteen teams who do not refer 
gave a reason (24 reasons in total). The most common reasons were that 
professionals are unsure when to refer Patients with Cystic Fibrosis to 
palliative care  (n=9), this was followed by over half of the respondents stating 
that Cystic Fibrosis teams themselves can manage palliative care needs. 
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The issue of patients not wanting to be referred to palliative care was stated 
by 4 respondents. This issue was discussed further in the interviews in Phase 
3. Table 19 below illustrates the reasons why patients are not routinely 
referred to palliative care services. Interestingly the palliative care team 
response is higher than the Cystic Fibrosis teams in regards to difficulty in 
knowing when to refer to palliative care services. 
Table 19. Reasons why patients are not routinely referred to Palliative care 
services (n=24 responses from n=14 respondents) 
Reason 
Number of respondents 
SPC CF Total 
CF teams can manage PC needs 3 4 7 
Implications for staff training 2 0 2 
Lack of PC resource  1 1 2 
CF patients not wanting referral 2 2 4 
Difficulty re timing of when to refer 6 3 9 
 
In terms of referral numbers, the majority of teams (n=14) stated that between 
1 and 9 Patients with Cystic Fibrosis are referred to palliative care in a 12 
month period. It was also evident that four teams referred 10-25 patients and 
three teams referred 25-49 patients. One team recognised that on occasion a 
patient can be referred several times during the course of one admission. 
Interestingly of the teams who answered positively to Patients with Cystic 
Fibrosis being routinely referred to palliative care,  54% of these referrals were 
made through the Multi DisciplinaryTeam meeting. Alternatively referrals are 
commonly made by telephone. In addition one team stated they would make 
referrals directly to the consultant via email. 
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This needs to be interpreted in the context that 11 of the teams stated the 
numbers of Patients with Cystic Fibrosis seen annually by their service. For 
those who saw >100 patients per year, one referred 25-49 patients to 
palliative care per year, 3 referred 10-25, 4 referred 1-9 and one referred no 
patients to palliative care. The two smaller centres who reported seeing 50-
100 patients per year both referred 1-9 patients. 
 
For the 9 Cystic Fibrosis teams that reported seeing >100 patients per year, 
they referred between 3-8 patients for transplant each year. Three of these 
teams considered transplant a trigger for referral to palliative care, 
interestingly these three teams all reported weekly meetings between Cystic 
Fibrosis and palliative care and a ‘fully integrated’ service. Within this question 
the respondents were given the option of considering if their service was fully 
integrated, partially integrated or not integrated at all. A fully integrated service 
was one where Cystic Fibrosis and palliative care teams were working closely 
together meeting regularly, using shared guidelines for the management of 
symptoms. For the 6 teams who did not use transplant as a trigger, three of 
them stated that they thought this might be important. Of the 6 teams, 3 never 
met with their palliative care team and 3 met with them ‘as needed’ and they 
described their services as partially integrated (n=1) or not integrated (n=5). 
The two smaller services (50-99 CF patients per year) referred 3-5 patients for 
transplant and one considered transplant a trigger for referral to palliative care 
, neither had regular meetings with the palliative care  services. 
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Full integration referred to Cystic Fibrosis and palliative care teams working 
closely together meeting regularly, using shared guidelines for the 
management of symptoms. This was described by four teams (3 above plus 
one smaller team). Only two of the teams recognised that they were working 
towards developing shared guidelines, therefore none of the services were 
currently providing a fully integrated service based on the offered definition. 
Over half the teams do not have joint meetings (56%); but for those who do 
meet (44%) they tend to meet on a weekly basis. The teams acknowledged 
the level to which they work together. The majority of teams, 54%, identified 
that they did not feel they were integrated at all. Partial integration was 
reported by 31% respondents and 15% felt they were fully integrated and 
worked closely together. 
 
In trying to understand what teams’ cognise about the meaning of palliative 
care they were offered to select from two definitions, the definition that best 
fitted their current practice. The majority of the respondents declared that the 
most recent WHO (2002) definition best reflected their practice (early referral 
as opposed to end of life). The definition selected by 81% of the respondents 
declares that palliative care should be offered to patients early in the stage of 
their illness in conjunction with other therapies that are intended to prolong 
life. Interestingly one team acknowledged that they use the first definition 
(end-of-life) but believed the 2nd (early referral). A further team identified that 
in their service most teams are referred for the former definition and are not 
referred earlier in the disease pathway. 
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Participants were invited to consider 9 reasons for referral between Cystic 
Fibrosis and palliative care and they could select more than one reason for 
referral by their service. 26/28 responded and selected each of the 9 
responses on 4-23 occasions (total 122). The most common response 
(selected 23 times) was that patients would be referred for symptom control. 
The prevalence of symptom burden is recognised in patients with Cystic 
Fibrosis especially within the last week of life (Dellon et al. 2010). The 
question in the survey did not differentiate at what stage of the patient’s illness 
would trigger a referral for this. The second most frequent reason was patients 
being referred for end of Life Care (19), with advance care planning, support 
with end of life care pathways and psychological support being the joint 3rd 
most common reasons for referral (16 each). Community Support and Support 
with family discussions may be lower as patients with Cystic Fibrosis tend to 
be admitted to hospital for end of life care due to strong relationships with the 
team who will have had many family discussions over the course of the illness 
and patients wishing to be in a safe environment (Bourke et al. 2009). The 
reasons for referral are illustrated in Figure 6. 
The newer definition of palliative care (WHO 2002), which teams stated 
working to, identifies an important element in addition to symptom control, 
psychosocial support and focus on quality of life. It also includes access to 
early palliative care which runs alongside and in conjunction with other 
treatment modalities. Interestingly the response to ‘When to introduce 
palliative care’ did not reflect that teams were working to this expanded 
definition with few respondents selecting introduction early in the pathway or 
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Figure 6: Referral Reason between Cystic Fibrosis and Palliative care 
 
 
for support in the community setting. A referral early in the patient’s disease 
pathway was perceived to be one of the least important times to introduce 
palliative care. This may be important as it has been suggested that 
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Figure 7: When is the Best Time to Introduce Palliative care to Patients with 
Cystic Fibrosis 
  
6.5.3 Models of Care 
In aiming to establish the current model of care provided, participants were 
invited to select a description of their current service provision between Cystic 
Fibrosis and palliative care. This was to try and understand if the teams were 
working together at any stage of the patient’s illness or if it was focused more 
towards end of life care. 
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treatment options limited. The models of care were based on information from 
the National Council for Palliative Care and are the most common practices of 
hospital Palliative care teams (NCPC 2006). In this question 18 responses 
were received; half of these described concurrent management versus 
consultative (as required) only. Where there was concurrent management 2/3 
occurred only when treatment options had become limited rather than 
throughout the course of the illness. Currently there are no nationally agreed 
guidelines on the referral criteria between Palliative care other specialities 
(APM 2012). Referral criteria to Palliative care and models of care are 
individually constructed by teams based on the service they offer. 
 
Resource issues were not highlighted by teams in a previous question as 
being a limiting factor of service provision.  Thus it is more likely that the 
observations could be related to difficulties in determining the referral criteria 
for this group of patients. Interestingly one team suggested that Cystic 
Fibrosis teams may still not refer patients with complex needs as they feel 
they have the skills to manage them and therefore education as to what 
Palliative care can offer is likely to be invaluable to both patients and staff. 
This is addressed further in the results of the patient/staff interviews. 
 
Regarding guidelines for referral between services, 17 respondents answered 
this question with a universal response of 100% of teams identifying that there 
were no specific guidelines for referrals between Cystic Fibrosis and Palliative 
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care. Interestingly two teams identified that they were working towards specific 
guidelines between Cystic Fibrosis and Palliative care teams. Other teams 
identified that they worked within generic guidelines for referral to Palliative 
care. As there is a lack of clarity relating to referral between the teams specific 
guidelines may help in determining when to refer patients with Cystic Fibrosis 
to Palliative care. 
 
Respondents identified that they were split in terms of whether they would 
make any changes to working together. Fifty per cent of teams reported that 
they would make some changes to the way they worked together whilst the 
remaining 50% believed the service worked well as it was. This is despite only 
four services reporting a fully integrated working service although only two of 
these were working towards shared guidelines. Of the teams that said they 
would like to make changes to the existing service, this was more likely to be 
raised by palliative care teams. However a third of Cystic Fibrosis teams 
commented that they wanted to increase links with palliative care teams. The 
perception is that palliative care feels that although the relationship is good 
with Cystic Fibrosis teams the service could be delivered in another way and 
would like to change some elements of the current service provision. 
 
6.5.4 Demographics of Respondents  
It is difficult to interpret all the results relating to the Whole Time Equivalent 
within each service due to the set-up of the question being unable to accept 
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non whole numbers. Whilst teams tried to complete this, some of the numbers 
are difficult to interpret. It would seem that from the respondents all teams 
have access to some members of the multidisciplinary team. The majority of 
the professionals had experience of either working in Cystic Fibrosis or 
palliative care for over ten years representing professionals who would have 
knowledge about the service delivery for both specialities. 
Additional comments generated from free text in the questionnaires can be 
viewed in Table 20 below. Cystic Fibrosis teams commented that they felt they 
could manage patients palliative care needs. They also recognised that they 
would like a more formal structure to the teams meeting up. 
Table 20. Information Generated from Additional Comments from the 
Questionnaire 
Additional Issue Cystic Fibrosis  Palliative care Cystic Fibrosis and 
Palliative are 
Lack of clarity 
and guidance 
about when to 
refer to Palliative 
care including a 
lack of referral 
guidelines and 
trigger points. 
 
  Nine respondents 
recognised clearer 
referral  guidelines and 
or triggers for referral 
between the 2 teams 
would be helpful 
Cystic Fibrosis n=3 
Palliative care n=6 
Team working 
and relationships 
 
5 respondents felt that 
CF teams could 
manage patients 
without additional 
support from Palliative 
care 
3 respondents from 
CF said they would 
like there to be a more 
formal structured 
approach to meeting 
with Palliative care 
 Seven respondents 
acknowledged that they 
wanted to work closer 
together with respective 
Cystic Fibrosis and 
Palliative care teams 
Cystic Fibrosis n=4 
Palliative care n=3 
 
 142 
 
6.6. Summary 
The findings from the survey demonstrate that there is no universal process 
within Trusts in terms of referral to palliative care services. It is clear that a 
lack of clarity around the timing of referral of patients with Cystic Fibrosis to 
palliative care is one of the key areas for further development. Transplant has 
been raised as a time point to consider referral to palliative care which does 
not fit with current practice according to the feedback from the questionnaire. 
The majority of teams meet on an “as required” basis and there are no shared 
guidelines to support the working practices between the two teams currently. 
The key issues that have emerged from the survey are; 
 lack of clarity around when to refer to Palliative care,  
 patients are considered to be referred too late,  
 lack of shared guidelines to work towards and there is limited integration 
between teams. 
 
The concept of timing of referral to palliative care along with perceptions of 
palliative care will help form the topic guide for the semi structured interviews 
in Phase 3 of the study. 
6.7. Phase 3. Findings from Patient and Professional Interviews 
The following section relates to the findings from the semi structured 
interviews conducted within Phase 3 of the study. Three themes have been 
generated from the interviews, namely, understanding of palliative care, 
establishing connections with service providers and constantly redefining the 
future.  The three themes can be viewed in Table 21 but will be discussed 
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individually throughout this section. The patients and professionals generated 
the same themes with an exception in theme 3 where the sub category of 
patients receiving affirmation from external sources regarding their life 
expectancy was identified. The interviews were organised using NVivo 10 and 
were categorised into nodes. The themes have been created using the 
principles of Grounded Theory analysis from the evolving categories and sub 
categories. The themes will be explored separately and dialogue from the 
interviews will show the emerging categories through the process of constant 
comparative analysis. For reference the extracts are coded Patient or 
Professional followed by a number to ensure anonymity of the participant. 
 
Table 21. Themes generated from Interviews 
Theme 1 Theme 2 Theme 3 
Understanding of 
palliative care 
Establishing 
connections with service 
providers 
Constantly redefining 
future 
 
6.7.1. The Interview Participants 
There were seventeen participants who agreed to be interviewed. Of these 
seventeen interviews, nine were health care professionals caring for patients 
with Cystic Fibrosis. The remaining eight interviews were patients with Cystic 
Fibrosis. One of the patients (Patient 02) had been diagnosed with the 
disease in the last decade and was older in age than the other participants. In 
terms of the interviews that took place on the research sites, eight of the 
interviews took place at a Trust B and nine took place at a Trust A. Information 
relating to the participants involved can be viewed in Tables 22 and 23 below. 
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Table 22. Patient Participant Demographics 
Participant ID Age  Diagnosis  
Patient 01 33 Cystic Fibrosis 1. 
Cancer 2. 
Female 
Patient 02 68 Cystic Fibrosis 
 
Female 
Patient 03 31 Cystic Fibrosis. Female 
Patient 04 26 Cystic Fibrosis. Female 
Patient 05 36 Cystic Fibrosis. Male 
Patient 06 25 Cystic Fibrosis. Female 
Patient 07 23 Cystic Fibrosis. Female 
Patient 08 37 Cystic Fibrosis. Male 
 
 
Table 23. Professional Participant Demographics 
Participant ID Age Speciality Length of 
experience 
working with CF 
Professional 01 27 Cystic Fibrosis. 18 months 
Professional 02 39 Palliative care 18months 
Professional 03 34 Cystic Fibrosis.   2 years 
Professional 04 34 Palliative care 19 months 
Professional 05 57 Cystic Fibrosis).   6 years 
Professional 06 36 Cystic Fibrosis 13 months CNS 
previous years 
with CF team 
Professional 07 43 Cystic Fibrosis. 15 years 
Professional 08 41 Cystic Fibrosis 5-6 years 
Professional 09 49 Palliative care  5 years 
 
The following section will present findings from Theme 1 which relates to the 
patients and staff understanding of palliative care. 
 
6.8. Theme 1: Understanding of Palliative care 
Understanding the term palliative care and what a referral to palliative care 
means is recognised as a known limiting factor in the referral process of 
patients to palliative care services. Heterogeneity in what palliative care 
services offer in different areas and in different organisations is complex and 
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equity in the way services are configured is dependent on localities (Ahmed et 
al. 2004). Understanding palliative care has been generated as a theme with 
categories of perceptions and knowledge of palliative care and concurrent 
active Cystic Fibrosis treatment and palliative care.  Sub categories of the 
term palliative care, access to information, time-points of referral to palliative 
care and access to services have been identified. Table 24 demonstrates the 
theme, categories and sub categories. A copy of the development of theme 1 
can be viewed in Appendix 23. 
 
Table 24. Theme 1 Categories and Sub Categories 
Theme Category Sub-Category 
 
Understanding of 
palliative care  
Perceptions and Knowledge 
about Palliative care from 
both patients and staff 
 
Concurrent Active Cystic 
Fibrosis treatment and 
palliative care  
The term palliative care 
 
Access to information  
 
Time points of referral to 
palliative care 
 
Access to services 
 
6.8.1. Perceptions and Knowledge 
The perceptions and knowledge of palliative care was generated from the data 
as a category. Perceptions and knowledge are influenced by a myriad of 
issues and in this study influenced the ways in which patients and staff 
understood palliative care. Studies have previously demonstrated that patients 
with other non-malignant conditions have recognised palliative care as being 
synonymous with end of life care (Metzger et al. 2013). 
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6.8.1.1. The Use of the Term “Palliative care” 
 
Patients and staff had different views about the term palliative care. There was 
confusion varying from not understanding palliative care at all to only 
associating it with death and dying. Some of the professionals had 
experienced positive responses when they first discussed a referral to 
palliative care with patients with Cystic Fibrosis. One of the professionals in 
Cystic Fibrosis discussed that sometimes it is the professionals who are more 
concerned about referring to palliative care than patients are of actually 
hearing about the service. This is reflected in an extract below from one of the 
professionals. Interestingly this was also identified within the Focus Group 
data. 
 
A lot of the patients really appreciate meeting palliative care early and don’t 
find it as scary as we think they will. I think sometimes staff perception is oh 
God but actually they (patients) go oh brilliant you know so and so who I 
spoke to on face book met you and you were really helpful with them and I 
have this horrid pain and they can’t get rid of it can I talk to you about it and 
they find it really positive. I think sometimes staff preconceptions of palliative 
care rather than patients because they won’t have any because they won’t 
know what it is if they haven’t met pall care probably. Patients don’t always 
find it as scary as we think they will I think sometimes staff perception oh God 
don’t refer them to palliative care because they’ll think they’re dying… I’ve only 
ever I think once mentioned to patient about palliative care and they’ve said 
no thank you I don’t need them I’m not dying but every other time the patients 
have always been receptive (Professional/CF 01). 
 
 
In one of the research sites the professionals acknowledged a change in the 
way palliative care was referred to and described what that change meant. 
They recognised that palliative care was no longer considered solely at the 
end of life and should be associated with helping patients to live with a life 
threatening illness both earlier in their disease and for longer periods of time. 
This resonated with the definition of palliative care (WHO 2002) but not all 
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professionals thought this. One of the palliative care professionals described 
this below. 
 
Maintaining a quality of life within the, context of that life threatening illness. 
So whether that be through symptom control, emm maintaining their 
independence making sure that they can ye know they’re socially able to 
function emmm support for their family and sometimes it’s actually the small 
things that make all the difference. And that’s very much about what palliative 
care is, I’ve learned very much that it’s not about end of life care it’s not purely 
about dying anymore. It’s about living with a life threatening illness but living 
well with a life threatening illness and seeing patients early and longer 
possibly. (Professional/PC 02). 
 
 
Another of the palliative care professionals acknowledged that they 
considered the term palliative care to refer to patients who were in the last 
year of life. Interestingly if patients were referred earlier in their disease they 
referred to their service as either symptom control team or described being 
there to provide other support services. This was also discussed by other 
professionals. The rationale behind this was to ensure the patient was not 
distressed at being introduced to palliative care. This is of interest as one 
would believe that palliative care specialists would feel confident in introducing 
their speciality but not in the case below. 
 
I would describe palliative care as care for a person that has been diagnosed 
with an incurable disease or illness; however you want to describe it.  And 
particularly I feel palliative care is or should be involved in the last year of the 
patient’s life. Obviously, we are asked quite early on in the stage of the illness, 
and then I would describe myself as a specialist who is here to look maybe at 
symptom control or to provide psychological support. We don’t want to upset 
anyone with what we say (Professional/PC 04). 
 
One of the Cystic Fibrosis professionals discussed how they understood that 
all Patients with Cystic Fibrosis have palliative care needs. She became quite 
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angry when talking about palliative care being introduced and indicated that 
patients would not believe that palliative care is not about dying. Her anger 
seemed to depict her own view of palliative care and was transferring this onto 
what she thought the patient would say. 
 
R. Do you think palliative care may have an impact on hope and the 
future? 
 
No. Not at all! But I think it’s more the stigma that, for our patients anyway, it’s 
about stigma.  And they all have... in my opinion they all have their little 
milestones, if you like, as to stigma attached to it, so it’s like, for example, 
once you start using a certain nebuliser – that’s because... the other one isn’t 
working and they’re not working any more.  Do you know what I mean? So 
the... there’s like a little  and I had a really in-depth conversation with the 
patient just before Christmas who – and in fact I’ve known her since I first 
qualified, she obviously feels comfortable with me and she’s saying, ‘This last 
year I’ve been in hospital three times. So if were to bring in a palliative care 
nurse, even at that point, she might not believe me. She’s not going to believe 
me (Professional/CF 06). 
 
R. Because of what palliative care means? 
 
Yes. 
 
R. Which is? 
 
That it’s the beginning of the end. Yes, yes. I mean our patients are all 
palliative all the time regardless.  But it’s at what point is that palliation the 
beginning of the end?  And that’s the difference with our patients. I mean 
things, things are changing but they are different do you understand, you 
know, there are a lot of fitter patients through. But we’re also getting a cohort 
of patients that their... transition they are poorly and they’re in and out all the 
time. So they are having constant palliation because – and they’re the ones 
that the nurses think, ‘Oh for God’s sake, don’t do it if they don’t feel like 
exercising today,’ you know what I mean? (Professional/CF 06) 
 
 
The association of palliative care with cancer is recognised as being an issue 
in understanding what the service can offer patients with non-malignant 
disease (Fallon & Foley 2012). One of the Cystic Fibrosis professionals 
described how difficult they find discussing palliative care issues. This 
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illustrated the need to help support Cystic Fibrosis clinicians in terms of 
education and training around principles of palliative care issues and difficult 
conversations. 
 
What I usually say to patients is, because patients, when they’re palliative, 
they don’t understand it.  Or they do and they immediately associate it with 
cancer. So I possibly kind of mention it in an offhand sort of way, palliative 
care is a term that is associated with cancer, it doesn’t mean death and dying 
and all that kind of thing, it’s just a term that’s used for sort of long term care 
or – I don’t know, I find it really difficult to broach it, very difficult to broach that 
sort of aspect of it, unless I’ve got a really good rapport with them.  And I know 
the patient and I know that I can be open and honest and come straight out 
with it (Professional/CF 07). 
 
 
For the patients there were mixed views about the use of the term palliative 
care. Patients felt that if it was explained properly there most likely was not a 
need to change the name to something else although this was not unanimous. 
For Patient 03 at the beginning of the interview she did not think it would be 
necessary to change the name but on talking about it she then changed her 
mind. 
 
 If you were coming to say, ‘Oh we’re going to help with symptom control,’ 
you’d think, ‘Oh yes; I’m feeling I’d like to have a relationship with her because 
she’s going to help me.’  Now, but right at the beginning I thought, ‘Ooh... 
changing the name won’t matter’  As we’re talking, yes probably because 
symptom control makes it easier to understand what palliative care is… 
maybe I do think it’s about death (Patient 03). 
 
 
One of the patients raised an interesting point in that patients with Cystic 
Fibrosis are a younger population and they would search the term on the 
internet which will inform them that it has something to do with end of life care. 
In the extract below Patient 05 suggested that a better description of what 
palliative care is about would help. The information that is available invariably 
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relates to end of life care which may not always be applicable to this group of 
patients. This is described in the extract below. 
 
Oh yes, I’d probably change it if – yes, if I mean, if people google it man.  But, 
yes, unless of course you say, ‘I’m from palliative care, which means...better 
control of symptoms and blah, blah, blah.’ So yes maybe don’t change it just 
offer a better description (Patient 05). 
 
 
Patients 06 and 08 also recognised that when they had symptoms they were 
not concerned with the name of the team they just wanted their symptoms 
eased. Patient 08 also acknowledged that over time the public view towards 
issues change but recognised that explaining that palliative care is more than 
death and dying was important. 
 
I think it’s just a new generation growing up will learn it means a different 
thing.  So it will be fading out in the end. You know, as they do with driving 
tests now, it’s all done differently, whereas my generation it was done 
differently. So they phase it out rather than change it.  I think it would be a 
waste of time trying to change it. It will cause confusion. I think it’s better 
phasing it out and the next generation will come through and will know it 
means something different but people need to explain it better. When you’re 
sick you just want help doesn’t matter about the name (Patient 08). 
 
 
The term palliative care continues to have an association of death and dying. 
It has been recognised that from a professional perspective the name 
supportive care is better than palliative care (Fadul 2009). The perception is 
that supportive care does not take away hope from patients and families and 
in the cancer population has encouraged oncologists to refer to the palliative 
care team (Fadul 2009). There appears to be a gap for both patients and staff 
in understanding what the term palliative care means. The patients would in 
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the main, be in agreement with the term being the same if there was better 
explanation around what the service can offer.  
 
6.8.1.2. Access to Information 
Both patients and professionals recognised that information relating to 
palliative care as a service and what it has to offer could be portrayed in a 
better way. palliative care staff discussed how not being part of the Cystic 
Fibrosis information that was available to patients did not make them feel part 
of the extended team and patients spoke of not knowing what palliative care 
could offer. It was acknowledged by both patients and staff that this influenced 
perception of palliative care and how it was viewed as being integrated with 
Cystic Fibrosis. For one of the professionals, working in palliative care and not 
being referred to anywhere in the Cystic Fibrosis patient information 
exemplified the lack of integration perceived between Cystic Fibrosis and 
palliative care which is captured in the extract below. 
I mean they think we do work together and we do I guess, it’s just we are not 
on the patient information board with the rest of the MDT or mentioned in any 
of the booklets. (Looks disappointed) it’s a bit gutting really you try so hard to 
be part of it all. What’s that all about...? It’s like we are the service that comes 
out of hiding when they (CF) want us (Professional/PC 02). 
 
 
Providing appropriate and timely information to patients has been recognised 
within the literature. Intrinsically linked to patient’s agreeing to have support 
from palliative care is their understanding of what the service is trying to offer. 
It has been identified that patients have often not had access to information 
about services delivering care (Ronaldson & Devery 2001; APM 2012). 
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Professionals in Cystic Fibrosis also described that they would like access to 
more information on what palliative care services can provide. For 
professionals 07 and 09 knowing what the palliative care service could offer 
was important. This is highlighted by Professional 07 in the extract below. 
Interestingly although part of the core Multi- Disciplinary Team, she did not 
feel she had a role to play in initiating discussion about referrals to palliative 
care. 
 
I think for a start it would be nice for everyone to know exactly what palliative 
care do in our setting, if we know exactly what they do and what they can 
offer, because I don’t know exactly because obviously I don’t get involved in 
referrals maybe I should but am there supporting patients.. And I don’t know 
any other way or who else would help us know what palliative care can offer. 
(Professional/CF 07). 
 
From a patient’s perspective it was acknowledged that it was only when she 
was given written information about palliative care that she realised more than 
physical symptom control was on offer as part of the service to patients. 
 
 
Yes, I mean they were very clear with, with the role of kind of – well in terms of 
dealing with the sickness, they didn’t say too much about their roles generally. 
But they said about, you know symptom control and so that was very much 
what I was aware that they were there to sort of deal with. And yes they were 
helpful kind of with suggestions and talking things through. But it was only 
when I got given the leaflet a while later that I saw about the emotional and 
practical sort of side, because that’s never been sort of mentioned before 
(Patient 06). 
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A further patient acknowledged that not knowing about the service made her 
scared and if staff did not inform her about the service how would patients find 
out about it. 
I, I didn’t really know what palliative care had to offer. If you knew what it was 
about it wouldn’t be scary. If the staff won’t talk about it then how can we ever 
know what it is? Yes and living with it and...you know, if you can get your pain 
under control and stuff like that, then you can get on with... a normal day and 
stay and go to work or whatever.  So all that side of life... life planned out for 
you. And I think yes the ones that... might not die from it and those that might 
are as important (Patient 07). 
 
The confusion of roles has been previously highlighted in the literature relating 
to other non-cancer diseases as well as difficulties around the organisation of 
health care and the unpredictable nature of the illness (Hanratty et al. 2002). 
Knowing what the service can offer was important to the patients and 
highlighted in the extracts below. In the extract below Patient 04 felt left in the 
dark about services and what else was on offer. 
 
Yes, or I think just be more open about what actually the service can offer, 
sort of maybe even just posters on the wall, you know, around the walls or 
something, just, because I wasn’t aware of much at all. And sort of I miss quite 
a lot. And yes it was like saying, they sort of mentioned to me about the 
sickness, nothing at all about any other things that could be talked through. So 
perhaps just more information available to patients about what they can 
access from palliative care really (Patient 04). 
 
For one of the patients below being able to make a self-referral to palliative 
care was a consideration following access to an information booklet on what 
the palliative care team could offer. 
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Yes, I mean just if I, if I was sort of feeling very down, I don’t really know who I 
would tell in the CF team, So I suppose if a leaflet could be given out at the 
annual review, I think that would be helpful. But then I think, as well if there 
was some information, even if it was just a few posters around the ward. So 
kind of two approaches really, you know, so one at the annual review, but also 
if people come in and feel they need that bit of extra support or help with 
symptoms, you know, they can kind of access it in both (Patient 05).  
 
 
From these extracts it is evident that clear information in a variety of formats 
for both patients and staff may help in determining what a palliative care 
service has to offer and help in empowering the patients to feel in control of 
the support they need. However, equity and barriers of access to palliative 
care for patients cannot go unnoticed. Local services define referral patterns 
and modify services accordingly. This has previously been recognised in the 
literature looking at access to palliative care services (Ahmed et al. 2004). The 
following section will discuss the second category of concurrent active Cystic 
Fibrosis treatment and Palliative care with sub categories of time points of 
referral to palliative care and access to services. 
 
6.8.1.3. Concurrent Active Cystic Fibrosis Treatment and Palliative care 
The benefits of palliative care being involved in cancer patients earlier in their 
disease process have been recognised previously (NICE 2004; Temel et al. 
2010). This study looked at patients with lung cancer but acknowledged that in 
this group most health care professionals believed that palliative care is 
synonymous with end of life care. Some of the participants in the interviews 
found it difficult to consider active care for patients with Cystic Fibrosis and 
palliative care running in parallel. 
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It is recognised that patients’ survival with Cystic Fibrosis is increasing which 
is leading to an adult population living with this disease (CF Trust 2013). 
Patients with Cystic Fibrosis experience exacerbations of their illness and the 
unpredictability of what the future holds can be challenging for staff being able 
to determine if the patient will survive the next exacerbation or not Cystic 
Fibrosis. Professionals acknowledged that treating patients’ right to the end of 
life was important. 
 
6.8.1.4. Time Points to Referral to Palliative care 
The professionals discussed the confusion relating to when to refer to 
palliative care and both patients and staff highlighted transplant and the 
Annual Review as key time points to consider accessing palliative care. Six 
professionals indicated that lack of guidance regarding when to refer to 
palliative care was a barrier, which was directed towards the unpredictability of 
the patient’s prognosis. This was recognised by specialists from both areas 
signifying their belief that palliative care related to end of life. Two of the 
professionals alluded to this in the extracts below 
 
We haven’t got a clue when to see patients with Cystic Fibrosis because the 
CF team are so involved with their care we’re not sure when to push to see 
people likewise I think they’re kind of not sure when to get us involved 
because it’s hard to know when the patient is dying (Professional/PC 09). 
 
Our patients are fighters being referred to palliative care would just be a sign 
that they’re dying and would not be helpful. They’re not like other patients, like 
cancer patients they live when they’re well and don’t want reminded that 
they’re dying and we know that’s what palliative care is about 
(Professional/CF 07). 
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It was recognised by both staff and patients that waiting until transplant was 
discussed was too late and a referral to palliative care should happen earlier 
as the burden of symptoms could be problematic. One of the professionals in 
the extract below recognised that waiting until transplant was being 
considered might be too late to be seen by palliative care. 
I think we should use this as a trigger but…., I mean transplant is used for a 
kind of marker, but I think nowadays we have so many other patients that 
they, even though they’re getting close to transplant, you know, assessment 
or getting close to that point, they feel they still have quite a high burden of 
symptoms that’s the time to say, ‘Okay you should now be seen, you know, or 
just introduced to the palliative care team (Professional/CF 03). 
 
 
One of the patients was surprised to hear that one of her friends with Cystic 
Fibrosis has been referred for a transplant but has not been introduced to a 
palliative care team. She went on to discuss that she felt confused as to why 
she had been referred and her friend who was on the transplant list which she 
saw as a last resort had not been referred. 
 
Yes definitely. I was really surprised that she didn’t really have...it it’s like that 
is crunch time kind of thing.  Actually I say that she’s now on the new drug 
Kalydeco.  I think she loves it at the moment.  But yes I would have thought 
that that would kind of go... perfect being referred when on the transplant list 
and seeing palliative care (Patient 07). 
 
 
A patient also recognised the importance of adequate symptom control when 
waiting to hear about a transplant to allow as normal a life as possible to 
continue. This patient was quite unwell and felt that his pain control had 
improved significantly following review by palliative care 
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Yes, when you’re on the transplant list, if you’re waiting, you’re forever waiting 
for that phone call.  But if you can wait without pain, you know, that’s a relief 
so seeing the palliative care team before might be a better way. The palliative 
care team really helped me and my mum; don’t care what it’s called (Patient 
08). 
 
 
In one of the centres when transplant is considered the patient would be 
referred for review by palliative care. All the patients acknowledged that this 
would be a good time to trigger a referral. This is highlighted in the extract 
from one of the patients below. 
 
I think when you are being considered for transplant you kind of know things 
are not looking good, you’re kind of dreading that happening but I would 
imagine by the time you’re at that stage your symptoms are pretty rubbish and 
if palliative care can help with symptoms then we should be referred (Patient 
01). 
 
 
Most patients with Cystic Fibrosis are invited to attend an “annual review” 
where they meet all members of the Multi- disciplinary team and have a 
review of their disease. At this review they have access to all the support 
services involved in their ongoing care. The patients and staff brought this 
time period up as a potential time to be introduced to palliative care or to at 
least be offered information on what the service provides. 
 
And obviously you see your consultant, physiotherapist, the dieticians and the 
diabetics. And again that can be quite informal. It’s like just having a chat and 
saying, you know, what they’ve got for you this time, and if you want to, you 
just chat and then all you have to do is come anyway so palliative care that 
could be introduced at the same time. Yes, then it would be, yes.  I think we 
would accept it as part of the team (Patient 03). 
 
One of the patients recognised that knowing about palliative care when you 
are well and getting information at the Annual Review would be helpful. 
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I mean if it was introduced maybe a bit earlier, so like at an annual review or 
something, so it’s just the standard thing, where someone actually saying, 
‘Look you need to,’ or someone’s coming to see you or might do from 
palliative care, at least that way, you know, people can have a chat then with 
someone about it, and if they’re feeling well, that’s fine, and if they’re not, then 
at least they can get it fixed. So, but I think the whole kind of introducing 
someone like just like now coming in and saying, ‘I’m from palliative care, I 
need to speak to you,’ then, you know, okay. So yes, I mean, even if it’s 
written information (Patient 05). 
 
 
One of the professionals was cognisant of the fact that involving palliative care 
at the Annual Review through some form of communication would help with 
integration and make it seem like part of the Cystic Fibrosis service. 
 
 
I don’t know why we don’t have palliative care at the annual review maybe we 
could have a DVD or written information that we could show the patients I 
don’t know why we haven’t thought about that before as all the other MDT are 
there. Maybe resource would be an issue (Professional/CF 05) 
 
One of the palliative care professionals considered why palliative care might 
not be involved as routinely as they might be with other specialities and 
recognised that because the Cystic Fibrosis team is multi-disciplinary that the 
way Palliative care can help is limited. 
 
They’re not saying no to palliative care I think it’s because there are other 
members of the team that deal with the I think the barriers are they’re (CF) 
such a specialist team that I like as I said we get the left overs if you like so 
you’ve got the clinical psychologist dealing with all the psychology you’ve got 
the physio dealing with all the chest and the breathing you’ve got the 
consultants dealing with all the drugs emm you’ve got the dieticians dealing 
with all the nutrition  emm so actually the barrier is so where actually do we fit 
in to this specialist team where is our role I think that’s the only thing that they 
get stuck on is the symptom control it’s kind of like we will get you in this way 
(Professional/PC 02). 
 
 
It is evident that considering an introduction to the palliative care team is 
important around the time of the annual review to make it link in with the other 
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services that are available. Resource would not allow for all patients to be 
reviewed face to face but this could be a trigger to ensure information relating 
to palliative care is available. 
 
6.8.1.5. Access to Services for Patients 
Being able to access certain services in a timely way for patients was 
recognised as being important. The following patient extract recognised that 
access to some services was limited and was something she found quite 
frustrating as she was unable to do anything about this herself. 
 
If I come in now and if I said to them today, ‘I think I could do with speaking to 
the counsellor,’ I don’t have, I know that a counsellor may be available, but I 
don’t feel that if I really needed to speak to a counsellor this afternoon, that 
somebody would be available, because I know it’s arranging the time and 
booking it. So I wouldn’t have confidence if I said, ‘Can I speak to a 
counsellor?’  It could be a week or two weeks before I got to speak to one, I 
don’t really know what’s on offer (Patient 01). 
 
 
Patients felt strongly that if one centre was going to have access to palliative 
care then other patients in other centres should have similar access to ensure 
equity. They also mentioned how they felt disempowered on occasions as 
they were not always aware of the services that were available or how to 
access them. 
 
I just think generally with the CF care, I think it’s really important to have an 
equitable experience. So if it’s something that’s going to be introduced here 
(research site) or whatever, I think it should, if it is found to work, it should be 
available to everybody that has a need for it.  Also remember to make sure 
that everyone on the team remembers to talk about it – that’s the problem I 
had that with the psychologist, like no one was talking about the fact that it 
was there.  And so yes just make sure that everyone kind of is aware that the 
resource is there, so then they can start referring them or let us refer 
ourselves maybe?(Patient 04). 
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Some of the professionals also acknowledged the challenge there might be 
from a resource point of view meeting the needs of the Cystic Fibrosis teams 
were referrals made on a regular basis. The following professional recognised 
that their service would more than likely be limited to hospital care although 
acknowledged that being accessible for outpatients might be a good idea. 
 
 
We couldn’t have that, I mean at the moment I’m not sure what their need will 
be because we don’t even go in there so I don’t have that many patients that 
they that are symptomatic or needing end of life care. I think to accommodate 
the clinic; we wouldn’t have the resource for that at the moment. I’m not sure 
to be honest (Professional/PC 04). 
 
 
This professional recognised that it would not be possible to stay for the whole 
of the multi-disciplinary team as this goes on for the whole day but has found 
a way of working with the team to be able to discuss patients and be informed 
of any new referrals. One of the professionals recounted this below. 
 
I think because the MDT goes on all day I don’t think it’s possible from a 
resource point of view… so we tend to go in when the psychology team are 
there as that’s usually a good way of us picking up our patients but also I will 
say so these are the patients on my list that are in patients is there anybody 
else that you are concerned about elm  and obviously they will be talking 
about patients that are due to come in or are coming in to clinic and also if I 
have had cos I am actually now referring a lot more of the CF patients out to 
the community palliative care teams am so that’s the number of referrals to 
CPC teams are now picking up emm and then I have been reporting back if I 
have had contact from CPCT I will be feeding that back to the CF team 
(Professional PC 02). 
 
A further professional was concerned that waiting for symptoms to build up 
and then refer was too late and that resources may inhibit palliative care being 
able to see patients at an earlier stage in their illness.  
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You shouldn’t wait until the patient actually has got a lot of symptoms and a 
low lung function, that you’re then referring them for transplant – I think you 
should start thinking, ‘Okay that patient has a low lung function,’ but they 
might not have a lot of symptoms, but they’re probably going to have lots of 
symptoms very soon.  So I think maybe, again it’s a matter of resources, 
we’ve got a lot of patients, we can’t get them to see everyone, you know, it’s 
quite a demanding job (Professional/CF 03). 
 
Access to palliative care services is increasing however, it is important to 
remember that the majority of patients with Cystic Fibrosis will be seen by 
palliative care in the hospital setting. Seeing patients for a consultation, 
offering advice to the Cystic Fibrosis team and then withdrawing may help with 
the resource issue. Palliative care teams need to consider different models of 
care to ensure they do not review patients and maintain them on caseloads for 
indefinite periods of time. Offering advice and seeing patients intermittently 
can help in meeting the demands for access to palliative care (Quill & 
Abernethy 2013).  
 
6.9. Theme 2: Establishing Connections between teams and Service 
Users 
 
The second theme relates to the development of relationships between staff 
and patients and specialist teams. The relationship between the patients and 
the Cystic Fibrosis team is built up over a number of years. Staff and patients 
recognise the importance of this relationship and the familiarity of the 
environment in hospital. The table below illustrates the theme of relationships 
and the category and subcategories developed from the data using constant 
comparative analysis. 
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Table 25. Theme 2: Category and Sub Categories 
 
Theme 
 
Category 
 
Sub Category 
 
Establishing 
connections between 
teams and service users  
 
 
Integrated Care 
Development of 
relationships between 
staff and patients/ 
specialist to specialist 
 
The “fit” of Palliative 
care within the speciality 
of Cystic Fibrosis (both 
patients and staff) 
 
 
6.9.1. Establishing Connections between Teams and Service Users  
In a general health setting there is consensus that it is important to get to 
know a patient and their family and to understand their understanding and 
views about a situation and to build relationships (Radwin 1996; Luker et al. 
2000; Canning et al. 2007; Skills for Care 2014). All the patients interviewed 
discussed the importance of having a relationship with the team that were 
caring for them. The patients discussed the significance of knowing teams by 
sight and how that helped in them feeling part of a community. 
 
6.9.1.1. Integrated Care 
The category of integration between the teams includes the sub categories of 
development of relationships and the “fit” of Palliative care within the Cystic 
Fibrosis team. The difference in team working was apparent between both 
sites. One site had a more proactive system between Cystic Fibrosis and 
Palliative care and the other team was much more limited in their relationship 
with Palliative care. The aim of this study was not to compare the two 
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research sites however the data gathered indicated that both research sites 
worked in different ways.  
 
6.9.1.2. Development of Relationships 
The importance of relationships was recognised by both patients and staff. 
One of the patients below described the importance of knowing people that 
are looking after them and seeing new people was disconcerting. 
 
The longer you know somebody, the more you have a personal contact with 
them. The more personal you can be as in, ‘How are you?’ I think you get your 
message across easier, you know, people are more confident to talk to you, 
like all the team here. I know xxxx is a dietician, I know the physios and I know 
everybody and it’s on a personal level and I think it’s better. One of the nurses 
is leaving...I am absolutely gutted. It’s like family you feel part of a community. 
For me knowing the palliative care team or anybody for that matter would be 
better for me and my family (Patient 08). 
 
A professional from the Cystic Fibrosis team discussed how the relationship 
between the patient and professional is built over many years and reiterated 
the difficulty for patients in meeting new team members. 
 
We tend to build up hopefully quite a good rapport because they build up such 
a trust with the MDT within CF because you’ve looked after them for ten 
twenty years when you meet a new team member of the team it’s always 
going to be difficult at any time so if it’s done in an earlier more sort of relaxed 
way I think it works better so I think and every admission they will have met all 
those people emm and I think they get similar to psychology which we’re 
trying to change as well but so I suppose if you’ve been in for 15 years and 
you’ve never met someone from palliative care and then you do. I think I’d 
want the palliative care team to be able to build up a rapport with patients 
before they’ve started before they ended up in a tricky situation 
(Professional/CF 01) 
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In one of the centres where palliative care is accessed on a more regular 
basis one of the Cystic Fibrosis professionals recognised how important it can 
be for the patients to be seen by someone they know and acknowledged the 
importance of seeing patients earlier. 
 
I think now, because there’s involvement early on, patients are used to getting 
the symptom control.  And when they do, you know, when the moment does 
come and they are fighting infection and they’re struggling and everything, it’s 
not an alien person that comes to see them (Professional/CF 03). 
 
 
One of the professionals below acknowledged how staff became friends with 
the patients and viewed the relationship important in following the patient 
through from the beginning to the end of their disease. The blurring of 
boundaries between patients with Cystic Fibrosis and staff has been identified 
previously when it was disclosed that the circle of support other than including 
parents, siblings and families would also include various health care 
professionals that may be subject to obscured boundaries (Jessup & 
Parkinson 2009). 
 
So they know them totally in and out. Whereas I think for CF, in the CF world, 
I think it is different, because they have months and many years as a family 
and, you know, when I used to work in CF years ago, you know, we used to 
go out with them, become friends with them and we socialised with them, you 
know.  I think, you know, any speciality that deals with the younger population, 
I think people just relate to it in a different way, and become much more 
protective and mothering that patient part of that doesn’t facilitate referrals to 
palliative care (Professional/PC 09). 
 
 
One of the patient extracts below discussed the importance of the Cystic 
Fibrosis staff and getting to know them as people and being seen as a person 
not just a patient. The sense of not being treated as a number but as a person 
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was important for all of the patients. The patient below became quite tearful 
when considering how well the Cystic Fibrosis team knew him illustrating the 
strength of trust and the relationship that has been developed over time. The 
patient refers to “our girls” in reference to the clinical nurse specialists inferring 
the continued perception of the community spirit within Cystic Fibrosis  
 
I think it’s because they get to know you as people. And will listen to what 
you’ve got to say, where I come across people in different positions and we do 
find some professionals will treat you as another number, you know, you’re 
just a patient and I have had crossed wires. And I think, because our girls 
know us, and they know, you know, what’s important to us and they know us 
as individuals, we trust them. So you feel comfortable with that (Patient 03). 
 
 
The need to meet professionals earlier and to be able to build some kind of 
relationship was reiterated as being important for the patients. One of the 
patients recognised how difficult it was being admitted into an environment 
where you were not known, whereas being admitted with the Cystic Fibrosis 
team in the specialist centre he didn’t need to explain anything about 
medications. 
 
It does help a lot because I think with patients with CF you kind of, you get 
people that are kind of, you know, live their life by it, if that makes sense.  So, 
you know, and the doctors would know, ‘Okay we know he’s been a little bit 
rough, you know, but he’s not that bad,’ type of thing.  Whereas a new team or 
someone that doesn’t know me, would be like, ‘Bloody hell, he feels this and 
he feels that.’  So yes I think building up a relationship with patients is very 
good. There was a couple of times last year though that I kind of needed to 
get in to hospital, but obviously rooms were very busy, so I had to spend some 
time between home and the local hospital. But I had pretty much a punch-up 
with them to get a room for myself.  So yes, yes, so, but I mean fair play to 
here like, as soon as a room became free, it was like two days they got me up 
here. So, but that was pretty horrible actually because the local hospital 
doesn’t know anything about you, and you get quite a bad rap, you know 
(Patient 05). 
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The professionals acknowledged how getting to know teams better had 
helped in developing a more integrated service. Although this was not the 
same for everyone the professional below recognised how it was only when 
she spent some time with the palliative care team that she realised what they 
could offer. The Cystic Fibrosis professional appeared surprised by the 
response of the palliative care team which appeared to be based on a 
perception that palliative care had to see every patient and would not be able 
to support staff alone. 
 
I had a chat with one of the palliative care team about something that a patient 
had said to me and I wasn’t quite sure what I should have said back. It was 
really cool actually because I was a little bit worried that they would just say 
they would go and see the patient and I wasn’t sure how the team would feel 
about that, but actually I was kind of surprised as what they did was talk me 
through it and upskill me with how to deal with the situation which was really 
helpful, I would ask them again for help (Professional/CF 01). 
 
 
A different side to this indicated a limited relationship between Cystic Fibrosis 
and palliative care services. The Cystic Fibrosis professionals reported that 
they would not ask nurses and doctors to contact the palliative care team out 
of hours for fear that the wrong advice would be offered. This was mainly due 
to concerns that treatment might be stopped or that inappropriate advice 
would be offered by a Palliative care service who might think the patient was 
dying. One of the professionals clarifies this below. 
 
That is always our advice when it comes to that (advice overnight).  So being 
told to refer to Marie Curie where they wouldn’t necessarily give the right 
advice, because we continue our IVs until their last breath and they don’t do 
that (Professional/CF 06). 
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A further Cystic Fibrosis professional recognised that they did not have a 
personal issue with the palliative care team they simply did not need to have a 
relationship with them. 
 
We don’t really have much to do with the palliative care team so haven’t really 
established any relationships with them. It’s not personal though. We only get 
them in when we really need them for our patients, not often (Professional/CF 
07). 
 
 
For the patients who had experienced palliative care they recognised the 
importance of having their involvement and seeing them on a regular basis. 
The following two extracts were from patients who had been referred to the 
service for symptom control that illustrated how the integration can occur 
within the team alongside active treatment. 
 
I think palliative care have been really helpful, this time they have changed my 
meds but they always say they are going to run it by the CF team before they 
change anything to make sure it’s ok with the bosses and doesn’t make 
anything worse with all the antibiotics. They don’t interfere with anything else 
but it does help when they sort out my pain when I’m having physio (Patient 
06). 
 
 
The sickness has been awful this time with the antibiotics but palliative care 
have waved their magic wand actually I think they just help me feel relaxed 
and safe that someone will keep trying whilst I go through these wretched 
times and feel rubbish. It’s really good when you come in and you know the 
CF team will get in touch with them to pop in (Patient 03). 
 
 
The relationships between patients with Cystic Fibrosis and their health care 
professionals are clearly important. Patients in this study recognised that 
knowing people earlier in their disease trajectory is important for ongoing care 
which will be significant in service provision of Palliative care to patients with 
Cystic Fibrosis.  
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6.9.1.3. The “fit” of Palliative care within the Speciality of Cystic Fibrosis 
Where the teams had worked together there was recognition that when 
palliative care was involved the Cystic Fibrosis team had found this beneficial 
and supportive. An integrated approach between palliative care and other 
specialities and in particular Cystic Fibrosis has been recognised as a model 
of care to take forward (Bourke et al. 2009; Quill & Abernethy 2013). One of 
the professionals indicated that having the palliative care team around to 
support the junior doctors in prescribing medications to help with symptoms 
can be very helpful. 
 
It is getting easier, I guess, nowadays, because we know we can straightaway 
involve the CF doctors if we feel it’s needed, if the medical team is feeling that 
this patient is struggling. So I feel it’s good in a way because the medical team 
sometimes have problems writing the treatment and they’re not really sure of 
how much and what they can give. Whereas the palliative care team come 
and they know exactly what is involved (Professional/CF 08). 
 
 
Five of the eight professionals felt strongly that palliative care could offer help 
with the symptom burden of the patients and to be reviewed at an earlier time 
point they felt would help with this, one of the professionals summed this up in 
the following extract. 
 
And you can get emm maybe members of the team that think that that 
person’s not going to make it and those who do which is why it’s like what 
you’re saying palliative care needs to be involved earlier because there’s 
people admitted with the symptom load they do or end up in such distress and 
if Palliative care is involved earlier then I think their experience would be 
amazing to be able to help guide us and then like work more as a team to 
identify where the patients are going (Professional/CF 01). 
 
 
The value of the contribution that palliative care could make to support Cystic 
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Fibrosis teams was recognised by some professionals but not all. Some of the 
working seemed historical and both teams sounded like they would consider 
looking at different ways of working. An interesting point by Fonseca suggests 
that when people are thought of as part of the system, they are governed by 
rules of the system and their actions result in it being difficult to consider 
different ways of working within the organisation (Fonseca 2002). This alone 
can challenge professionals in considering different ways of working and 
inhibit integrated working. 
 
Four of the participants spoke about how special the Cystic Fibrosis team 
were and described this as eliteness although felt uncomfortable using this 
term. Three of the participants identified this through the hesitance in their 
voice when discussing this. This was not described as a personal issue in fact 
the palliative care professionals had respect for the job that the Cystic Fibrosis 
team do. Two of the professionals summarised this below. 
But I think if you sort of start to encroach on their speciality, they feel a little bit 
threatened.  And I think they want to maintain, I don’t want to use the words, 
‘eliteness’ but I think specialness! They’re quite isolated and choose to keep 
themselves isolated. I’m not saying that they should take their hope away, 
absolutely not, but I think something, they can be a little bit unrealistic. And I 
think, rather than the patients reaching a crisis, or coming in and everything 
seems to happen so quickly, I think if we were involved earlier then...I think 
that probably protecting their role because they are so specialised, and 
obviously if you let people in to view that role and to view how things are 
managed, then that’s when people start questioning your practice. I think they 
might feel that they will lose some control of those patients, and the 
relationship might not be as good as it was (Professional/PC 04) 
 
 
It’s just that, you know, ‘we can do it.  You know, we’ve coped with them so 
far, we want to support them until they die.’ ‘palliative care doesn’t have an 
understanding of our disease group.’ You know, that our disease group is very 
special because of this, this and that. And they don’t appreciate that 
(Professional/CF 09). 
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The patients identified that palliative care should be part of the team and 
integrated as the other disciplines are. This thought was indicated by all of the 
patients except one who was unsure. Two of the patients below captured this 
in the extracts below. 
 
I think they should just be like the physios and others, just normal CF team. 
The doctors come and go all the time so we get used to that so we don’t need 
to see the palliative care team all the time but they should be part of the team 
(Patient 05). 
 
Meeting people when you are sick is rubbish I’m happy to meet the palliative 
care team anytime at least knowing them when you’re well would be good. I 
guess we depend on the CF team to let us know when we should say them 
maybe that’s not right (Patient 03). 
 
 
There appeared to be a sense of teams not working together. In some 
instances the Cystic Fibrosis team seemed hesitant to include palliative care 
in case they took over the patient’s care, or offered advice that would not be 
supported by the Cystic Fibrosis team. The concept of teams working together 
is not new. Cancer and palliative care have learned to work together for the 
benefit of the patient as have other non-malignant groups such as cardiology 
(Caring together Programme 2010). From an organisational perspective any 
change has to consider where the demand is coming from; this could be from 
the demand side or changes on the supply side (Fonseca 2002). There may 
be resource issues that will affect innovation in Cystic Fibrosis and palliative 
care teams working together and this will be explored further within the 
discussion chapter. The following section will consider the final theme that 
relates to constantly redefining the future. In this section patients only referred 
to the sub category of affirmation from external sources regarding their 
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prognosis.  
 
6.10. Theme 3: Constantly Redefining the Future 
The final theme that has been generated relates to the patients constantly 
redefining their future and staff acknowledging that this happens. It is 
recognised that patients with Cystic Fibrosis face an uncertain disease 
trajectory and they are constantly redefining their future which indicates that 
palliative care needs to consider offering services to this group of patients in a 
different way (Jessup & Parkinson 2009). 
 
The theme of constantly redefining the future was informed by the category of 
reality bites and sub categories of affirmation of life and death from external 
sources and trying to live a life when well. The sub category of affirmation 
from external sources relates to patients only. The theme, category and sub 
categories are illustrated in Table 26 below. 
 
Table 26. Theme 3, Category and Subcategories 
 
Theme Category Sub Category 
Constantly redefining 
the future 
 
“Reality Bites” 
Refers to patients and 
health care 
professionals 
recognising how limited 
the patient’s life might 
be and how that can 
happen unexpectedly 
 
Affirmation from external 
sources that death will 
occur young (patients 
only) 
 
Patients with Cystic 
Fibrosis living normally 
when well 
 
 
6.10.1 Reality Bites  
Patients discussed throughout the interviews trying to live a normal life when 
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they were feeling well and how they did not always want to be reminded of the 
possibility of dying young. Health Care professionals also discussed that they 
recognised how patients live well when they can but that this can change 
quickly with an exacerbation of infection. The patients also discussed how 
their lives can change from one day to the next if an infection occurs. This is 
an important issue to consider in developing models of care as the currently 
the delivery of palliative care services which is determined by prognosis could 
be viewed as a barrier to referrals for this group.  
 
6.10.1.1. Affirmation from External Sources of Seriousness of Illness. 
The patients reported how when growing up there were constant reminders of 
their own mortality and how that made them feel growing up. One of the 
patients recounted hearing about a Cystic Fibrosis charity appeal on a 
children’s television show and how they discussed life expectancy and she 
spoke of how she felt her privacy had been intruded upon as her peers would 
have probably watched the programme. 
 
And then like on Blue Peter, when we were little, when I was ten or eleven, 
they had this CF, they do this charity appeal, and CF was the charity.  So 
again like all my peers would have watched that and they knew my life 
expectancy then.  And I just, I don’t know, maybe it was me, but other people 
I’ve spoken to have kind of said, do you have like a number at the back of 
your head, and very aware of your life will be shorter and what you do now 
could affect that, I was feeling well at the time and then got a chest infection 
and boof you hear that (Patient 07). 
 
 
One of the patients remembered being at school when a teenager and hearing 
about people with Cystic Fibrosis in a Biology lesson. She recounted hearing 
that she was likely to die young and how some years on she hoped that things 
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might be changing in view of the fact that patients with Cystic Fibrosis are 
living longer although with uncertainty. 
 
I think, hopefully it’s changing now, but people of my generation with CF are 
so well, that life expectancy is unbelievable.  They’re like, yes when we were 
sixteen, we had to study it in Biology at school, and they tell the whole class 
that your life expectancy is thirty-two.  I think I was only fifteen all my peers 
were there, I know the future is still uncertain but it is looking better but it 
doesn’t mean we don’t need help with symptoms when they are bad we just 
don’t want to talk about death all the time, I don’t really think about it when I’m 
well. (Patient 04).  
 
 
A further patient also alluded to how a charity that supports Cystic Fibrosis 
also reminded them of their limited life span and whilst she acknowledged why 
they have to do this it is a constant reminder for her of her mortality and 
something that she wished she could get away from. 
 
Oh okay. And I think, I mean I know why they do it, because I used to be a 
fundraiser for the Teenage Cancer Trust. So I understand why the CF Trust 
talk about it so much, and I know what it is and they need money and so 
obviously they’ve go on about it.  But like they’ve just released this campaign 
saying, ‘Oh we’ve got, the CF Trust is fifty years old, so they’re campaign is all 
around the fact that most people with CF don’t reach fifty.’  Great, thanks!  
That’s just what you want to wake up to on a Tuesday morning.  So it’s sort 
of...a constant reminder from the outside so to speak (Patient 08). 
 
 
In the two extracts below, patients discussed that they felt families and 
professionals tried to protect them but that they all knew the potential outcome 
of what their future might hold based on what was said from school age 
through to becoming an adult and how being with people who knew them and 
their disease was important in trying to live a normal life. One of the patients 
(Patient 02) became quite tearful when she spoke demonstrating how 
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emotional she felt about not being the same and the importance of being seen 
to be like everyone else.  
 
I know my mum and dad and my siblings all try to protect me but when you’re 
at school I was kind of on my own (eyes well up with tears), I didn’t tell my 
family too much of what was said but kids can be quite hurtful sometimes, 
truthful but, yeah hurtful there was no doubt I knew I wasn’t like the other kids 
(Patient 02). 
 
 
When I went to high school I met some really good friends who, it’s kind of 
good cos you didn’t have to keep explaining what was wrong with you, 
likewise through university and because we are all living longer, marriage and 
kids and things, normal things are options (Patient 06)  
 
 
Patients acknowledged that at times there were sources of frustration in 
reminding them of their life expectancy and prognosis. This again is important 
to consider in the planning of introducing palliative care if the connotation is 
with death and dying as this may inhibit patients accepting being referred to 
palliative care. 
 
6.10.1.2. Patients with Cystic Fibrosis Living a Life When Well 
Both patients and staff acknowledged that when feeling well the Patients with 
Cystic Fibrosis try and retain as normal lifestyles as possible. The following 
professional extract recognised that patients would not want to talk about 
dying if they were well. 
 
Very very difficult because when the CF patients are well they just want to live 
life they want to go out get married have a job and they want to be here 
(hospital) as little time as possible and they definitely don’t want to talk about 
dying, so wouldn’t want to be seeing palliative care but things can change for 
them quite quickly (Professional/CF 01). 
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One of the professionals indicated the difficulty supporting Patients with Cystic 
Fibrosis in the community when they are well as they will want to be 
independent. This supports challenges in determining when is a good time for 
the patients to meet palliative care both in and of the hospital setting and 
recognises that the way some services are set up are currently configured are 
not best suited to the needs of the patient. 
 
I personally think, when patients are out in the community emm and they’re 
well with their CF they’re encouraging them to stay well and stay independent 
so I think then to link them in with CPCTeams (community palliative care 
teams)  might give a bit of a mixed message because they want them to be 
functioning they want they to be independent and they want  them to be going 
to work they want them to be going to college ye know they try they try and 
promote that emm so I think then linking in patients at that point is probably 
not good (Professional/PC 02). 
 
 
One of the patients reflected on how she had been a relatively well patient but 
how she was now reflecting on her life and was considering how she felt being 
in hospital feeling relatively well but being aware that other patients were sick 
and thinking about when that would happen to her. 
 
I was quite a well patient. But I do think it affected me.  At the time I didn’t 
realise and I think now I’m evaluating my life recently, coming in to a hospital 
when you’re that age and you are relatively well and I had a job and I had a 
normal life and then suddenly you’re taken from that and you’re in a hospital 
environment for two weeks, which is quite a long time. And you see other 
patients that are poorly, that were quite sick. And it would actually make you 
question, ‘What’s going to happen to me?’  And you might not really ask 
people about it, but just seeing the people around you made you think, ‘I could 
be like that one day, I wonder what age it’s going to be when that happens to 
me.’ And it does make me think that there is the sort of things that doctors 
don’t realise when they’ve got a patient maybe that’s quite well (Patient 01). 
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Trying to live a normal life and be a mother was seen as being quite hard at 
times. One of the patients recognised how she tried to be as normal as 
possible but feels this is hard when she has to be admitted and leave her 
children behind. 
 
At times I don’t really suffer at all. I go, what I see as normal with my friends, 
and I just suffer with my stomach, so I was taking Creon every day but my 
chest was fine.  So I tried to not let it bother me. And then I started getting like 
a lot of chest infections when I was fourteen and the first one started with a... 
collapsed lung so I came in at the deep end. And I just sort of adjusted to what 
I had to adjust to.  But it’s hard to have it with children, because it’s hard to 
explain to them why mummy’s ill and it’s harder to leave them. Even though 
they’ve grown up with it, they know, they knew...everything I never hide 
anything from them.  Obviously I told them what they needed to know, for their 
ages (Patient 03).  
 
 
One of the patients below also discussed how she has tried to be as normal 
as possible but had now acknowledged that she has had to consider not doing 
the things she used to do as she is limited by her breathing and sums up her 
thoughts when she says she has stopped dreaming about a happy ending. 
 
Yes loads of stuff, it’s really, you know, I’ve had to sort of change direction....  I 
wouldn’t say its like stopped me doing, I wouldn’t say that, it would have 
stopped me trying. Yes, yes.  And I’ve stopped dreaming about certain things, 
that kind of thing…happy endings, it’s good to talk (Patient 07). 
 
Some of the professionals acknowledged how keeping the patients well was 
their utmost priority and how they would fight to ensure that they remained 
well. 
And actually until they draw their last breath, we’re also fighting because they 
still want to go back home to their family, so they go back home, even though 
they are on the transplant list, they may still get the call, even if they know and 
we know that they know – they still want that kind of bit of hope. There’s 
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always hope that this is just another dip and not the end. And it’s always very 
difficult for us to know.  If this is just another dip or if it’s the dip that’s going to 
be the end – so because we don’t ever know, is it fair to actually broach that in 
case it’s not?(Professional/CF 08). 
 
 
The ability to lead a normal life is important to this group of patients and is 
encouraged by the professionals. Being able to do this and encouraging 
independence is recognised as important in helping towards making decisions 
about their ongoing care and treatment (Sands et al. 2011).  
 
6.10.1.3. Summary of the Findings from all the Interviews 
Within this chapter areas of organisational differences, language and 
information that are used to inform patients of palliative care and time points to 
consider a referral to palliative care have all been raised repeatedly as well as 
the significance of relationships between patients and the Cystic Fibrosis 
team. The key issues of the interviews are; 
 The definitions and understanding of the term palliative care and the language 
used to describe it 
 Integrated Care and relationships between patients and the specialist teams 
 Access and barriers of referrals to palliative care and organisational influences 
 Patient contribution to the development of services 
 
From these issues theory is emerging relating to the needs and understanding 
of the patients and professionals regarding palliative care and how 
relationships can be fostered between teams involved in the care of the 
patient with Cystic Fibrosis. The constraints of developing a more integrated 
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approach between services are also emerging with conceivable solutions. 
These issues will be further explored within the following discussion chapter. 
 
6.11. Summary of Data from Phases 1, 2 and 3 
 
Each phase of this study has contributed towards answering the research 
questions and has allowed the researcher to see the research topic from 
different perspectives from both patients and health care professionals. In 
phase 1 of the study the perceptions and previous experiences of 
professionals from both Cystic Fibrosis and palliative care were established. 
This demonstrated the challenges the teams face in using the term palliative 
care because of its connotation with death and dying. The teams also 
discussed the challenges of knowing when to refer to palliative care as there 
were no distinct guidelines. This was verbalised by both Cystic Fibrosis and 
palliative care teams. Interestingly the complex language used to describe 
palliative care was highlighted in all three phases within the study from both 
patients and professionals thus recognising the confusion that exists 
surrounding this area. A lack of clarity in knowing when to refer patients with 
Cystic Fibrosis to palliative care teams was also acknowledged by 
professionals within all phases of the study. Barriers of referrals to palliative 
care were also identified in all three phases alongside the identification of 
limited integration. The significance of relationships was highlighted in phase 
three of the study only. This particularly related to patients and their views on 
their need to know the teams who could be involved in their care. They 
identified that information relating to palliative care services would be helpful 
 179 
 
and should be available at time points such as their annual review. In phase 
three only,   
the patients discussed how they were often made aware of their life limiting 
illness from external sources. They discussed television, radio programmes 
and school where Cystic Fibrosis was discussed and how that made them feel 
in front of their peers. The commonalities in all three phases of the study and 
findings that were present from phases two and three only are illustrated in 
Table 27 below.  
 
Table 27. Commonalities and differences from datasets 
Commonalities in all 
3 phases of the 
study 
Phase 2 only Phase 3 only 
Perceptions and 
understanding of 
palliative care 
 
Barriers and enablers 
of referral to palliative 
care 
 
Lack of clarity 
regarding when to 
refer to palliative care 
 
Terminology/language 
of palliative care 
 
Limited integration 
Early referral to 
palliative care 
not seen as 
important 
The significance of 
relationships for 
patients with teams 
 
 
The influence of 
external sources 
on patients as a 
reminder they are 
living with a life 
limiting illness 
(patients only)  
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CHAPTER 7: DISCUSSION  
7.1. Introduction 
The findings from the study have demonstrated that integrating the specialities 
of Cystic Fibrosis and palliative care comes with challenges. The number of 
patients with Cystic Fibrosis is relatively small as indicated in Chapter 2, 
however, the identified symptom burden need of patients identified in Chapter 
3 and the information gathered in the data collection has demonstrated 
limitations in the development of integrated services between the two 
specialities. The data have demonstrated a lack of understanding regarding 
palliative care from both professionals and patients, a lack of clarity regarding 
when to refer to the palliative care service, and has also highlighted patient’s 
needs with regards to the development of relationships. 
 
This chapter will offer a discussion related to the information that has emerged 
from the data analysis. This will include perspectives of palliative care, 
including the name and the meaning attached to this. Considerations in 
reconfiguring services and the involvement of the patient will be discussed 
followed by integrated working and the significance of relationships between 
patients and health care professional teams. Organisational influences 
affecting hospital Trusts will also be considered. A unique integrated model of 
care that has emerged from the data will be proposed for use in patients with 
Cystic Fibrosis when considering the involvement of palliative care. 
Implications for practice and future research recommendations will also be 
discussed. The research aim and research questions are re iterated below. 
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Research Aim and Questions 
Research Aim 
1. To explore the experiences and perceptions of patients with Cystic 
Fibrosis and staff regarding palliative care and the acceptability of this 
as a service early in the patient’s disease trajectory.  
Research Questions 
1. What are patients with Cystic Fibrosis and health care professionals’ 
experiences and perceptions of palliative care? 
2. What are the barriers and facilitators of a palliative care referral in 
Cystic Fibrosis? 
3. Are the services for the provision of palliative care within Cystic 
Fibrosis integrated as part of an multi-disciplinary team 
 
7.2. Information Gathered Through Mixed Methods and Inference to the 
Research Questions  
 
As recognised in Chapter 4 the data analysis for the exploratory sequential 
design study followed recommendations as suggested by Creswell & Plano 
Clark (2011). It is recommended that in considering connected results the 
researcher considers drawing conclusions from the mixed methods. In the 
exploratory sequential design applied to this study the researcher considered 
how each method had contributed in answering the research questions 
(Creswell & Plano Clark 2011). This is illustrated below in Figure 8. 
 
The Focus Group highlighted the perceptions and experiences professionals 
had with the name palliative care and what it meant. They spoke of how they 
changed the name of the palliative care team when talking to patients. The 
issue of knowing when to refer to palliative care was also raised. The Focus 
Group identified important issues and from this helped in constructing 
questions to be asked throughout the survey which helped identify if the 
perceptions raised in the focus group were generalised. The focus group did 
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answer only part of research question 1 as patients were not part of this Focus 
Group. 
 
Figure. 8 How each method contributed to answering the research question. 
 
 
 
The survey identified from the respondents the size of the problem and 
demonstrated that the issues raised in the focus group were also being 
illustrated in other areas of the United Kingdom. The survey confirmed other 
teams do not know when to refer to palliative care and many teams do not 
have an integrated approach to care. Figure 9 below illustrates an example of 
how the issue of knowing when to refer to palliative care was connected 
through the three methods applied. Lack of clarity regarding when to refer 
patients with Cystic Fibrosis to palliative care was raised in all three phases of 
the study and findings from this research can support defining a more 
integrated approach to care.  
Focus 
Group 
(Phase 1) 
• Answered part of research question1 relating to professional perception and experience 
of Palliative care from 2 centres  
• Identified existing barriers and facilitators to referral answering part of Question 2 
• Informed questions to be asked in National Survey 
 
Survey 
(Phase 2) 
 
• Affirmation of professional perceptions nationally of Palliative care answering question 1 
• Confirmed barriers and facilitators and further considered timepoints for referral 
Question 2 
• Addressed issues of integrated services between Cystic Fibrosis and Palliative care 
Question 3 
• Informed topic guide for interviews 
 
Interviews 
(Phase 3) 
• Answered additional part of question 1 through establishing patient perceptions of 
Palliative care 
• Offered further insight into timepoints for referral and deeper understanding of barriers 
• In depth understanding of configuration of services and considerations for integrated 
care which answered  Question 3 
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Figure 9: Example of how an issue raised in the findings was connected and 
analysed through the study. 
 
 
 
The application of mixed methods research gave a comprehensive view of the 
findings from original data and resulted in a more generalised understanding 
of the issues established and offered the opportunity to see perspectives 
through differing lenses. 
 
7.3. Perspectives of Palliative care 
Alongside the finding of palliative care being introduced by professionals as a 
symptom control team, patients felt when they met palliative care it had been 
viewed as a last resort. It is difficult to determine why palliative care is viewed 
in this way. One reason is the meaning attributed to Palliative care regarding 
the connection with death and dying. When palliative care reviewed patients 
with Cystic Fibrosis, the patients did expect the palliative care team to help 
with symptom control. This was highlighted with Patients 06 and 07 who were 
referred for pain and nausea. Whilst this research was not to examine end of 
life care in patients with Cystic Fibrosis, they do have a life limiting illness 
therefore seeing patients for symptom control before the patients are entering 
the dying phase allows for a rapport between patients and professionals to be  
Focus Group 
•Lack of clarity 
regarding when to 
refer to palliative 
care raised as a 
barrier by experts 
in the Focus 
Group 
Survey 
•Specialist teams 
asked about 
referral patterns 
in the 
questionnaire 
Interviews 
•Patients and 
professionals 
asked about 
timing of referral 
to Palliative care 
services 
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established. This can help if patients deteriorate and need end of life care 
(Dalal et al. 2011). From the interviews, patients (06 and 08) spoke of feeling 
so desperate to feel better that they did not care what the palliative care team 
was called. 
 
Within the literature it is recognised in the cancer population how palliative 
care might be introduced to patients. Oncologists recognise that they suggest 
the patient meeting the palliative care team so they can get to know them 
when they are feeling well and can establish a relationship with them rather 
than waiting until they are too sick to benefit from meeting the team (Broom et 
al. 2013). Similarities between this study and the findings from the 
researcher’s study are evident. Patients with Cystic Fibrosis want a 
relationship with health care professionals involved in their care including the 
palliative care team.  Patients want care to feel personalised and not to be 
viewed as a statistic. 
 
Various approaches of manipulating the meaning associated with palliative 
care have been considered. One suggestion about “getting around the 
problem” is by not getting entrenched in the name of what the service is 
called. The “getting over it” approach considers continuing to demystify the 
hidden meaning of palliative care (Meier 2005; Cherny 2009). This has in the 
last few years been endorsed in the cancer population through the American 
Society of Clinical Oncology releasing a new statement endorsing the WHO 
definition (2002) which confirms palliative care being applicable throughout a 
patient’s illness and continuing through active treatments. Ultimately all of 
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these versions relate to palliative care but describe it in an acceptable way for 
professionals and patients. 
 
Whilst it is clear that palliative care has developed from within the cancer 
model, there remains evidence more than two decades on that referral 
pathways for palliative care in cancer remain unclear and at times ambiguous 
with changes being made to names of services and various definitions 
underpinning what palliative care is about (Doyle 2003; Cherny 2009; Melvin 
2010; Dalal 2011). It would appear that professionals have transferred a less 
than perfect model of care to a population with non- malignant disease that 
has created even more confusion around definitions of palliative care and in 
determining when a referral to palliative care should occur. If referral to 
palliative care is to be based on need rather than disease or extent of disease 
then different models of care must be established for patients with non-
malignant disease, in particular within the context of this study. Fundamentally 
palliative care services should be responsive to individual patient needs. Due 
consideration must be given to the referrers knowledge and beliefs about the 
speciality and if they perceive palliative care is about death and dying then 
palliative care services should consider a name change. Alternatively 
education and training within organisations related to the WHO (2002) 
palliative care definition could be offered with teaching punctuated by clinical 
scenarios of care that have demonstrated the benefits early palliative care can 
offer. 
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7.4. Considerations for Designing Services and Patient Involvement 
Confusion around terminology used in palliative care and professionals 
knowing when to consider a referral to the service are all limiting factors in the 
referral process and access to services. This was highlighted in all three 
phases of the study. Participants disclosed how they refer to palliative care as 
“symptom control” and others described throughout the findings the difficulty in 
knowing when to refer to palliative care. Based on the needs of the patients 
with Cystic Fibrosis a referral to palliative care earlier in the disease trajectory 
may help in reducing symptom burden and improve quality of life as in other 
disease groups (Sawicki et al. 2008; Dellon et al. 2010; Temel et al. 2010). 
 
Definitions can be important as they can influence how palliative care is 
practiced and to whom palliative care is offered (Pastrana et al. 2008). In the 
United States the name palliative care was seen as a barrier of referrals to 
palliative care as the oncologists felt it reduced hope for patients (Dalal et 
al.2011). This was felt to be one of the main reasons for a lack of early referral 
to an established palliative care service. The name was changed to supportive 
care that resulted in an increase in appropriate referrals with an overall 
increase in patient referrals of 41% (Dalal et al. 2011). The findings of the 
Dalal et al.’s (2011) study are important within the context of this study as the 
term palliative care and the meaning of it held professional and personal 
significance for both patients and staff. It is acclaimed that without clear 
understanding of what palliative care is, people will reflect upon previous 
experience of palliative care with friends or families (Maciasz 2013). 
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The involvement of patients in the redesigning of services is well established 
in current policy (Kings Fund 2013; Health Foundation 2014). It is evident that 
patients with Cystic Fibrosis are not as involved in their care as they would 
prefer. However when patients do become involved, health care decisions are 
improved, outcomes improve and importantly for this study, resources are 
allocated more efficiently (Kings Fund 2014). Patient involvement coheres with 
establishing integrated services between Cystic Fibrosis and palliative care. 
The voice of patients and integrated services have been viewed by policy 
makers as two major connecting priorities in developing future services which 
resonates with the results of this study in the planning of future services 
(Kings Fund 2014). 
 
The issue of considering patient experience and participation in their care is 
important in considering palliative care involvement. Currently patients with 
Cystic Fibrosis are unable to make an informed choice about access to this 
service as in the main they are unaware that this service exists to support 
them early in their disease journey and not just as they approach death. 
 
Patients recognised that they were unsure about what palliative care services 
could offer them and stated that having information available would help them 
understand the service (Patients 02, 03, and 04). The “symptom control team” 
was a phrase alluded to by participants in the Focus Group and the interviews 
and was identified in the survey as being one of the main triggers for referral 
to palliative care. Interestingly within the literature this term is not recognised 
within the systematic review looking at terminology used to describe palliative 
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care (Hui et al. 2013). When patients were asked about the term symptom 
control they felt it described better what the team were coming to provide but 
also felt that if the term palliative care was used, that was acceptable as long 
as they were made aware of what it was about and not just about end of life 
care. 
 
This research has recognised that patients are requesting more information 
regarding palliative care services and access to information. This information 
is currently limited or not available. In order to support the patient in making 
informed choices Piper (2014) suggested applying four indicators which 
included a shift in power from professionals to the patient, informed individual 
choice, individual patient control over decision making and two way 
professional patient partnership working. As indicated in this study patients 
were cognisant of the lack of information pertaining to palliative care. 
Working to support patient empowerment would offer patients with Cystic 
Fibrosis the right to participate in considering informed choices and to 
consider referral to palliative care when they felt it was appropriate. Previous 
evidence has suggested that self- management education has improved 
knowledge of Cystic Fibrosis and its management for patients and carers 
(Savage et al. 2014). This concurs with the current study that patients having 
better knowledge of palliative care may help in patients initiating discussions 
regarding palliative care with health care professionals. 
 
In contrast to this professionals are advised to carefully consider supporting 
patient involvement and be mindful of the fact that patients may not have the 
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skills to make informed choices and decisions regarding which services to 
access and when to activate them (Bradshaw 2008). The literature affirms that 
patient choice is influenced by a number of antecedents including a wider 
personal agenda for the patient, life context, financial issues and spiritual and 
cultural beliefs (Piper 2009; Anderson & Funnell 2010). Patient choice in 
relation to palliative care has in the past focused primarily on issues relating to 
end of life care. The emphasis for the speciality in the last six years has 
focused on patient choice regarding their preferred place of care and death 
and whether these preferences have been achieved (DH 2008; Oxenham et 
al. 2013). Enhancing the experience of patients with Cystic Fibrosis would 
mean supporting them with information ensuring they were aware of the 
service much earlier in their disease journey.  Promoting the integration of 
palliative care services and knowing who the team were and how to contact 
them are pivotal in meeting the needs of the patients. Information regarding 
the service would need to include appropriate timelines for referral to guide 
the patient. 
 
In the patient interviews the findings highlighted patient self-referral to the 
palliative care service was discussed. Historically hospital palliative care 
services have not encouraged patient self-referrals to the service (Dunlop 
&Hockley 1998). This has predominantly been based on the hospital palliative 
care services originating as advisory teams only and out of professional 
respect have always requested approval from the primary team to become 
involved in the patient’s care (Dunlop & Hockley 1998). 
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The issue of inviting patient views should be encouraged however the 
overarching issue of resources and financial constraints within the NHS 
cannot be overlooked. Although resources and financial constraints did not 
emerge from the data as barriers of referral to palliative care, they do 
ultimately underpin the configuration of services. The solution for meeting the 
needs of the patients and to prevent a further drain on resources lies in a 
more integrated model of delivering care from a palliative care service that 
reviews patients intermittently based on need rather than stage of disease. 
7.5 Integrated Working 
This section will explore integrated working between teams to support 
referrals to palliative care services in the hospital. The impact of the 
relationships between specialists and the relationship between the health care 
professional and the patient will also be considered. 
 
7.5.1 Integrated Working between Specialists 
There are several models of care alluded to in the literature relating to 
services working towards integrated models of care (Krause et al. 2006; 
Selman et al. 2007; Bourke et al. 2009; Disler et al. 2013).  In the cancer 
literature it is still believed that patients continue to be referred to palliative 
care services too late and that different models of integrated care need to be 
developed (Bruera & Hui 2010). From this research project it was evident that 
integrated models of working are limited between Cystic Fibrosis and palliative 
care and that development of new ways of working are needed to support 
patients earlier in the disease trajectory (Bourke et al. 2009). 
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It is imperative that palliative care specialists and the leading clinician for the 
patient promote joint working between the teams to meet patient needs (APM 
2012). A lack of coordination of care amongst professionals from differing 
specialities has also been cited as a reason for patients not expressing their 
needs which can lead to a delay in palliative care being considered as part of 
their care (Mahtani & Chugani 2010). The principles of integrated working can 
be considered across many differing boundaries, namely, organisational 
and/or team practices. Integrated working aims to encourage people to work 
collectively to meet the needs of the patients. The need to review established 
working patterns between teams is useful. However, creating new service 
arrangements may disrupt some well established relationships or question 
areas where a lack of relationship is established. In the latter circumstance 
priority should be given to the establishment of new networks and 
relationships to enhance patient care and possibly influence commissioning 
strategies (Skills for Care 2014). 
 
Integrated working of the Cystic Fibrosis team with other teams out with the 
core MDT will be for some a completely different way of working. In order to 
gain a rapport within Cystic Fibrosis and palliative care teams, some teams 
have developed a service where patients are seen under a joint review 
(Boland et al. 2013); this not only supports the patient seeing the teams 
working together but allows a trusting relationship to build between the Cystic 
Fibrosis and palliative care specialists. This type of service is currently offered 
in the minority of services based on the current research findings. 
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Bourke et al. (2009) determined from a retrospective note review that an 
integrated model of care provision should be offered to patients with Cystic 
Fibrosis. This should be established when the Cystic Fibrosis team feel this is 
necessary and suggested that palliative care and Cystic Fibrosis teams should 
work together when patients’ disease is advanced and active therapies are 
coming to an end. This model could perhaps be challenged in that whilst 
palliative care specialists are not expert in the management of Cystic Fibrosis, 
they do have a responsibility to ensure Cystic Fibrosis professionals are 
equipped to offer modern day palliative care and may not consider earlier 
referral to the service.  Relationships with Palliative care teams and other 
specialists have been alluded to in previous research (Broome et al. 2012). 
The evidence states that if palliative care clinicians are readily available and 
visible then timely referrals are more likely to occur (Broom et al. 2012). 
 
From the findings of the current research project patients want more than 
being referred to palliative care when the Cystic Fibrosis team are ready. The 
patients require a relationship with the Palliative care team earlier in their 
disease journey and want to feel that they know the professionals whom will 
be caring for them. This will be further discussed later in this section. An 
integrated team is more than a number of health care professionals coming 
together; it is one that comes together with members using open and honest 
communication based on mutual respect and trust which for many teams will 
take time in establishing new innovative working relationships (Skills for Care 
2014). Within Cystic Fibrosis and palliative care for some teams there is no or 
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limited existing relationships so this model of care would be innovative for 
some services. 
 
Within this study there was evidence of respect between palliative care and 
Cystic Fibrosis teams.  However, this was limited in numbers as only a small 
number of respondents described a fully integrated model of care. In many 
chronic conditions professionals have known patients and their families over 
many years. This is also true of patients with Cystic Fibrosis. Professionals 
working within Cystic Fibrosis acknowledged that they felt they knew the 
patient the best and verbalised that they felt they could meet their needs. 
Although not expressed in all interviews with professionals there was concern 
that when palliative care was involved active treatment would need to stop. In 
developing new models of care patients with non-curable lung disease should 
be able to access palliative care services on an as required basis with the 
primary team remaining the clinical lead for the patient. This would mean 
patients being reviewed for short periods of time for a particular symptom and 
then not accessing the service again for months even years (Boland et al. 
2013). This would have a three-fold benefit. Firstly the patient has additional 
access to specialist symptom control advice, the Cystic Fibrosis professionals 
have access to specialist advice and thirdly the patient has the opportunity to 
meet the palliative care team with whom they can begin to build a rapport with. 
 
7.5.2. Multidisciplinary Team Working 
There are many published benefits of multi -disciplinary team working with 
recognised benefits in decision making in patient care as well as notably 
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having a positive impact on the numbers of differing decisions being made by 
independent practitioners (Pfeiffer & Naglieri 1983; Sim & Joyner 2002; MNDA 
2011). A further study identified that as a result of the integration of services 
from within an MDT there had been substantial improvements in the physical 
and psychological well- being of patients dealing with multiple chronic 
illnesses (Krause et al. 2006). Within the speciality of cancer care, palliative 
care is recognised in peer review standards as a key member of most cancer 
specific multidisciplinary team meetings that occur in the acute setting. In 
order to meet the needs of these services there is usually shared 
responsibility between team members to ensure palliative care is represented 
at these meetings. When resources are limited there is often negotiation 
between the teams to discuss the current joint patients at the beginning of 
meetings or to discuss patients that the cancer teams are concerned about 
and need consideration of referral to palliative care. This method of 
attendance at multidisciplinary team has been established over the last two 
decades. Involvement of Palliative care within non-malignant multi -
disciplinary teams is still in the early stages of development, in Cystic Fibrosis 
there are pockets of teams where palliative care is included within their  
multidisciplinary team meeting. 
 
Whilst increasing communication between the specialists is an added benefit 
of palliative care teams attending the Cystic Fibrosis multi -disciplinary team 
the opportunity of shared learning between the teams can also be realised 
(Ruhstaller et al. 2006). Shared learning within the multi -disciplinary team 
may allow for new referrals to palliative care to be discussed and a better 
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understanding of the Cystic Fibrosis disease and treatments available may 
lead to enhanced integrated working. 
 
7.5.3 The Significance of Patient/Professional Relationships 
In palliative care it is recognised through literature the benefits of having a 
therapeutic relationship between the patient and the professional (Luker et al. 
2000; Kennedy 2005). Part of establishing a good relationship with patients 
and families relates to being able to best support patients and families when 
they enter the end of life phase (Kennedy 2005). 
 
Nurses have recognised that knowing a patient who has a life limiting illness 
earlier in their disease trajectory allows for the building of relationships 
between the patient and the family with the health care professional and 
allows trust to be fostered (Tomison & McDowell 2011). This study also 
indicated that for the patients building a relationship with professionals was 
important. Within the interviews all the patients with Cystic Fibrosis alluded to 
the importance of having a therapeutic relationship with the teams looking 
after them. They actively stated that they would not want to be seen by a team 
that was unknown to them when they were dying. Tomison & MacDowell 
(2011) also established that patients with non-malignant conditions were much 
less likely to be referred early to palliative care and that the first meeting of the 
patient and family was usually at a crisis point when patients were distressed 
and families were frightened. Interestingly not all relationships between health 
care professionals and patients require longevity. Hill et al. (2014) recognised 
that psycho-social support could be delivered on the first meeting with a 
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patient and did not require an established professional patient relationship. 
However patients with Cystic Fibrosis have established relationships with 
most of the core multi-disciplinary team throughout their illness and it is 
understandable that they want some kind of relationship with palliative care. 
 
Patients with Cystic Fibrosis have an established relationship with the health 
care professionals caring for them. The care they receive may be as an in- 
patient requiring treatment for an exacerbation episode or may be as an out- 
patient for a regular review. Patients with Cystic Fibrosis state that when they 
come and see the Cystic Fibrosis team they feel similar to seeing “the family” 
so strong is the relationship. From a health care professional perspective the 
team deliver specialised care but running alongside this they observe patients 
reach milestones of university, relationships, marriage and pregnancies.  For 
others as the patient’s disease progress they observe the patient reverting 
back into child mode and observe parents/family rediscovering the caring role. 
With the relationship between the patient and the Cystic Fibrosis team being 
well established trying to introduce a different team (palliative care) not seen 
as part of the core Cystic Fibrosis team will more than likely be unsuccessful 
unless the palliative care team is endorsed by the Cystic Fibrosis team. This 
would involve acknowledging the palliative care tam as established members 
of the Cystic Fibrosis team. 
 
Recommendations to demonstrate palliative care involvement could be firstly 
information booklets, either stand-alone palliative care booklets but specifically 
written for Patients with Cystic Fibrosis and their families explaining what the 
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palliative care team is with an emphasis on early referral for symptom control, 
for symptoms such as antibiotic induced nausea. Secondly being visible on 
the wards with the Cystic Fibrosis team seeing patients together will help 
establish closer links between the teams and the patients. Even if there are no 
shared patients between the two teams, staff will become used to seeing the 
palliative care team on the wards and will begin to recognise who they are and 
what the service can offer. This would hopefully result in the palliative care 
team being seen as an integrated member of the Cystic Fibrosis team and 
encourage referrals by staff and reassure patients. Most hospital wards have 
team member photograph boards visible for patients and staff so they know 
who core team members are. It was recognised from the findings of this study 
that even when a palliative care service is viewed as being an extended 
member of the Cystic Fibrosis team they were not recognised on the picture 
board or in the literature. Having an identified palliative care team link with 
representation on photograph boards may also affect relationships between 
staff and patients as well as confirm for staff who to call if a referral needs to 
be made. Some of these recommendations may seem simplistic but these are 
strategies that will help establish palliative care becoming more integrated 
within Cystic Fibrosis teams. 
 
Resources may be a consideration in meeting the needs of the Cystic Fibrosis 
team but information booklets could be available with other patient information 
leaflets and it has been established previously in this thesis that attendance at 
the full MDT may be required in the short term only until relationships are 
established. Patients with Cystic Fibrosis clearly want to know who the 
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palliative care team are, what the service offers and want to feel like they 
know the team and have an established link with them which is not something 
that has been recognised previously. 
 
Whilst integrated working has been identified as a way forward for Cystic 
Fibrosis specialists and palliative care teams this ethos may be a step too far 
for teams where there is a limited or no relationship between Cystic Fibrosis 
and palliative care. Setting triggers for referral may guide referrers to palliative 
care in order that teams can build relationships with one another. There is a 
need for palliative care to be seen as part of the existing Cystic Fibrosis team 
as reported by patients interviewed in this study. 
 
7.6. Organisational Influences in the Integration of Cystic Fibrosis and 
Palliative care 
 
The following section will discuss the organisational influences in the place of 
palliative care within the Hospital. Consideration will be given to organisational 
influences that impact on Palliative care services in the hospital Trusts and 
inform integrated working. Influencing factors such as funding of palliative care 
and the culture of the organisation towards palliative care will be addressed. 
 
7.6.1 Financial Influences Affecting Interpretation of Palliative care 
From a Government perspective there is a commitment to funding Palliative 
care but currently there is still no agreed mechanism for funding it in the UK. 
Much of palliative and end of life care is provided by hospices based in the 
 199 
 
voluntary sector. The level of statutory funding they receive varies significantly 
and many hospices will run on donations, fundraising and legacies (National 
Council for palliative care 2011). Community palliative care services are in the 
main funded from Clinical Commissioning Groups (CCGs). Hospital palliative 
care teams are infrequently non- profit making teams as currently there is no 
tariff for palliative care services. More recently commissioners have rewarded 
healthcare providers by linking sums of money to local quality improvement 
measures and the achievement of such measures. Commissioning for Quality 
and Innovation (CQUIN) has been agreed by many providers across the UK to 
improve services. Many services across South East England have End of Life 
Care as one of these measures. The focus is on identifying patients who are 
entering the end of life phase with an emphasis on ensuring their preferences 
are acknowledged and where possible their preferred place of care and death 
achieved. The cost attached to each CQUIN varies but, end of life care is 
approximately worth between; £450,000 - £550,000 if the measures are 
achieved. Hospital palliative care teams are currently not paid for the service 
they provide and therefore generating significant monies as in the case of 
achieving a CQUIN is an incentive for both the team and the hospital Trust. 
The dichotomy here is with an emphasis and drive on monies linked with end 
of life care palliative care teams could be in a position of shifting their focus 
towards end of life care and therefore not seen to be promoting earlier 
referrals to their services. This has in turn supported the earlier views of 
palliative care as an end of life care service. 
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A further end of life care financial incentive has been around the Quality, 
Innovation, and Productivity and Prevention (QIPP) agenda. The aim of this 
has been to develop key performance indicators to improve the numbers of 
patients who die in their own home, a further end of life care initiative. The 
End of Life Care Strategy (DH 2008) was the first document to look at end of 
life care for all patients with a life limiting illnesses. With this strategy money 
was ring fenced for innovations in care, research and new work streams to be 
created. This strategy has been successful is ensuring end of life care has 
been brought to everyone’s attention but the unintended effect of this strategy 
has been palliative care once again being viewed as an end of life care 
service dictated to by funding and overriding strategies and changes in 
Government. 
 
In 2010 the Government initiated an independent review of palliative care 
funding, interestingly to offer yet a further definition regarding what constitutes 
dedicated palliative care services and to propose a mechanism for funding 
such services (Hughes-Hallett 2011). A first draft of the suggested funding 
stream for palliative care services was published in November 2014 and it is 
clear that palliative care services will be paid based on the needs of the 
patients. It is important to consider funding issues and the implications of this 
upon Trusts. Innovative ways of working need to be founded on outcomes, for 
patients with non-malignant disease and in particularly those patients with 
Cystic Fibrosis early. These patients will die and therefore early palliative care 
can help support patients throughout their disease. The challenge for palliative 
care is in ensuring that it is not viewed solely as a provider of end of life care. 
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7.6.2. Culture of organisations  
The cultural ethos of palliative care is seen as an influencing factor in the 
delivery and uptake of services with patient expectation viewed as having an 
impact on the make-up of palliative care services (Abernethy & Currow 2008).  
 
In any organisational culture it is important to ascertain the place and 
perception of palliative care. In a cancer setting palliative care may be viewed 
as being important but would not want to highlight the service outcomes in 
case of affecting the way it is perceived by commissioners and the public 
which may be as a place of cure. The need for cultural change is invariably 
related to organisational performance (Scott et al. 2003). Changing culture 
within organisations is not easy but changing conversations can support staff 
to consider why they do what they do (Shaw 2002). Talking about the 
relationships between Cystic Fibrosis and palliative care will help the situation 
evolve; understanding locally what the teams want and what the patients need 
can help influence perceptions of teams working together at Trust Board level. 
Within the current study, the experts from the focus group acknowledged that 
they never meet in normal circumstances to have conversations about the 
way the teams work together. The focus group in itself, had inadvertently 
changed a conversation about the way teams work together within 
organisations that seemed to ignite other ideas for the experts to take forward 
within their own organisations. 
 
The significance of changing cultures within organisations to embrace 
integrated care has been highlighted in health policy documents (Shaw et al. 
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2011; Kings Fund 2013). Within policy reference is made to ensuring hospital 
organisations pledge more immediate access to specialist advice for patients 
(Kings Fund 2013).  It is known that patients circulate between organisations 
on their healthcare journey, and there is often inefficiency and waste that can 
create a poor experience (Skills for Care 2014). This is relevant in the 
researcher’s study as the anticipated outcome of this work will encourage 
organisations to focus attention on how different services can work together to 
benefit patients. Any potential change to the culture of an organisation will 
challenge previous practices and historical ways of delivering care. For 
change to occur to support integrated working, the focus will need to relate to 
encouraging new relationships, a different power base and new ways to 
communicate (Shaw et al. 2011; Skills for Care 2014). 
 
Innovation in hospitals will need to cross organisational boundaries and in 
doing so can pose threats to established groups than can in turn result in a 
degree of conflict (Fonseca 2002). This, along with a challenge to 
professionals’ beliefs about an organisation, can result in “identity threats” that 
can be disruptive and have a negative impact on innovation which can impact 
on developing integrated care (Ravasi & Schultz 2006). There is evidence to 
support palliative care being involved with patients earlier (Temel et al. 2010; 
Stevens et al. 2014). Organisations would struggle to argue with this, 
however, they need the speciality of palliative care to be clear about what is 
on offer and how that can benefit the patient and increase revenue. There is 
no mandate to refer to Palliative care services other than those offering  
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monies for end of life care improvements. Hospital palliative care is dependent 
on specialists from areas such as Cystic Fibrosis referring patients to the 
service. In the event that patients self -refer to a palliative care team, 
permission from the primary treating team will always be ascertained. This is 
mainly due to support of any recommended changes to current medical 
management such as pharmacology. 
 
Organisational learning may be able to help with knowledge and 
understanding about the place of palliative care within an organisation (Carroll 
& Edmondson 2002). Tensions between early referral and end of life care can 
be demystified through effective conversations which can be helpful towards 
establishing goals not just for palliative care but for the Trust as a whole 
(Carroll & Edmondson 2002). 
 
With competing priorities for services there is a lack of recognition of palliative 
care contribution within organisations some of which may be related to a lack 
of visual representation regarding what defines a palliative care regardless of 
organisational position or culture. 
 
7.7. Considerations for Future Palliative Care 
The challenge for palliative care is in considering working in a different way to 
meet the needs of patients with Cystic Fibrosis. The current practice for 
referral to most palliative care teams is based on the prognosis of the patient. 
In most centres the last twelve months of life is seen as appropriate for a 
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referral to palliative care. However this can also be harnessed as end of life 
care therefore the language and the confusion around the terms relating to 
palliative care does not help patients with Cystic Fibrosis as prognosis is 
unpredictable and patients are denied access to services as a result of this. 
 
Palliative care has to decide on whether it is a service as defined in the 
definition adopted within this study (WHO 2002) or an end of life care service. 
Introducing different models of care that are integrated will help balance the 
resources needed to meet the needs of these patients. Being involved with 
patients on a short term basis throughout periods of an exacerbation is one 
way of achieving this as well as getting to know the patient and family. An 
uncertain prognosis should not deny patients access to this service or occur 
so late that the patient or family have no relationship with the team. 
 
7.8. Proposed Model of Integrated Care  
The following section addresses how the results of this study and 
development of a theoretical model from these results can influence clinical 
practice. The findings from the literature review the findings and discussion 
have led to discernible issues that can change the way Cystic Fibrosis and 
palliative care Teams work together. Figure 10 below illustrates concepts to 
be considered in developing a theoretical model of integrated care and Figure 
11 illustrates a theoretical model that has emerged through the findings of this 
study. 
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This theoretical model illustrated in Figure 11 represents the ways in which 
palliative care can be conceptualised within Cystic Fibrosis. This model is 
developed from the data generated from the focus group, the survey and the 
interviews. It challenges the current dialogue within the Cystic Fibrosis 
literature that equates palliative care being involved at the end of the patient’s 
life. It represents views from patients which have not been identified 
previously and which have highlighted the significance of relationship building 
with palliative care and of being made aware of what services can offer earlier 
in their disease. The model involves palliative care being viewed as part of the 
Cystic Fibrosis team but acknowledges that palliative care resources are not 
infinite and new ways of working need to evolve. The model highlights that 
having referral guidelines will help in recognising patients and demonstrates 
how the four segments of the model are integrated and inter-connected. 
 
Whilst the model illustrates the way forward it also recognised the concepts to 
be considered before the model could be implemented. This information is 
taken from the data generated from the research. The findings from the 
research suggested that in some cases the professionals felt the patients with 
Cystic Fibrosis would be distressed by having palliative care mentioned. In 
most cases the patients did not express this; therefore this model challenges 
some of the mis-conceptions held by professionals and encourages specialist 
palliative care to at least have information about the service accessible to 
patients. This clarifies the importance of patients being involved in the 
planning and organisation of services and in listening to what their needs are. 
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The current view of palliative care among specialist Cystic Fibrosis health care 
professionals is one based on the association of death and dying and not on 
the needs of the patient as demonstrated in section 3.4 of the literature 
review. The existing literature elucidates the associated symptom burden of 
this group of patients and from the patient interviews it was identified that 
accessing palliative care to help with this was perceived to be a last resort. 
Being able to challenge the existing model of care through defining palliative 
care in a way that fits with the organisational culture and dispel the association 
of death and dying will help towards patients being able to access an 
integrated service between Cystic Fibrosis and palliative care. 
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Figure 10: Concepts to be considered to develop an Integrated Model of Care 
between Cystic Fibrosis and Palliative care Teams. 
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Figure 11: Proposed model of Integration between Cystic Fibrosis and 
Palliative Care based on results from research data 
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7.9. Implications for Practice 
This study has highlighted that patients with Cystic Fibrosis are living longer 
into adulthood but are living with a heavy symptom burden at different times in 
their disease (Stenekes et al. 2009). The role of palliative care is under 
researched in this area and research studies in the main have focused on end 
of life care (Mitchell et al. 2000; Chapman et al. 2005; Sawicki & Robinson 
2008). The findings from this three-phase study have highlighted issues that 
need to be considered in future service provision between both Cystic Fibrosis 
and palliative care services.  
 
The uncertainty regarding when to refer patients with Cystic Fibrosis to 
palliative care services was apparent in all three phases of the study from the 
health care professional participants. There is now a recognised need for both 
Cystic Fibrosis teams and palliative care teams to work together to define a 
set of triggers to support the referral pathway and a more integrated approach 
to care. Transplant, whilst identified in the findings as perhaps being too late 
for consideration of a referral to palliative care services, is a defined time point 
when referral to palliative care team should at least be considered. This study 
has highlighted that in all the adult specialist Cystic Fibrosis centres there is 
access to a hospital palliative care team. Communication between the two 
services need to be developed to find a more integrated way of working to 
support patients. The dissemination of the results of this study will help in 
presenting the viewpoints and needs of the patients which to date had not 
been represented. 
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The connotation of the meaning of language used to describe palliative care is 
important in considering implications for practice. This study has identified 
how professionals change the name of palliative care services to make it 
easier to raise the subject with patients and carers. This appears to be related 
to the connotation of palliative care and its association with death and dying. 
In the  literature relating to cancer treatment, there is now evidence that a 
change of name can influence professional referrals (Dalal 2011). This study 
has highlighted that some of the difficulty with the term, ‘palliative care’ relates 
to professionals’ concerns about it rather than patients’. Findings 
demonstrated that in the majority of cases patients were in agreement with 
being seen by a palliative care service as long as it was explained to them 
what palliative care could offer and why they were seeing the patient. At a 
fundamental level this could be addressed through education and training to 
professionals about palliative care and how best to refer to the introduction of 
this service. Palliative care should also be seen as integral to the 
multidisciplinary team where they could be part of patient information forums 
alongside the Cystic Fibrosis team. The literature has supported the fact that 
the name of the service is irrelevant unless it is preventing referral to the 
service. 
 
Palliative care teams may need to consider a name change to make it clearer 
as to how to introduce their service to patients with Cystic Fibrosis which may 
increase referrals, as seen in the cancer population (Dalal 2011). Finally 
specialists from both Cystic Fibrosis and palliative care teams need to 
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consider the significance for the patients in being able to build a relationship 
with palliative care teams. This study did not specifically look at resources but 
it is recognised from the literature that different models of care need to be 
developed to meet the needs of patients (Quill & Abernethy 2013). Developing 
short term interventions for patients with Cystic Fibrosis may be helpful in 
establishing relationships with palliative care services, especially when 
patients experience uncontrolled symptoms. As the symptoms resolve, 
palliative care services would become less involved and return care solely to 
the Cystic Fibrosis team thus developing a more integrated approach to care.  
 
The implementation of the proposed model for integration between the two 
services as presented on Figure 11 does not necessarily require additional 
resources. What it does need is for both Cystic Fibrosis and palliative care 
teams to consider working in a different way and applying a more integrated 
approach to care. Cystic Fibrosis teams should consider palliative care as an 
integral service to multidisciplinary working and palliative care teams should 
consider seeing patients on a short term intervention and then withdrawing 
from the patient’s care until needed in the future. This prevents a drain on 
resources and helps build a relationship with the patients and their families. 
The more strategic challenge for palliative care services is in redefining what 
their service can offer in terms of palliative and end of life care. Many teams 
are now focusing on end of life care due to financial implications as previously 
discussed in chapter 7 (section 7.6.1). The ethos of palliative care is to be 
receptive to the needs of patients at any time of their disease trajectory (WHO 
2002). Coupled with the emphasis of palliative care on end of life care and the 
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confusion regarding the terminology being used to describe the service, 
require further consideration and attention for all palliative care services. 
Communication, between the two services, is key in the development of 
services. Whilst palliative care attendance for the whole multidisciplinary team 
meeting may not be possible, negotiation around discussing patients who may 
be of shared interest at either the beginning or the end of the meeting may be 
one way of building relationships between the teams without having a 
significant impact on resources. The data from the patients are explicit in 
describing the need for information regarding palliative care services which 
could be easily achieved through adding palliative care into existing patient 
information. This would, however, require some negotiation with Cystic 
Fibrosis teams in realising the needs of the patients in terms of understanding 
that palliative care is about more than death and dying. Below in Table 28 the 
implications for practice are summarised with potential solutions. 
Table 28. Summary of Implications for Practice 
Implication Practical Solution 
Uncertainty of when to refer to 
palliative care 
Development of triggers for referral to 
palliative care and shared guidelines 
Language used to describe palliative 
care 
Consider changing the name of 
palliative care to a term better 
understood and easy to understand 
for patients such as “symptom control 
team” 
Building of relationships Introduce palliative care as an integral 
part of the Cystic Fibrosis service. 
Palliative care to consider different 
models of care such as short term 
interventions to support the patients 
and avoid draining resources and 
allowing patients to live their life when 
well 
Hesitancy by Cystic Fibrosis 
Specialists introducing palliative care 
Education and training by palliative 
care to Cystic Fibrosis teams in how 
to introduce palliative care 
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7.10. Strengths of the Study 
One of the main strengths of this study is the overall contribution to knowledge 
in relation to Cystic Fibrosis and palliative care. It stands alone in terms of 
assessing the views of patients with Cystic Fibrosis in highlighting how they 
feel about being reviewed by palliative care services early in their disease 
trajectory. A further strength of this study is that it draws on the current 
practice of two different Trusts. Interspersed with information from national 
data in Phase 2 of the study helped piece together the perception of palliative 
care within Cystic Fibrosis and thus influence the proposal of an integrated 
model for ongoing service developments. This proposed model is unique in 
that it is based on the results from the data and reflects the needs of patients 
with Cystic Fibrosis that have been previously under researched from a 
palliative care perspective. 
 
This study contributes to knowledge relating to patient views and their 
perceptions of palliative care and what teams could do to harness these 
viewpoints to move services forward. In particular the lack of information about 
what palliative care can provide and the importance for the patients to 
perceive palliative care as part of the Cystic Fibrosis team is pivotal. 
 
The use of a mixed method study has offered valuable perspectives on the 
issues between Cystic Fibrosis and palliative care teams. Being able to 
understand what both Cystic Fibrosis and palliative care teams are currently 
offering to patients whilst understanding in more depth why some of these 
occurrences happen is insightful in strengthening integration between these 
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two services. Changes to services will require discussions within organisations 
and cultural changes to the perception of palliative care which may be a 
challenge for some teams depending on the existing views of palliative care 
and organisational influences. 
 
7.11. Limitations of the Study 
The total number of questionnaires distributed was small but represented the 
specialist Cystic Fibrosis adult centres at this time. Returned questionnaires, 
for the survey which informed phase 2 of the study, was 61%, this response 
could have been increased by the avoidance of  forwarding the questionnaires 
leading up to the summer holidays.  A further limitation in the study relates to 
the lack of doctors interviewed in Phase 3. As doctors often initiate the referral 
to palliative care, their views would have been helpful. Although medical staff 
were approached to be interviewed, they did not come forward to participate. 
The majority of people with Cystic Fibrosis are diagnosed in childhood and 
this study is limited to adults only and is therefore recognised as being limited 
in its transferability to all services providing Cystic Fibrosis and palliative care. 
 
7.12. Implications for Future Research 
This innovative study recruited participants from several different Cystic 
Fibrosis and palliative care services across the United Kingdom, however only 
two centres formed part of the semi structured interviews. Taking this research 
wider to other Cystic Fibrosis centres may result in more generalizable 
findings and help understand how patients and professionals feel about an 
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earlier referral to palliative care for patients with Cystic Fibrosis. A further 
consideration for future research should consider a more longitudinal 
approach in assessing the benefit of palliative care being involved earlier in 
the patient’s disease journey and the outcomes as the end of life approaches. 
Considering comparing patients and families’ experience of current practice 
against integrated care when palliative care was involved early in the patient’s 
illness and followed through to bereavement for the families would help in 
determining if palliative care affects the long term bereavement follow up for 
carers. The development of triggers to guide clinicians should be developed 
as a pilot to research if this would change the way that specialists working in 
Cystic Fibrosis  
 
7.13. Summary 
There are many challenges that face palliative care in being viewed as a   
service that can be accessed anywhere in the disease journey. If it is to be 
based on need then patients with Cystic Fibrosis have an established 
symptom burden and therefore a need is established. Funding around end of 
life care places tensions between services and resources and there results in 
competing priorities between the palliative care service. Patients with Cystic 
Fibrosis have identified that they want to know who is looking after them and 
though different ways of working with a more integrated approach to care and 
flexibility for patients to dip in and out of the service within which organisations 
require to listen to the needs of the patient. The following chapter will offer a 
conclusion of the study. 
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CHAPTER 8: CONCLUSION OF THESIS 
This study has been undertaken to contribute to the existing body of 
knowledge between Cystic Fibrosis and palliative care. The rationale behind 
the choice of the research subject was two- fold. Exposure to delivering a 
service to patients with Cystic Fibrosis highlighted a question when it became 
apparent that palliative care services were only accessed at the end of a 
patient’s life. This study is innovative in that it is the first study to ascertain the 
wishes of adult patients with Cystic Fibrosis and their views on palliative care 
being involved earlier in their disease pathway. Following further exploration of 
this topic through the literature, it became apparent that the focus of palliative 
care and Cystic Fibrosis research was based mainly on end of life and 
bereavement care. The need for further research into the acceptability of 
palliative care earlier in the patient’s illness within this speciality was important 
to explore in a changing NHS climate with limited resources and a focus 
towards integrated care for chronic illness. 
 
This study has been underpinned by mixed methods and a theoretical model 
of integrated care. The methodology allowed the researcher to see the 
research topic through different lenses and different perspectives from 
patients and professionals.  Within this three phase study, data have been 
gathered from experts in Cystic Fibrosis and palliative care as well as patients 
living with Cystic Fibrosis. This study has identified not only how professionals 
and patients perceive palliative care but has also illustrated current practices 
of service provision between the two specialities from a national perspective. 
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The findings from this study have highlighted the need for a more integrated 
approach between Cystic Fibrosis and palliative care services. Patients voiced 
that they would like information regarding what a palliative care service can 
offer. They require a service where they feel they have a relationship with the 
palliative care team and are known to them throughout their illness. The 
theoretical model of integration between Cystic Fibrosis and palliative care 
highlights a way for professionals and commissioners to consider what an 
integrated service would look like. It is cognisant of how patients would like the 
services configured and what they feel would be best for them. Introducing the 
proposed integrated model from within this study would be instrumental in 
providing equity of access to palliative care services for patients and equip 
professionals in deciding which patients to refer to palliative care in a timely 
way before death is imminent. This research has offered insight into how 
integrated care could be achieved between palliative care and Cystic Fibrosis. 
The findings are timely as palliative care teams await the final report from the 
National Funding review due in January 2015. Preliminary reports from this 
have already suggested future funding will be based on the needs of the 
patients which will help palliative care in the reconfiguration of services.  In 
considering the provision of future integrated services, incorporating the 
patients’ needs alongside professional expertise will be pivotal in ensuring 
palliative care does not remain limited to end of life care for patients with 
Cystic Fibrosis. 
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Appendix 1. Reflections on part of data collection (2nd Interview) 
 
This interview with the patient was interesting. She really did not know what 
Palliative care was about and when prompted felt it was about death. This was 
based on what she had observed on television. I don’t think I had considered 
that someone might have very limited knowledge of Palliative care. The 
patient knew what a Macmillan Nurse was but then associated Palliative care 
with cancer. This interview demonstrated that there might be some patients 
who know very little about Palliative care other than what had been observed 
through external sources. This interview made me realise that as in Grounded 
Theory aiming to recruit participants who had been referred to Palliative care 
would be helpful exploring if this group of patients already referred to a 
Palliative care service felt the same. 
 
This patient was breathless throughout the interview and I had to remind 
myself not to be side tracked in trying to help her symptoms as I would do in 
the clinical setting but to focus on the research. 
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Appendix 4. 
 
Invitation Letter / Focus Group 
Dear  
I am writing to invite you to take part in a focus group as part of a study by the 
Royal Marsden and Royal Brompton Palliative care service and the University 
of Surrey.  
 
We are conducting a study exploring the introduction of Palliative care to adult 
patients with Cystic Fibrosis (CF). We are keen to also determine if there is a 
need for referral to Palliative care in adult patients with CF and to examine 
staff perceptions of introducing a Palliative care service as part of the care of 
this group of patients at any stage of the adult patient with CF disease 
trajectory. 
 
The first phase of this study is to determine questions to be asked in a survey. 
The survey will be forwarded to the CF centres in the United Kingdom and 
their respective Palliative care services. In order to develop domains and 
questions for this survey an expert panel of CF and Palliative care clinicians 
will be established to create the domains for this survey. Patient participation 
will also be included in the focus group.   
 
I have attached a copy of the information sheet (attach appendix 2) for you to 
read. 
 
Once you have made a decision about whether to participate I would be most 
grateful if you could either email me at anna-marie.stevens@rmh.nhs.uk or 
contact the Palliative care secretary on 0207 808 2761 to let us know your 
decision 
 
If you wish to participate, once we receive a reply from you we will contact you 
to arrange a convenient time and place for the focus group. 
 
If we have not heard from you within 2 weeks from the date of this letter we 
will contact you by telephone to remind you about the study and arrange a 
time and day for the focus group if you are willing to participate  
 
Thank you for reading this letter and for considering taking part in this 
research. 
 
Yours sincerely 
Anna-Marie Stevens 
Macmillan Nurse Consultant Palliative care 
The Royal Marsden and Royal Brompton Palliative care Service 
Department of Palliative Medicine 
Royal Marsden NHS Foundation Trust 
Chelsea, 
London 
0207 808 2761 
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Appendix 5. 
 
Information sheet (Focus Group) 
 
An exploration of early Palliative care in the adult Cystic Fibrosis 
population  
 
(A mixed method study exploring  the introduction of Palliative care to adult 
patients with Cystic Fibrosis (CF) and to understand the perceptions of staff 
and patients of such a referral). 
 
Protocol number:  
 
‘We would like to invite you to take part in a study. Before you decide, it is 
important for you to understand why the research is being done and what it 
will involve. 
 
Please take time to read the following information and please ask us if there is 
anything that is not clear or if you would like more information. Thank you for 
reading this’ 
 
What is the purpose of the study? 
 
This study is trying to find out what professionals understand about Palliative 
care. We are particularly interested in understanding at what point do staff 
consider making a referral to Palliative care and for what reasons. We are also 
keen to identify how staff perceive a referral to Palliative care.   
 
This study is a 3 phase study. The first phase will involve developing domains 
and  questions for a survey that will be forwarded to CF and Palliative care 
specialists in the United Kingdom. In order to develop the correct questions for 
this survey an expert panel of CF and Palliative care experts will be 
established to help with this.  
 
Why have I been chosen? 
 
You have been invited to take part because you are an expert health 
professional in Cystic Fibrosis or Palliative care and are working at a specialist 
centre caring for patients with Cystic Fibrosis.  
 
Do I have to take part? 
 
It is up to you whether or not you take part. If you decide to take part you will 
be given this information sheet to keep and you will be asked to sign a 
consent form.  
 
What will happen to me if I take part? 
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You will be part of a focus group that will be made up of clinicians working 
locally within CF and Palliative care. The focus group will also be supported by 
patient representation. The focus group will take place at a time and place 
convenient to you. The focus group will be audiotaped and will be facilitated 
by the researcher.  
 
Will my taking part in this study be kept confidential? 
 
If you consent to take part in the research your identity will be kept strictly 
confidential. You will not be identified in any report or publication that arises as 
a result of the study. Your audiotape recording and raw data taken from the 
audiotapes will be anonymised and stored securely. Sections of your 
interviews may be transcribed and used in publications including academic 
medical, education journals and/or conference presentations however 
anonymity will always be preserved. 
 
What will happen to the results of the study? 
 
The results of the study will not be available for about 2 years. The 
researchers will write a report, which will be publicised at various medical 
meetings, and in various medical journals. If you would like a summary of the 
results when available please inform the researcher. 
 
Who is organising and funding the research? 
 
The study is being organised by the Royal Marsden and Royal Brompton 
Palliative care Service and the University of Surrey. The study is being funded 
by the Royal Marsden NHS Foundation Trust. 
 
Who has reviewed the study? 
 
The Royal Marsden NHS Foundation Trust/ Institute of Cancer Research’s 
Research and Local Ethics Committee have reviewed the study and given 
their approval. 
 
Contact for further information: 
 
If you would like further information about the study, then please contact the 
researchers (see below) 
Thank you for reading this information sheet, and for considering taking part in 
this research. 
 
Anna-Marie Stevens 
Macmillan Nurse Consultant Palliative care 
The Royal Marsden and Royal Brompton Palliative care Service 
Department of Palliative Medicine 
Royal Marsden NHS Foundation Trust 
Chelsea, 
London                                                0207 808 2761 
Appendix 6. Consent Form/Focus Group 
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Appendix 6 
Study Number:  
Health Care Professional Identification for this trial: 
 
CONSENT FORM  
 
 
Title of Project: An exploration of early Palliative care in the adult Cystic 
Fibrosis Population 
 
Name of Researcher:  Anna-Marie Stevens 
    
                                                                            
      Please initial box 
 
1. I confirm that I have read and understand the information 
sheet for the above study. I have had the opportunity to 
consider the information, ask questions and have had these 
answered satisfactorily. 
  
  
2.  I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving any reason and 
without my legal rights being affected.  
  
  
4. I understand that everything that is said within the room will 
be confidential including what I say and what others in the 
group may say and that the focus group will be audiotaped. 
 
  
  
5 I understand that sections of the focus group will be 
transcribed and used in publication including academic 
medical education journals and/or conference presentations 
and that my anonymity will be preserved. 
 
  
   
6 I understand that I can leave the focus group at any time. I 
understand that at my request any sections of the audiotape 
that I have contributed to can be excluded from the analysis 
  
 
   
   
7 
 
I understand that audio/ tapes will be treated as strictly 
confidential and will be kept in accordance with research 
governance policies and that any raw data on which the 
results of the project  depend will be retained in secure 
storage in accordance with the Data Protection Act (1998)   
  
  
 
 
8. I agree to take part in the above study 
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________________________ ______________           
________________ 
Name of participant  Date Signature 
 
 
 
________________________ ______________              
________________ 
Name of person taking consent Date  Signature 
(if different from researcher) 
 
 
 
________________________ _____________                 
________________ 
Researcher   Date  Signature 
 
 
When completed -  1 for the participant;  
   1 (original) to be kept in research site file 
 
 
Would you like a summary sheet of research findings       YES/NO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 253 
 
Appendix 7 
 
Topic Guide for the Focus Group 
 
After the researcher has introduced themselves, discussed the study and 
gained consent the focus group discussion will commence. 
 
1. Understanding of definition of Palliative care 
2. Current service provision 
3. Trigger for referral to Palliative care 
4. Stage of referral (influence of patient’s disease stage) 
5. Barriers/Enablers to referral to Palliative care 
6. Access to Palliative care 
7. Are there referral criteria to support a the process of referring adult patients 
with CF to Palliative care 
8. What would appropriate Palliative care look like 
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Appendix 8.  
Interactions within the Focus Group 
It has been acknowledged that it is important to consider the use of analytical 
questions to analyse important elements in the group interactions (Stevens 
1996). Identifying what opinions were agreed upon and where conflict was 
evoked is important to consider as well as whose interests were being 
introduced within the group and issues relating to how the group dealt with the 
ideas of others need to be considered. 
There was general consensus on most aspects of the issues relating to the 
meaning of Palliative care and the complexities around referral to Palliative 
care.  It was clear that both teams involved within the Focus Group worked in 
a very different way to each other. When there was a different way of working 
recognised the group become supportive of the team who were not doing 
things in the same way to them and acknowledged that their previous 
experience had been similar 
Reference FG 1 
I sometimes think there’s a bit of a if I’m honest we don’t want to relinquish 
your patient over to a different team and you know we are sort of reluctant to 
involve a team until you know quite late on especially with patients who you’ve 
had a relationship with for many years and ye know if I’m honest that is partly 
that ye think no we’re not going to bother involve the Palliative care team ye 
know and we know what we’re doing sort of thing and it’s almost like you’re a 
bit possessive of your patient I think  
 
Reference FG 3 
I think it was a bit like that here (Brompton) to start with 
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Yeah 
Before you guys came … 
I agree I’d absolutely agree with that 
It was with the CF people  
 
Reference FG 4 
Um and I guess I don’t know how much Palliative care is available in your 
service let alone whether they see themselves as being there for a CF group 
of patients  
 
Reference FG 1 
I think our Palliative care nurse would like to get involved much more to be 
honest  cos she’s been she’s quite new to to the hospital and I don’t think she 
think she’s got enough to do (laugh) 
 
Reference FG 4 
And what do you think stops her getting involved 
 
Reference FG 1 
Us probably to be honest, us not referring people ye know ..what I said before 
being a bit possessive ye know 
 
Reference FG 1 
 We tend we tend not to involve the nurse (voice goes really quiet) 
unless…things are really ….we are really struggling  
 
Reference FG 5 
Yeah and there is sometimes I mean we have that don’t we sometimes that a 
nurse can go in but you you sense that you’re not either being believed or you 
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know they want the assurance often from a consultant emm on AICU in 
particular there’s … once they know you there is … but they still often it’s 
consultant to consultant  that actually makes the decision change especially 
on somewhere like AICU I think  
 
Common experiences were discussed in terms of finding it difficult to share 
Patients with Cystic Fibrosis with the Palliative care team and whilst 
differences in the teams were perceived there were shared commonalities 
relating to the association of Palliative care with death and dying and the 
concerns around dispelling hope if Palliative care was involved. It would have 
been easy for the viewpoint of the team to be silenced where there was less 
integration between Cystic Fibrosis and Palliative care but the other group 
members encouraged them to talk about the differences with the support of 
the moderator. 
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Appendix 9. Questionnaire design checklist based on De Vaus (2002). 
 
Questionnaire design checklist 
Is the research question clear 
What is the content of the question designed to measure 
If the question is about an attitude or belief , what is it that you want to know 
Is each question (reliable, valid, likely to achieve a good response, have the 
same meaning to all respondents 
Is the specific wording suitable 
What time of response format does the research question require (open, 
closed) 
What level of measurement do you want the item to achieve (nominal, ordinal, 
interval) 
For closed questions, which format rating, scores, ranking, checklist 
How will non-committal responses be handled (middle response or don’t know 
be available 
Are clear instructions provided throughout the questionnaire 
Is there sufficient space 
Are any skips clear and easy to follow 
Does the order of questions conform to the principles of question order 
How will data be entered onto the computer 
Will pilot testing be used 
Do the questions work 
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Appendix 10. Question Wording Checklist (De Vaus 2002) 
 
Question Wording Checklist 
1. Is the language simple 
2. Can the question be shortened 
3. Is the question double-barrelled 
4. Is the question leading 
5. Is the question negative 
6. Is the respondent likely to have the necessary knowledge 
7. Is there a prestige bias 
8. Will the words mean the same to everyone 
9. Is the question ambiguous 
10. Is the question too precise 
11. Is the frame of reference for the question sufficiently clear 
12. Does the question artificially create opinions 
13. Is personal or impersonal wording preferable 
14. Is the question wording unnecessary detailed or objectionable 
15. Does the question have dangling alternatives 
16. Does the question contain gratuitous qualifiers 
17. Is the question a dead giveaway 
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Appendix 11 
 
Sample of Questionnaire  
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Appendix 12 
 
 
Invitation Letter to Professionals/Survey 
 
Dear  
 
 
I am writing to invite you to take part in a survey as part of a study conducted 
by the Royal Marsden and Royal Brompton Palliative care service and the 
University of Surrey. We are conducting a study exploring the introduction of 
Palliative care to adult patients with Cystic Fibrosis(CF). We are keen to also 
determine if there is a need for referral to Palliative care in adult patients with 
CF and to examine how both CF and Palliative care teams currently work 
together. We are also interested in identifying any triggers for referrals to 
Palliative care or potential barriers. 
 
This survey involves part of a larger study that includes interviewing patients 
and staff in two specialist CF centres. 
I have attached a copy of the information sheet (Appendix 6) for you to read. 
 
Once you have made a decision about whether to participate I would be most 
grateful if you could complete the online survey 
 
If we have not heard from you within 2 weeks from the date of this letter we 
will send an email to remind you about the study. 
 
Thank you for your time in considering participating in this study 
 
Yours sincerely 
 
 
 
Anna-Marie Stevens 
Macmillan Nurse Consultant Palliative care 
The Royal Marsden and Royal Brompton Palliative care Service 
Department of Palliative Medicine 
Royal Marsden NHS Foundation Trust 
Chelsea, 
London 
0207 808 2761 
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Appendix 13 
 
 
Health professional information sheet (Survey) 
 
An exploration of early Palliative care in the adult Cystic Fibrosis 
population  
 
(A mixed method study exploring  the introduction of Palliative care to adult 
patients with Cystic Fibrosis (CF) and to understand the perceptions of staff 
and patients of such a referral). 
 
Protocol number:  
 
‘We would like to invite you to take part in a study. Before you decide, it is 
important for you to understand why the research is being done and what it 
will involve. 
 
Please take time to read the following information and please ask us if there is 
anything that is not clear or if you would like more information. Thank you for 
reading this’ 
 
What is the purpose of the study? 
 
This study is trying to find out what professionals understand about Palliative 
care. We are particularly interested understanding at what point do staff 
consider making a referral to Palliative care and for what reasons. We are also 
keen to identify current working patterns between Cystic Fibrosis and 
Palliative care teams.This survey is part of a larger study that will also look at 
the views and feelings of patients and the staff involved in their care. The aim 
of the study is to explore the introduction of Palliative care to adult patients 
with CF and to understand the perceptions of staff and patients of such a 
referral. 
 
Why have I been chosen? 
 
You have been invited to take part because you are a health professional 
working at a specialist centre caring for patients with CF.  
 
Do I have to take part? 
 
It is up to you whether or not you take part. If you decide to take part you will 
be given this information sheet to keep. In returning the completed survey this 
will be viewed that consent has been given to participate in this research. 
 
What will happen to me if I take part? 
 
You will be asked to complete an online survey by the researcher. This will 
take about 20-30 minutes to complete. 
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Will my taking part in this study be kept confidential? 
 
If you consent to take part in the research your identity will be kept strictly 
confidential. You will not be identified in any report or publication that arises as 
a result of the study. Your reply to the survey questions will be returned to a 
secure email address which will be anonymised and stored securely.  
 
What will happen to the results of the study? 
 
The results of the study will not be available for about 2 years. The 
researchers will write a report, which will be publicised at various medical 
meetings, and in various medical journals. If you would like a summary of the 
results when available please inform the researcher. 
 
Who is organising and funding the research? 
 
The study is being organised by the Royal Marsden and Royal Brompton 
Palliative care Service and the University of Surrey. The study is being funded 
by the Royal Marsden NHS Foundation Trust 
 
Who has reviewed the study? 
 
The Royal Marsden NHS Foundation Trust/ Institute of Cancer Research’s 
Research and Local Ethics Committees have reviewed the study and given 
their approval. 
 
Contact for further information: 
 
If you would like further information about the study, then please contact the 
researcher (see below) 
Thank you for reading this information sheet, and for considering taking part in 
this research. 
 
 
Anna-Marie Stevens 
Macmillan Nurse Consultant Palliative care 
The Royal Marsden and Royal Brompton Palliative care Service 
Department of Palliative Medicine 
Royal Marsden NHS Foundation Trust 
Chelsea, 
London 
0207 808 2761 
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Appendix 14. 
Topic Guide for Professionals 
 
After the researcher has introduced themselves, discussed the study and 
gained consent the interview will commence. 
 
1. What is your understanding of the term Palliative care 
 
2. Have you referred anyone to Palliative care 
  
3. What is the perception of such a referral 
 
4. Where was the patient in terms of stage of disease/ Timing of referral 
 
5. What Triggers made you think of referring to Palliative care 
 
6. What if anything has prevented you from referring to Palliative care  
 
7. What would appropriate access to Palliative care look like? 
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Appendix 15 
 
Topic Guide for Patients 
 
After the researcher has introduced themselves, discussed the study and 
gained consent the interview will commence. 
 
1. Have you heard of the term Palliative care 
 
2. What is your understanding of the term Palliative care 
 
3. Have you been seen by anyone from a Palliative care team 
 
4. Does being referred to Palliative care mean anything to you 
 
5. When do you think would be a good time to meet the Palliative care team 
 
6. Would you like the name Palliative care to be something different? i.e. 
symptom control 
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Appendix 16 
 
Patient Information Sheet (Interview) 
 
An exploration of early Palliative care in the adult Cystic Fibrosis 
population  
 
(A mixed method study exploring  the introduction of Palliative care to adult 
patients with Cystic Fibrosis (CF) and to understand the perceptions of staff 
and patients of such a referral). 
 
Protocol number:  
 
‘We would like to invite you to take part in our study. Before you decide, it is 
important for you to understand why the research is being done and what it 
will involve for you. One of our team will go through the information sheet with 
you and answer any questions you have. 
 
Please take time to read the following information carefully and discuss it with 
friends, relatives and your doctor if you wish. Please ask us if there is anything 
that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. 
Thank you for reading this’ 
 
What is the purpose of the study? 
 
This study is trying to find out about what you and the staff caring for you 
understand by the term Palliative care. We would like to try and find out when 
would be a good time for your doctors and nurses to ask for help for you from 
the Palliative care team.  
 
We are studying patients like you who are cared for by the specialist Cystic 
Fibrosis centre at your hospital and who may  need additional treatment and 
support from time to time.  
 
This study will look at your views and feelings,  as well as those of the hospital 
doctors, nurses, dieticians and physiotherapists. The aim of the study is to 
better understand how you and the professionals caring for you feel about 
Palliative care services and the best time for you to be seen by the Palliative 
care team..  
 
Why have I been invited to take part? 
 
You have been invited to take part because you are a person with Cystic 
Fibrosis attending the specialist centre. We are inviting other people in a 
similar situation to you to take part in the study. 
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Do I have to take part? 
It is up to you to decide to join the study. We will describe the study and go 
through this information sheet. If you decide to take part you will be given this 
information sheet to keep and you will be asked to sign a consent form. If you 
decide to take part, you are still free to withdraw at any time and without giving 
a reason. A decision to withdraw at any time, or a decision not to take part, will 
not affect the standard of care you receive. 
 
What will happen to me if I take part? 
 
You will be visited either at home, in the hospital (or elsewhere if more 
convenient to you) by the researcher and take part in an interview with the 
researcher. You will be asked some basic questions about yourself and then 
you will be interviewed specifically regarding your feelings and views about 
Palliative care and any information you can share with researcher about when 
you feel would be a good time for Palliative care services to be introduced into 
your treatment. This interview will be audiotaped and is likely to last between 
45 minutes to one hour. 
 
What are the possible disadvantages of taking part? 
 
Taking part in the study will not adversely affect any aspect of your treatment 
at home or in hospital. Sometimes being asked about your feelings may be 
difficult to answer. If so, you do not have to continue or answer anything you 
do not feel comfortable with. You can stop the interview at any time and if you 
do not wish to continue the audio recording the recording will be erased and 
the information provided will not be included in the study. If you feel after 
answering our questions you need more support to deal with any emotions 
you have we will arrange this for you. 
 
What are the possible benefits of taking part? 
 
We cannot promise the study will help you but the information we get from this 
study will help improve the way we deliver Palliative care services to people 
with Cystic Fibrosis. These interviews are part of a larger study looking at 
what patients and staff understand about Palliative care and when is the best 
time for Palliative care services to be involved in your care.  
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. If you have a concern about 
any aspect of this study, you should ask to speak to the researchers who will 
do their best to answer your questions. The names of the researcher and the 
supervisors of this study are listed below 
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Anna-Marie Stevens 
Macmillan Nurse Consultant Palliative care 
The Royal Marsden and Royal Brompton Palliative care Service 
Department of Palliative Medicine 
Royal Marsden NHS Foundation Trust 
Chelsea, 
London 
0207 808 2761 
 
Dr Wendy Knibb 
Doctorate of Clinical Practice Mentor Health and Social Care 
University of Surrey 
Guildford Surrey GU2 7XH 
01483 68 4631        
 
Professor Sara Faithful 
Professor of Cancer Nursing Practice 
University of Surrey 
Guildford Surrey GU2 7XH 
01483 68 2568 
 
If you remain unhappy and wish to complain formally, you can do this through 
the NHS Complaints Procedure. You can contact the Patient Advice and 
Liaison Services office your hospital 
 
 
Will my taking part in this study be kept confidential? 
 
Yes. We will follow ethical and legal practice and all information about you will 
be handled in confidence. If you consent to take part in the research, any of 
your medical records may be looked at by a member of the research team or 
regulatory authority. Your name, however, will not be disclosed. You will not 
be identified in any report or publication that arises as a result of the study. 
Your audiotape recording will be anonymised and stored securely. Sections of 
your interviews may be transcribed and used in publications including 
academic medical education journals and/or conference presentations 
however anonymity will always be preserved. 
 
What will happen if I don’t want to carry on with the study? 
 
You will be free to withdraw from the study at any time. This will not prejudice 
the care you receive in any way. If you withdraw from the study we will destroy 
any information you have shared with us. 
 
Will my General Practitioner / Family doctor (GP) be informed of my 
involvement? 
 
Provided you consent to this, your GP will be informed that you are 
participating in the study.  
 276 
 
What will happen to the results of the study? 
 
The results of the study will not be available for about 2 years. The 
researchers will write a report, which will be publicised at various medical 
meetings, and in various medical journals. If you would like a summary of the 
results when available please inform your doctor or research nurse.  
 
Harm 
 
If the event that something does go wrong and you are harmed during the 
research and this is due to someone’s negligence then you may have grounds 
for legal action for compensation against your hospital but you may have to 
pay your legal costs.  The normal National Health Service complaints 
mechanisms will still be available to you. NHS indemnity does not offer no-
fault compensation i.e. for non-negligent harm, and NHS bodies are unable to 
agree in advance to pay compensation for non-negligent harm. 
 
Who is organising and funding the research?  
 
The study is being organised by the Royal Marsden and Royal Brompton 
Palliative care Service and the University of Surrey. The study is being funded 
by the Royal Marsden NHS Foundation Trust. 
The researchers will not be paid for including you in the study. 
 
Who has reviewed the study? 
 
All research in the NHS is looked at by an Independent group of people, called 
a Research Ethics Committee to protect your safety, rights, wellbeing and 
dignity.  This study has been reviewed and given favourable opinion by  South 
East Coast-Surrey Ethics Committee in addition approval has been gained 
from local research and development offices at your hospital.  
 
Contact for further information: 
 
If you would like further information about the study, then please contact the 
researcher (see below) 
Thank you for reading this information sheet, and for considering taking part in 
this research. 
 
 
Anna-Marie Stevens 
Macmillan Nurse Consultant Palliative care 
The Royal Marsden and Royal Brompton Palliative care Service 
Department of Palliative Medicine 
Royal Marsden NHS Foundation Trust 
Chelsea, 
London 
0207 808 2761 
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Appendix 17 
 
Health professional information sheet (Interviews) 
 
An exploration of early Palliative care in the adult Cystic Fibrosis 
population  
 
(A mixed method study exploring  the introduction of Palliative care to adult 
patients with Cystic Fibrosis (CF) and to understand the perceptions of staff 
and patients of such a referral). 
 
Protocol number:  
 
‘We would like to invite you to take part in a study. Before you decide, it is 
important for you to understand why the research is being done and what it 
will involve. 
 
Please take time to read the following information and please ask us if there is 
anything that is not clear or if you would like more information. Thank you for 
reading this’ 
 
What is the purpose of the study? 
 
This study is trying to find out what professionals understand about Palliative 
care. We are particularly interested understanding at what point do staff 
consider making a referral to Palliative care and for what reasons. We are also 
keen to identify how staff perceive a referral to Palliative care.   
 
This study will look at the views and feelings of patients and the staff involved 
in their care. The aim of the study is to explore the introduction of Palliative 
care earlier to adult patients with CF and to understand the perceptions of 
staff and patients of such a referral. 
 
Why have I been chosen? 
 
You have been invited to take part because you are a health professional 
working at a specialist centre caring for patients with CF. You have also been 
chosen as you have more than 1 year of experience working with patients with 
CF. We are also interviewing patients regarding their opinions. 
 
Do I have to take part? 
It is up to you whether or not you take part. If you decide to take part you will 
be given this information sheet to keep and you will be asked to sign a 
consent form.  
 
What will happen to me if I take part? 
 
You will be interviewed by the researcher at a time and place convenient to 
you. The interview will be audiotaped. The interview will be semi-structured 
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and contain questions specifically regarding your feelings and views about 
palliative. The interview is likely to last between 45 minutes to one hour. 
 
Will my taking part in this study be kept confidential? 
 
If you consent to take part in the research your identity will be kept strictly 
confidential. You will not be identified in any report or publication that arises as 
a result of the study. Your audiotape recording and raw data taken from the 
audiotapes will be anonymised and stored securely. Sections of your 
interviews may be transcribed and used in publications including academic 
medical education journals and/or conference presentations however 
anonymity will always be preserved. 
 
What will happen to the results of the study? 
 
The results of the study will not be available for about 2 years. The 
researchers will write a report, which will be publicised at various medical 
meetings, and in various medical journals. If you would like a summary of the 
results when available please inform the researcher. 
 
Who is organising and funding the research? 
 
The study is being organised by the Royal Marsden and Royal Brompton 
Palliative care Service and the University of Surrey. The study is being funded 
by the Royal Marsden NHS Foundation Trust 
 
Who has reviewed the study? 
 
The Royal Marsden NHS Foundation Trust/ Institute of Cancer Research’s 
Research and Local Ethics Committees have reviewed the study and given 
their approval. 
 
Contact for further information: 
 
If you would like further information about the study, then please contact the 
researcher (see below) 
Thank you for reading this information sheet, and for considering taking part in 
this research. 
 
 
Anna-Marie Stevens 
Macmillan Nurse Consultant Palliative care 
The Royal Marsden and Royal Brompton Palliative care Service 
Department of Palliative Medicine 
Royal Marsden NHS Foundation Trust 
Chelsea, 
London 
0207 808 2761 
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Appendix 18. Patient Consent Form 
 
Centre Number:  
Study Number:  
Patient Identification for this trial: 
 
CONSENT FORM  
 
 
Title of Project: An exploration of early Palliative care in the adult Cystic 
Fibrosis Population 
 
Name of Researcher:  Anna-Marie Stevens 
    
                                                                            
      Please initial box 
 
1. I confirm that I have read and understand the information 
sheet for the above study. I have had the opportunity to 
consider the information, ask questions and have had these 
answered satisfactorily. 
  
  
2.  I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving any reason, 
without my medical care or legal rights being affected.  
  
  
3. 
 
 
 
I understand that sections of any of my medical notes may be 
looked at by responsible individuals from regulatory 
authorities or from the NHS Trust, where it is relevant to my 
taking part in research. I give permission for these individuals 
to have access to my records. 
  
  
4. I understand that my participation will be audio taped  
 
  
  
5 I understand that sections of my interviews will be transcribed 
and used in publication including academic medical education 
journals and/or conference presentations and that my 
anonymity will be preserved. 
 
  
   
6 I understand that I can stop the interview at any time if I do 
not wish to continue the audio recording and that the 
recording will be erased and the information provided will not 
be included in the study. 
  
 
   
7 
 
I understand that audio/video tapes will be treated as strictly 
confidential and will be kept in accordance with research 
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governance policies and that any raw data on which the 
results of the project  depend will be retained in secure 
storage in accordance with the Data Protection Act (1998)   
  
 
8. I agree to my GP and medical team being notified of my 
agreement to take part in this study 
  
 
9. I agree to take part in the above study 
 
  
 
 
 
 
________________________ ______________           
________________ 
Name of patient  Date Signature 
 
 
 
________________________ ______________              
________________ 
Name of person taking consent Date  Signature 
(if different from researcher) 
 
 
 
________________________ _____________                 
________________ 
Researcher   Date  Signature 
 
 
When completed -  1 for patient;  
   1 (original) to be kept in research site file;  
   1 for medical notes;  
 
Would you like a summary sheet of research findings       YES/NO 
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Appendix 19. Health Care Professional Consent Form/Interviews 
 
Study Number:  
Health Care Professional Identification for this trial: 
 
CONSENT FORM  
 
 
Title of Project: An exploration of early Palliative care in the adult Cystic 
Fibrosis Population 
 
Name of Researcher:  Anna-Marie Stevens 
    
                                                                            
      Please initial box 
 
1. I confirm that I have read and understand the information 
sheet for the above study. I have had the opportunity to 
consider the information, ask questions and have had these 
answered satisfactorily. 
  
  
2.  I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving any reason and 
without my legal rights being affected.  
  
  
4. I understand that my participation will be audio taped  
 
  
  
5 I understand that sections of my interviews will be transcribed 
and used in publication including academic medical education 
journals and/or conference presentations and that my 
anonymity will be preserved. 
 
  
   
6 I understand that I can stop the interview at any time if I do 
not wish to continue the audio recording and that the 
recording will be erased and the information provided will not 
be included in the study. 
  
 
   
   
 
7 
 
I understand that audio/video tapes will be treated as strictly 
confidential and will be kept in accordance with research 
governance policies and that any raw data on which the 
results of the project  depend will be retained in secure 
storage in accordance with the Data Protection Act (1998)   
  
  
 
 
8. I agree to take part in the above study 
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________________________ ______________           
________________ 
Name of participant  Date Signature 
 
 
 
________________________ ______________              
________________ 
Name of person taking consent Date  Signature 
(if different from researcher) 
 
 
 
________________________ _____________                 
________________ 
Researcher   Date  Signature 
 
 
When completed -  1 for the Health Care Professional participant;  
   1 (original) to be kept in research site file 
 
 
Would you like a summary sheet of research findings       YES/NO 
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Appendix 20 
 
Example of Field Notes (Interviews) 
 
Interview Professional 06 
 
Interesting interview with a specialist in the field of Cystic Fibrosis. Loaded 
comments regarding the relationship between the two teams. Inferred that 
really there isn’t much of a relationship.  Was looking into space for most of 
the interview. Repeatedly mentioned that not referring to Palliative care was 
not based anything personal. Reiterated the difference with CF patients and 
the difficulty with their prognosis almost in an insular way that there was no 
way this group of patients could have similar needs to others with life limiting 
illnesses. This interview has questioned my own views about perceptions of 
Palliative care and perhaps some assumptions. I believe this participant was 
saying that they could manage with patients that were dying and that Palliative 
care was only needed as a last resort. I think my interpretation was that 
perceptions of Palliative care in some instances still thought of death and 
dying but I thought professionals had moved on. It feels like Palliative care has 
regressed 20 years. 
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Appendix 21. Example of line by line coding 
 
 An example of open coding Patient Transcript 06  
1. Yes, I do, yes.  What did you study? 
 
2. Ethics. 
 
3. Oh my goodness. Gosh I’m glad... we have don’t it all properly, did 
you enjoy your course? 
 
4. Yes I did, yes it was good, and because I live near Watford, so it was about 
a forty-five minute drive to get home. So I was independent but, you know, I 
was kind of able to get home if I needed to. Yes so it was a really good 
experience. 
 
5. Did your CF interfere much with... 
 
6. It didn’t, but around my exam time, I had to redo my exams because I was 
unwell for those. But generally it didn’t, I mean I had such few, so few 
lectures that it kind of that wasn’t a problem. But yes no generally I was well 
throughout university.  A few blips but I did some home IVs and I was able 
to manage it quite well. 
 
7. Yes, brilliant, that’s great isn’t it? So we have discussed this but you 
know what this study is about, and you’ve read the patient information 
leaflet. But had you heard the term ‘Palliative care’ before? 
 
8. I’d heard of it, but I didn’t really know what it meant. I mean I certainly had 
not heard it mentioned at the XXX. The only time it was mentioned was 
when I was very, was feeling very sick and that was probably about two 
years ago, on the Tigecycline, so they sort of brought in a couple of people 
to talk to me about possible sort of sickness medications. But that was, that 
was the only time that it’s ever really been mentioned. So I don’t really 
know too much about the service. 
 
9. No, and when they brought the people in, do you remember very 
much about what they explained to you about what they did?  Or who 
was it that initiated it, do you remember? Not personally, but was it a 
nurse? 
 
10. Yes, my consultant, I think he contacted Palliative care, but it was very 
much a kind of, because I’d been struggling with sickness for a few days, it 
was kind of, ‘Oh what are the other options here?’ And then it was the 
Palliative care team was kind of brought in, whereas I think perhaps if it had 
been done earlier, it would have been better to get control sooner rather 
than sort of last chance. You know, ‘What else?  What else is out there?’ 
But I think it was the consultant that kind of made the contact with the team. 
 
And when the team came, do you remember what they explained to 
you about they were going to do or? 
 
11. Yes, I mean they were very clear with, with the role of kind of – well in 
terms of dealing with the sickness, they didn’t say too much about their 
roles generally. But they said about, you know, symptom control and so that 
was very much what I was aware that they were there to sort of deal with. 
And yes they were helpful kind of with suggestions and talking things 
through. But it was only when I got given the leaflet that I saw about the 
emotional and practical sort of side, because that’s never been sort of 
 
 
 
 
 
 
 
Independent 
Could get 
home if 
needing to 
Positive 
experience 
studying 
 
 
Had to redo 
exams 
Well 
throughout 
university 
A few blips, 
home IV’s 
Managing to 
live well 
 
 
 
 
 
Not sure about 
what pall care 
means 
Hadn’t heard 
of it mentioned 
at XXX 
Mentioning 
just when sick 
knowing little 
about the 
service 
 
 
 
 
 
Was 
mentioned to 
talk about ant 
emetics 
struggling with 
sickness 
Consultant 
contacted pall 
care as pt 
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mentioned before.  
 
Yes, sure.  And how did that make you feel?  Is that the information 
leaflet? 
 
Yes. 
  
That I gave you? 
 
Yes, about the Palliative care team, yes. 
 
Yes, did that make you have any more questions or make you think in 
a different way? 
 
I suppose it just made me think, to kind of wonder what the emotional 
support could be offered was and just sort of – I mean mostly I feel quite, 
I’m quite positive and I’m very lucky in that my family are very supportive. 
But I think probably for patients who don’t, especially young CF patients, 
who don’t have a supportive family, that side of it could be sort of tapped 
into a bit more, I think. And perhaps on admission be given a leaflet and 
said, you know, ‘If you’ve got any emotional kind of issues or you want to 
talk things through,’ because that’s or you want to talk things through,’ 
because that’s never been addressed. And I think, you know, some people 
must struggle managing it all themselves. So that, I think, could be 
improved. 
struggling with 
nausea 
Feeling pall 
care last resort 
 
 
 
Focusing on 
symptom 
control team 
didn’t say too 
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information 
leaflet on pall 
care saw 
emotional 
support 
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admission 
Emotional 
issues never 
been 
addressed 
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Appendix 22. Risk Assessment 
Activity Hazard Level of Risk Control/Actions Who When 
Visiting patients in 
their own homes 
Lone worker Moderate For personal 
assistant to be 
aware of where I 
am going. To 
notify her by 
phone on entering 
and leaving the 
address 
To follow the RM 
lone worker policy 
researcher before 
and after 
interviews 
Being interrupted 
when undertaking 
interviews 
interruption 
disrupts 
interviews 
those 
interviewed 
feel 
vulnerable 
Minor to ensure private 
area secured for 
interviews in the 
hospital prior to 
and on the day off 
the interview 
 
notices on doors 
stipulating not to 
be disturbed 
researcher prior to 
hospital 
interviews 
Travelling to 
second site for 
interviews 
travelling a 
distance and 
staff not 
available 
Moderate (time 
and financial) 
to telephone staff 
the day before 
and have a plan in 
place to be 
contacted in the 
morning of 
interview prior to 
departure is staff 
unable to be at 
the interview 
to try and 
undertake several 
interviews on one 
day 
researcher prior to 
interviews 
Using equipment to 
undertake 
interviews (tape 
recorder) 
breakdown 
of 
equipment 
Moderate (time 
wastage for 
patient and 
professional 
have spare 
batteries at all 
times and when 
possible a spare 
recorder 
researcher ongoing 
through 
qualitative 
phase of  
the study 
Patients become 
distressed due to 
the sensitivity of 
the subject 
patient 
distress 
Moderate to offer to stop the 
interview and 
access support 
from the CF team 
or Palliative care 
team 
researcher 
CF team 
and 
Palliative 
care team 
ongoing 
through 
the 
qualitativ
e phase 
of the 
study 
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